Diarylthiohydantoin compound as androgen receptor antagonist

ABSTRACT

The present application belongs to the field of medicine. In particular, the present application relates to a diarylthiohydantoin compound as an androgen receptor antagonist or a pharmaceutically acceptable salt thereof, a preparation method of the same, a pharmaceutical composition comprising the compound, and a use thereof in treating a cell proliferative disease mediated by androgen. The compound of the present application has good antagonistic effect on androgen receptor and exhibits excellent antitumor effect.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims the priorities to and benefits of theChinese Invention Patent Application No. 201710667860.4 filed with theChina National Intellectual Property Administration on Aug. 7, 2017 andthe Chinese Invention Patent Application No. 201810333652.5 filed withthe China National Intellectual Property Administration on Apr. 13,2018. The entire contents of these patent applications are incorporatedherein by reference.

TECHNICAL FIELD

The present application belongs to the field of medicine, andspecifically relates to a compound of Formula (I) or a pharmaceuticallyacceptable salt thereof, a preparation method thereof, a pharmaceuticalcomposition comprising the compound, and use thereof in the preparationof a medicament for the treatment of androgen-mediated related diseases.

BACKGROUND

An androgen receptor (AR) belongs to a steroid receptor of the nuclearreceptor superfamily. When bound to androgen (such as testosterone anddihydrotestosterone), the AR is released from a complex formed by heatshock proteins, undergoes a phosphorylation reaction to form a dimer,which is transferred into a nucleus, and is bound to a DNA fragmentassociated with it, thereby stimulating the transcription of its targetgene. The transcriptional activity of the androgen receptor activated byligand binding is accomplished by the protein coordination ofco-activators. The main role of AR antagonists is to directly preventtestosterone or dihydrotestosterone from binding to the androgenreceptors, block the effect of the androgens on cells, play a role of anantiandrogen, inhibit cell growth, and ultimately promote apoptosis andachieve an important role in treating prostatic cancer. Enzalutamide, anandrogen receptor antagonist developed by Medivation & Astell as, hasbeen marketed.

In view of the important role of androgen receptor antagonists, it isparticularly important to develop androgen receptor antagonists suitableas therapeutic drugs. In general, a compound as a pharmaceutical activeingredient need to have excellent properties in the following aspects:bioactivity, safety, bioavailability, stability, and the like. Thepresent invention provides a diarylthiohydantoin compound having a novelstructure for use as an androgen receptor antagonist, and finds that acompound having such a structure exhibits excellent antitumor effectsand has the above-mentioned excellent properties.

SUMMARY OF THE INVENTION

In one aspect, the present application relates to a compound of Formula(I) or a pharmaceutically acceptable salt thereof,

-   -   wherein,    -   T is selected from the group consisting of CH and N;    -   R¹ is selected from the group consisting of hydrogen, halogen,        C₁₋₁₂ alkyl, and halogen-substituted C₁₋₁₂ alkyl;    -   the ring A is selected from the group consisting of

-   -   R² and R³ are each independently selected from C₁₋₁₂ alkyl, or        R² and R³ are connected to each other to form a 3- to 6-membered        cycloalkyl together;    -   X¹, X², X³, and X⁴ are each independently selected from the        group consisting of CH and N, and at least one of them is N;    -   n is 0, 1, 2, or 3;    -   each R⁴ is independently selected from C₁₋₁₂ alkyl;    -   the ring B is

-   -   R⁵ is selected from the group consisting of hydrogen, C₁₋₁₂        alkyl, C₁₋₁₂ alkoxy, and halogen;    -   R⁶ is selected from C₁₋₁₂ alkylaminocarbonyl;    -   one of X⁵, X⁶, and X⁷ is N(—R^(a)), and the others are CH or N;    -   R^(a) is selected from 5-membered heterocycloalkyl, wherein the        heterocycloalkyl is optionally substituted by halogen, C₁₋₄        alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, 3- to 6-membered cycloalkyl,        3- to 6-membered heterocycloalkyl, C₁₋₄ alkoxy, hydroxyl, or        amino;    -   X⁸, X⁹, X¹⁰, and X¹¹ are each independently selected from the        group consisting of CH, C(═O), N, and NH, and three of X⁸, X⁹,        X¹⁰, and X¹¹ are C(═O), N, and NH, respectively;    -   R^(b) is selected from C₁₋₁₂ alkyl, wherein the C₁₋₁₂ alkyl is        optionally substituted by halogen;    -   Y⁸, Y⁹, Y¹⁰, and Y¹¹ are each independently selected from the        group consisting of CH and N, and at least two of Y⁸, Y⁹, Y¹⁰,        and Y¹¹ are N;    -   m is 0, 1, or 2;    -   each R⁷ is independently selected from the group consisting of        halogen, C₁₋₁₂ alkyl, hydroxyl, C₁₋₁₂ alkoxy, amino, 3- to        10-membered cycloalkyl, 3- to 10-membered heterocycloalkyl, 5-        to 10-membered heteroaryl, and C₁₋₁₂ alkylamino, wherein the        C₁₋₁₂ alkyl, 3- to 10-membered cycloalkyl, 3- to 10-membered        heterocycloalkyl, 5- to 10-membered heteroaryl, or C₁₋₁₂        alkylamino is optionally substituted by halogen, and wherein the        hydroxyl is substituted by: —C₁₋₁₂ alkyl-OH, —C₁₋₁₂ alkyl-(3- to        10-membered heterocycloalkyl), —C₁₋₁₂ alkyl-S(═O)₂R^(c), —C₁₋₁₂        alkyl-NR^(d)R^(e), —C₁₋₁₂ alkyl-C(═O)NR^(f)R^(g), —C₁₋₁₂        alkyl-(3- to 10-membered cycloalkyl) optionally substituted by        halogen or hydroxyl, or 3- to 10-membered heterocycloalkyl        optionally substituted by halogen or hydroxyl;    -   Z⁸, Z⁹, Z¹⁰, and Z¹¹ are each independently selected from the        group consisting of CH, C(═O), and N;    -   j is 0, 1, or 2;    -   each R⁹ is independently selected from the group consisting of        halogen, C₁₋₁₂ alkyl, C₁₋₁₂ alkoxy, and hydroxyl, wherein the        C₁₋₁₂ alkyl is optionally substituted by halogen or C₁₋₁₂        alkoxy, and wherein the hydroxyl is optionally substituted by:        —C₁₋₁₂ alkyl-O—C₁₋₁₂ alkyl, —C₁₋₁₂ alkyl-OH, or —C₁₋₁₂        alkyl-C(═O)NR^(f)R^(g);    -   R^(c), R^(d), R^(e), R^(f), and R⁹ are each independently        selected from the group consisting of hydrogen, C₁₋₁₂ alkyl, 3-        to 10-membered cycloalkyl, 3- to 10-membered heterocycloalkyl,        C₁₋₁₂ alkoxy, hydroxyl, and amino;    -   two of X¹², X¹³, X¹⁴, X¹, and X¹⁶ are NH and C(═O),        respectively, and the others are CH₂, O, or S;    -   q is 0, 1, 2, 3, or 4; and    -   each R⁸ is independently selected from the group consisting of        halogen, C₁₋₁₂ alkyl, hydroxyl, amino, 3- to 10-membered        cycloalkyl, C₁₋₁₂ alkoxy, 3- to 10-membered heterocycloalkyl,        and C₁₋₁₂ alkylamino;    -   provided that: when the ring A is selected from

the ring B is not

and when R⁷ is selected from C₁₋₁₂ alkoxy, R⁷ substitutes the hydrogenon Y⁹, Y¹⁰, or Y¹¹.

In another aspect, the present application relates to a pharmaceuticalcomposition, comprising the compound of Formula (I) or apharmaceutically acceptable salt thereof of the present application. Insome embodiments, the pharmaceutical composition of the presentapplication further comprises a pharmaceutically acceptable excipient.

In still another aspect, the present application relates to a method fortreating an androgen-mediated disease in a mammal, comprisingadministering to a mammal, preferably a human, in need of the treatmenta therapeutically effective amount of the compound of Formula (I) or apharmaceutically acceptable salt thereof or the pharmaceuticalcomposition thereof; and the disease includes, but is not limited to,cell proliferative diseases (e.g., cancer).

In yet another aspect, the present application relates to use of thecompound of Formula (I) or a pharmaceutically acceptable salt thereof orthe pharmaceutical composition thereof in the preparation of amedicament for the treatment of an androgen-mediated disease, and thedisease includes, but is not limited to, cell proliferative diseases(e.g., cancer).

In still yet another aspect, the present application relates to use ofthe compound of Formula (I) or a pharmaceutically acceptable saltthereof or the pharmaceutical composition in the treatment of anandrogen-mediated disease, and the disease includes, but is not limitedto, cell proliferative diseases (e.g., cancer).

In a further aspect, the present application relates to the compound ofFormula (I) or a pharmaceutically acceptable salt thereof or thepharmaceutical composition for use in preventing or treating anandrogen-mediated disease, and the disease includes, but is not limitedto, a cell proliferative disease (e.g., a cancer).

DETAILED DESCRIPTION OF THE INVENTION

In one aspect, the present application relates to a compound of Formula(I) or a pharmaceutically acceptable salt thereof,

-   -   wherein,    -   T is selected from the group consisting of CH and N;    -   R¹ is selected from the group consisting of hydrogen, halogen,        C₁₋₁₂ alkyl, and halogen-substituted C₁₋₁₂ alkyl;    -   the ring A is selected from the group consisting of

-   -   R² and R³ are each independently selected from C₁₋₁₂ alkyl, or        R² and R³ are connected to each other to form a 3- to 6-membered        cycloalkyl together;    -   X¹, X², X³, and X⁴ are each independently selected from the        group consisting of CH and N, and at least one of them is N;    -   n is 0, 1, 2, or 3;    -   each R⁴ is independently selected from C₁₋₁₂ alkyl;    -   the ring B is

-   -   R⁵ is selected from the group consisting of hydrogen, C₁₋₁₂        alkyl, C₁₋₁₂ alkoxy, and halogen;    -   R⁶ is selected from C₁₋₁₂ alkylaminocarbonyl;    -   one of X⁵, X⁶, and X⁷ is N(—R^(a)), and the others are CH or N;    -   R^(a) is selected from 3- to 10-membered heterocycloalkyl,        wherein the heterocycloalkyl is optionally substituted by        halogen, C₁₋₁₂ alkyl, C₂₋₁₂ alkenyl, C₂₋₁₂ alkynyl, 3- to        10-membered cycloalkyl, 3- to 10-membered heterocycloalkyl,        C₁₋₁₂ alkoxy, hydroxyl, or amino;    -   X⁸, X⁹, X¹⁰, and X¹¹ are each independently selected from the        group consisting of CH, C(═O), N, and NH, and three of X⁸, X⁹,        X¹⁰, and X¹¹ are C(═O), N, and NH, respectively;    -   R^(b) is selected from C₁₋₁₂ alkyl, wherein the C₁₋₁₂ alkyl is        optionally substituted by halogen;    -   Y⁸, Y⁹, Y¹⁰, and Y¹¹ are each independently selected from the        group consisting of CH and N, and at least two of Y⁸, Y⁹, Y¹⁰,        and Y¹¹ are N;    -   m is 0, 1, or 2;    -   each R⁷ is independently selected from the group consisting of        halogen, C₁₋₁₂ alkyl, hydroxyl, C₁₋₁₂ alkoxy, amino, 3- to        10-membered cycloalkyl, 3- to 10-membered heterocycloalkyl, 5-        to 10-membered heteroaryl, and C₁₋₁₂ alkylamino, wherein the        C₁₋₁₂ alkyl, 3- to 10-membered cycloalkyl, 3- to 10-membered        heterocycloalkyl, 5- to 10-membered heteroaryl, or C₁₋₁₂        alkylamino is optionally substituted by halogen, and wherein the        hydroxyl is optionally substituted by: —C₁₋₁₂ alkyl-OH, —C₁₋₁₂        alkyl-(3- to 10-membered heterocycloalkyl), —C₁₋₁₂        alkyl-S(═O)₂R^(c), —C₁₋₁₂ alkyl-NR^(d)R^(e), —C₁₋₁₂        alkyl-C(═O)NR^(f)R^(g), —C₁₋₁₂ alkyl-(3- to 10-membered        cycloalkyl) optionally substituted by halogen or hydroxyl, or 3-        to 10-membered heterocycloalkyl optionally substituted by        halogen or hydroxyl;    -   Z⁸, Z⁹, Z¹⁰, and Z¹¹ are each independently selected from the        group consisting of CH, C(═O), and N;    -   j is 0, 1, or 2;    -   each R⁹ is independently selected from the group consisting of        halogen, C₁₋₁₂ alkyl, C₁₋₁₂ alkoxy, and hydroxyl, wherein the        C₁₋₁₂ alkyl is optionally substituted by halogen or C₁₋₁₂        alkoxy, and wherein the hydroxyl is optionally substituted by:        —C₁₋₁₂ alkyl-O—C₁₋₁₂ alkyl, —C₁₋₁₂ alkyl-OH, or —C₁₋₁₂        alkyl-C(═O)NR^(f)R^(g);    -   R^(c), R^(d), R^(e), R^(f), and R⁹ are each independently        selected from the group consisting of hydrogen, C₁₋₁₂ alkyl, 3-        to 10-membered cycloalkyl, 3- to 10-membered heterocycloalkyl,        C₁₋₁₂ alkoxy, hydroxyl, and amino;    -   two of X¹², X¹³, X¹⁴, X¹, and X¹⁶ are NH and C(═O),        respectively, and the others are CH₂, O, or S;    -   q is 0, 1, 2, 3, or 4; and    -   each R⁸ is independently selected from the group consisting of        halogen, C₁₋₁₂ alkyl, hydroxyl, amino, 3- to 10-membered        cycloalkyl, C₁₋₁₂ alkoxy, 3- to 10-membered heterocycloalkyl,        and C₁₋₁₂ alkylamino;    -   provided that: when the ring A is selected from

the ring B is not

and when R⁷ is selected from C₁₋₁₂ alkoxy, R⁷ substitutes the hydrogenon Y⁹, Y¹⁰, or Y¹¹.

The heteroatom(s) in the heterocycloalkyl or heteroaryl described hereinis(are) usually 1, 2, or 3 heteroatoms independently selected from thegroup consisting of sulfur, oxygen, and/or nitrogen; and in someembodiments, the heterocycloalkyl contains 1 or 2 O atoms, and theheteroaryl contains 1 or 2 N atoms.

In some embodiments, R¹ is selected from the group consisting ofhydrogen, halogen, C₁₋₆ alkyl, and halogen-substituted C₁₋₆ alkyl; insome embodiments, R¹ is selected from the group consisting of halogenand halogen-substituted C₁₋₄ alkyl; in some embodiments, R¹ is selectedfrom the group consisting of fluoro, chloro, bromo, andfluoro-substituted C₁₋₄ alkyl; in some embodiments, R¹ is selected fromthe group consisting of fluoro, chloro, and fluoro-substituted methyl;and in some embodiments, R¹ is selected from the group consisting offluoro, chloro, difluoromethyl, and trifluoromethyl.

In some embodiments, R¹ is selected from halogen-substituted C₁₋₄ alkyl;in some embodiments, R¹ is selected from fluoro-substituted C₁₋₄ alkyl;in some embodiments, R¹ is selected from fluoro-substituted methyl; andin some embodiments, R¹ is selected from trifluoromethyl.

In some embodiments, X¹, X², X³, and X⁴ are each independently selectedfrom the group consisting of CH and N, and one or two of X¹, X², X³, andX⁴ are N, and the others are CH.

In some embodiments, X¹, X², X³, and X⁴ are each independently selectedfrom the group consisting of CH and N, and one of X¹, X², X³, and X⁴ isN, and the others are CH.

In some embodiments, the ring A is selected from the group consisting of

wherein X¹ and X² are each independently selected from the groupconsisting of CH and N, and at least one of them is N, and n is 0, 1, 2,or 3.

In some embodiments, the ring A is selected from the group consisting of

and n is 0 or 1.

In some embodiments, the ring A is selected from the group consisting of

and n is o or 1.

In some embodiments, R² and R³ are each independently selected from C₁₋₆alkyl, or R² and R³ are connected to each other to form a 3- to6-membered cycloalkyl together; in some embodiments, R² and R³ are eachindependently selected from C₁₋₄ alkyl, or R² and R³ are connected toeach other to form a 3- to 4-membered cycloalkyl together; in someembodiments, R² and R³ are each independently selected from the groupconsisting of methyl and ethyl, or R² and R³ are connected to each otherto form a 3- to 4-membered cycloalkyl together; and in some embodiments,R² and R³ are selected from methyl, or R² and R³ are connected to eachother to form cyclobutyl together.

In some specific embodiments, the ring A is selected from the groupconsisting of

In some embodiments, each R⁴ is independently selected from C₁₋₆ alkyl;in some embodiments, each R⁴ is independently selected from C₁₋₄ alkyl;and in some embodiments, each R⁴ is independently selected from methyl.

In some specific embodiments, the ring A is selected from the groupconsisting of

In some embodiments, the ring B is

In some embodiments, R⁵ is selected from the group consisting ofhydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, and halogen; in some embodiments, R⁵is selected from the group consisting of hydrogen, C₁₋₄ alkyl, C₁₋₄alkoxy, and halogen; in some embodiments, R⁵ is selected from the groupconsisting of hydrogen, methyl, methoxy, fluoro, chloro, bromo, andiodo; and in some embodiments, R⁵ is selected from the group consistingof hydrogen, methyl, methoxy, fluoro, and chloro.

In some embodiments, R⁵ is selected from the group consisting ofhydrogen and halogen.

In some other embodiments, R⁵ is selected from the group consisting ofhydrogen and fluoro.

In some embodiments, the structural unit

and in some embodiments, the structural unit

In some embodiments, R⁶ is selected from C₁₋₆ alkylaminocarbonyl; insome embodiments, R⁶ is selected from C₁₋₄ alkylaminocarbonyl; and insome embodiments, R⁶ is selected from methylaminocarbonyl.

In some specific embodiments, the structural unit

In some embodiments, X⁵, X⁶, and X⁷ are each independently selected fromthe group consisting of CH, N, and N(—R^(a)), and at least two of X⁵,X⁶, and X⁷ are N and N(—R^(a)), respectively, and the other is CH or N.

In some embodiments, X⁵, X⁶, and X⁷ are each independently selected fromthe group consisting of CH, N, and N(—R^(a)), and two of X⁵, X⁶, and X⁷are N and N(—R^(a)), respectively, and the other is CH or N.

In some embodiments, X⁵, X⁶, and X⁷ are each independently selected fromthe group consisting of CH, N, and N(—R^(a)), and are different fromeach other.

In some embodiments, the structural unit

is selected from the group consisting of

in some embodiments, the structural unit

is selected from the group consisting of

and in some embodiments, the structural unit

is selected from the group consisting of

In some embodiments, R^(a) is selected from 3- to 7-memberedheterocycloalkyl, wherein the heterocycloalkyl is optionally substitutedby halogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, 3- to 6-memberedcycloalkyl, 3- to 6-membered heterocycloalkyl, C₁₋₆ alkoxy, hydroxyl, oramino; in some embodiments, R^(a) is selected from 5-memberedheterocycloalkyl, wherein the heterocycloalkyl is optionally substitutedby halogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄ alkynyl, 3- to 6-memberedcycloalkyl, 3- to 6-membered heterocycloalkyl, C₁₋₄ alkoxy, hydroxyl, oramino; in some embodiments, R^(a) is selected from 5-memberedoxacycloalkyl, wherein the oxacycloalkyl is substituted by hydroxyl; andin some embodiments, R^(a) is selected from

In some specific embodiments, the structural unit

and the structural unit

In some specific embodiments, the structural unit

is selected from the group consisting of

In some embodiments, X⁸, X⁹, X¹⁰, and X¹¹ are each independentlyselected from the group consisting of CH, C(═O), N, and NH, and they aredifferent from each other.

In some embodiments, the R^(b) substitutes the hydrogen on NH or CH.

In some embodiments, the R^(b) substitutes the hydrogen on NH.

In some embodiments, the structural unit

is selected from the group consisting of

and in some embodiments, the structural unit

is selected from the group consisting of

In some embodiments, the structural unit

is selected from the group consisting of

and in some embodiments, the structural unit

is selected from the group consisting of

In some embodiments, R^(b) is selected from C₁₋₆ alkyl, wherein the C₁₋₆alkyl is optionally substituted by fluoro or chloro; in someembodiments, R^(b) is selected from C₁₋₄ alkyl, wherein the C₁₋₄ alkylis optionally substituted by fluoro; in some embodiments, R^(b) isselected from ethyl, wherein the ethyl is optionally substituted byfluoro; and in some embodiments, R^(b) is selected from the groupconsisting of —CH₂CH₃ and —CH₂CF₃.

In some embodiments, R^(b) is selected from C₁₋₆ alkyl, wherein the C₁₋₆alkyl is substituted by fluoro or chloro; in some embodiments, R^(b) isselected from C₁₋₄ alkyl, wherein the C₁₋₄ alkyl is substituted byfluoro; in some embodiments, R^(b) is selected from ethyl, wherein theethyl is substituted by fluoro; and in some embodiments, R^(b) isselected from —CH₂CF₃.

In some specific embodiments, the structural unit

the structural unit

and the structural unit

In some specific embodiments, the structural unit

is selected from the group consisting of

In some embodiments, Y⁸, Y⁹, Y¹⁰, and Y¹¹ are each independentlyselected from the group consisting of CH and N, and two of Y⁸, Y⁹, Y¹⁰,and Y¹¹ are N, and the others are CH.

In some embodiments, the structural unit

In some embodiments, the structural unit

and insome embodiments, the structural unit

In some embodiments, the structural unit

In some embodiments, R^(c), R^(d), and R^(e) are each independentlyselected from the group consisting of hydrogen, C₁₋₁₂ alkyl, 3- to10-membered cycloalkyl, 3- to 10-membered heterocycloalkyl, C₁₋₁₂alkoxy, hydroxyl, and amino. In some embodiments, R^(c), R^(d), andR^(e) are each independently selected from the group consisting ofhydrogen, C₁₋₆ alkyl, 3- to 6-membered cycloalkyl, 3- to 6-memberedheterocycloalkyl, C₁₋₆ alkoxy, hydroxyl, and amino; in some embodiments,R^(e), R^(d), and R^(e) are each independently selected from C₁₋₄ alkyl;and in some embodiments, R^(e), R^(d) and R^(e) are each independentlyselected from methyl.

In some embodiments, R^(c), R^(d), R^(e), R^(f), and R^(g) are eachindependently selected from the group consisting of hydrogen, C₁₋₆alkyl, 3- to 6-membered cycloalkyl, 3- to 6-membered heterocycloalkyl,C₁₋₆ alkoxy, hydroxyl, and amino; in some embodiments, R^(c), R^(d),R^(e), R^(f), and R^(g) are each independently selected from the groupconsisting of hydrogen and C₁₋₄ alkyl; and in some embodiments, R^(c),R^(d), R^(e), R^(f), and R^(g) are each independently selected from thegroup consisting of hydrogen and methyl.

In some embodiments, m is 1 or 2.

In some embodiments, the R⁷ substitutes the hydrogen on CH.

In some embodiments, each R⁷ is independently selected from the groupconsisting of halogen, C₁₋₆ alkyl, hydroxyl, C₁₋₆ alkoxy, amino, 3- to6-membered cycloalkyl, 3- to 6-membered heterocycloalkyl, 5- to6-membered heteroaryl, and C₁₋₆ alkylamino, wherein the C₁₋₆ alkyl, 3-to 6-membered cycloalkyl, 3- to 6-membered heterocycloalkyl, 5- to6-membered heteroaryl, or C₁₋₆ alkylamino is optionally substituted byhalogen, and wherein the hydroxyl is optionally substituted by: —C₁₋₆alkyl-OH, —C₁₋₆ alkyl-(3- to 6-membered heterocycloalkyl), —C₁₋₆alkyl-S(═O)₂R^(c), —C₁₋₆ alkyl-NR^(d)R^(e), —C₁₋₆alkyl-C(═O)NR^(f)R^(g), —C₁₋₆ alkyl-(3- to 6-membered cycloalkyl)optionally substituted by halogen or hydroxyl, or 3- to 6-memberedheterocycloalkyl optionally substituted by halogen or hydroxyl, providedthat: when R⁷ is selected from C₁₋₆ alkoxy, R⁷ substitutes the hydrogenon Y⁹, Y¹⁰, or Y¹¹. In some embodiments, each R⁷ is independentlyselected from the group consisting of halogen, C₁₋₄ alkyl, hydroxyl,C₁₋₄ alkoxy, amino, 3- to 6-membered cycloalkyl, 5- to 6-memberedheteroaryl, and C₁₋₄ alkylamino, wherein the C₁₋₄ alkyl, 3- to6-membered cycloalkyl, or C₁₋₄ alkylamino is optionally substituted byhalogen, and wherein the hydroxyl is optionally substituted by: —C₁₋₄alkyl-OH, —C₁₋₄ alkyl-(3- to 6-membered heterocycloalkyl), —C₁₋₄alkyl-S(═O)₂R⁰, —C₁₋₄ alkyl-NR^(d)R^(e), —C₁₋₄ alkyl-C(═O)NR^(f)R^(g),—C₁₋₄ alkyl-(3- to 6-membered cycloalkyl) optionally substituted byhalogen or hydroxyl, or 5- to 6-membered heterocycloalkyl optionallysubstituted by halogen or hydroxyl, provided that: when R⁷ is selectedfrom C₁₋₄ alkoxy, R⁷ substitutes the hydrogen on Y⁹, Y¹⁰, or Y¹¹. Insome embodiments, each R⁷ is independently selected from the groupconsisting of methyl, ethyl, hydroxyl, methoxy, ethoxy, cyclopropyl,pyrazolyl, imidazolyl, and methylamino, wherein the methyl, ethyl, orcyclopropyl is optionally substituted by fluoro, and wherein thehydroxyl is optionally substituted by: -ethyl-OH, tetrahydropyranyl,-methyl-(oxetane), -propyl-S(═O)₂R^(c), -ethyl-NR^(d)R^(e),-methyl-C(═O)NR^(f)R^(g), cyclopropylmethyl-optionally substituted byhydroxyl, or tetrahydrofuranyl optionally substituted by hydroxyl,provided that: when R⁷ is selected from methoxy or ethoxy, R⁷substitutes the hydrogen on Y⁹, Y¹⁰, or Y¹¹. In some embodiments, eachR⁷ is independently selected from the group consisting of methyl, ethyl,hydroxyl, methoxy, ethoxy, cyclopropyl, pyrazolyl, imidazolyl, andmethylamino, wherein the methyl or ethyl is optionally substituted byfluoro, and wherein the hydroxyl is optionally substituted by:-ethyl-OH,

-propyl-S(═O)₂CH₃, —CH₂C(═O)NHCH₃, —CH₂C(═O)NH₂, -ethyl-N(CH₃)₂,

optionally substituted by hydroxyl, or

optionally substituted by hydroxyl, provided that: when R⁷ is selectedfrom the group consisting of methoxy and ethoxy, R⁷ substitutes thehydrogen on Y⁹, Y¹⁰, or Y¹¹. In some embodiments, each R⁷ isindependently selected from the group consisting of methyl, ethyl,cyclopropyl, hydroxyl, methoxy, ethoxy, pyrazolyl, imidazolyl,difluoromethyl, difluoroethyl, and methylamino, wherein the hydroxyl isoptionally substituted by: -ethyl-OH,

-propyl-S(═O)₂CH₃, —CH₂C(═O)NHCH₃, —CH₂C(═O)NH₂, or -ethyl-N(CH₃)₂,provided that: when R⁷ is selected from the group consisting of methoxyand ethoxy, R⁷ substitutes the hydrogen on Y⁹, Y¹⁰, or Y¹¹.

In some specific embodiments, each R⁷ is independently selected from thegroup consisting of methyl, ethyl, cyclopropyl, difluoromethyl,

methylamino,

methoxy, ethoxy,

In some more specific embodiments, each R⁷ is independently selectedfrom the group consisting of methyl, ethyl, cyclopropyl, difluoromethyl,

methylamino,

metoxy, ethoxy,

In some embodiments, each R⁷ is independently selected from the groupconsisting of halogen, C₁₋₁₂ alkyl, hydroxyl, amino, 3- to 10-memberedcycloalkyl, 3- to 10-membered heterocycloalkyl, and C₁₋₁₂ alkylamino,wherein the hydroxyl is substituted by: —C₁₋₁₂ alkyl-OH, 3- to10-membered heterocycloalkyl, —C₁₋₁₂ alkyl-S(═O)₂R^(c), or —C₁₋₁₂alkyl-NR^(d)R^(e), wherein the C₁₋₁₂ alkyl, 3- to 10-memberedcycloalkyl, 3- to 10-membered heterocycloalkyl, or C₁₋₁₂ alkylamino isoptionally substituted by halogen.

In some embodiments, each R⁷ is independently selected from the groupconsisting of halogen, C₁₋₆ alkyl, hydroxyl, amino, 3- to 6-memberedcycloalkyl, 3- to 6-membered heterocycloalkyl, and C₁₋₆ alkylamino,wherein the hydroxyl is substituted by: —C₁₋₆ alkyl-OH, 3- to 6-memberedheterocycloalkyl, —C₁₋₆ alkyl-S(═O)₂R^(c), or —C₁₋₆ alkyl-NR^(d)R^(e),wherein the C₁₋₆ alkyl, 3- to 6-membered cycloalkyl, 3- to 6-memberedheterocycloalkyl, or C₁₋₆ alkylamino is optionally substituted byhalogen. In some embodiments, each R⁷ is independently selected from thegroup consisting of halogen, C₁₋₄ alkyl, hydroxyl, amino, 3- to6-membered cycloalkyl, and C₁₋₄ alkylamino, wherein the hydroxyl issubstituted by: —C₁₋₄ alkyl-OH, 5- to 6-membered heterocycloalkyl, —C₁₋₄alkyl-S(═O)₂R^(c), or —C₁₋₄ alkyl-NR^(d)R^(e), wherein the C₁₋₄ alkyl,3- to 6-membered cycloalkyl, or C₁₋₄ alkylamino is optionallysubstituted by halogen. In some embodiments, each R⁷ is independentlyselected from the group consisting of methyl, ethyl, hydroxyl,cyclopropyl, and methylamino, wherein the hydroxyl is substituted by:-ethyl-OH, tetrahydropyranyl, -propyl-S(═O)₂R^(c), or-ethyl-NR^(d)R^(e), wherein the methyl, ethyl, cyclopropyl ormethylamino is optionally substituted by fluoro. In some embodiments,each R⁷ is independently selected from the group consisting of methyl,ethyl, hydroxyl, cyclopropyl, and methylamino, wherein the hydroxyl issubstituted by: -ethyl-OH,

-propyl-S(═O)₂CH₃, or -ethyl-N(CH₃)₂, wherein the methyl, ethyl,cyclopropyl or methylamino is optionally substituted by fluoro. In someembodiments, each R⁷ is independently selected from the group consistingof methyl, ethyl, cyclopropyl, hydroxyl, difluoromethyl, andmethylamino, wherein the hydroxyl is substituted by: -ethyl-OH,

-propyl-S(═O)₂CH₃, or -ethyl-N(CH₃)₂.

In some specific embodiments, each R⁷ is independently selected from thegroup consisting of methyl, ethyl, cyclopropyl, hydroxyl,difluoromethyl, methylamino,

In some specific embodiments, the structural unit

In some more specific embodiments, the structural unit

is selected from the group consisting of

wherein each R⁷¹ is independently selected from the group consisting ofhydroxyl and 5- to 10-membered heteroaryl, the hydroxyl is optionallysubstituted by: —C₁₋₁₂ alkyl-OH, —C₁₋₁₂ alkyl-(3- to 10-memberedheterocycloalkyl), —C₁₋₁₂ alkyl-S(═O)₂R^(c), —C₁₋₁₂ alkyl-NR^(d)R^(e),—C₁₋₁₂ alkyl-C(═O)NR^(f)R^(g), —C₁₋₁₂ alkyl-(3- to 10-memberedcycloalkyl) optionally substituted by halogen or hydroxyl, or 3- to10-membered heterocycloalkyl optionally substituted by halogen orhydroxyl; and each R⁷² is independently selected from the groupconsisting of C₁₋₁₂ alkyl, hydroxyl, C₁₋₁₂ alkoxy, 3- to 10-memberedcycloalkyl, and C₁₋₁₂ alkylamino, wherein the C₁₋₁₂ alkyl, 3- to10-membered cycloalkyl, or C₁₋₁₂ alkylamino is optionally substituted byhalogen, and wherein the hydroxyl is substituted by: —C₁₋₁₂ alkyl-OH, 3-to 10-membered heterocycloalkyl, —C₁₋₁₂ alkyl-S(═O)₂R^(c), or —C₁₋₁₂alkyl-NR^(d)R^(e).

In some embodiments, each R⁷¹ is independently selected from the groupconsisting of hydroxyl and 5- to 6-membered heteroaryl, the hydroxyl isoptionally substituted by: —C₁₋₆ alkyl-OH, —C₁₋₆ alkyl-(3- to 6-memberedheterocycloalkyl), —C₁₋₆ alkyl-S(═O)₂R^(c), —C₁₋₆ alkyl-NR^(d)R^(e),—C₁₋₆ alkyl-C(═O)NR^(f)R^(g), —C₁₋₆ alkyl-(3- to 6-membered cycloalkyl)optionally substituted by halogen or hydroxyl, or 3- to 6-memberedheterocycloalkyl optionally substituted by halogen or hydroxyl. In someembodiments, each R⁷¹ is independently selected from the groupconsisting of hydroxyl and 5- to 6-membered heteroaryl, wherein thehydroxyl is optionally substituted by: —C₁₋₄ alkyl-OH, —C₁₋₄ alkyl-(3-to 6-membered heterocycloalkyl), —C₁₋₄ alkyl-S(═O)₂R^(c), —C₁₋₄alkyl-NR^(d)R^(e), —C₁₋₄ alkyl-C(═O)NR^(f)R^(g), —C₁₋₄ alkyl-(3- to6-membered cycloalkyl) optionally substituted by halogen or hydroxyl, or5- to 6-membered heterocycloalkyl optionally substituted by halogen orhydroxyl. In some embodiments, each R⁷¹ is independently selected fromthe group consisting of hydroxyl, pyrazolyl, and imidazolyl, wherein thehydroxyl is optionally substituted by: -ethyl-OH, tetrahydropyranyl,-methyl-(oxetane), -propyl-S(═O)₂R^(c), -ethyl-NR^(d)R^(e),-methyl-C(═O)NR^(f)R^(g), cyclopropylmethyl-optionally substituted byhydroxyl, or tetrahydrofuranyl optionally substituted by hydroxyl. Insome embodiments, each R⁷¹ is independently selected from the groupconsisting of hydroxyl, pyrazolyl, and imidazolyl, wherein the hydroxylis optionally substituted by: -ethyl-OH,

-propyl-S(═O)₂CH₃, —CH₂C(═O)NHCH₃, —CH₂C(═O)NH₂, -ethyl-N(CH₃)₂,

optionally substituted by hydroxyl, or

optionally substituted by hydroxyl.

In some specific embodiments, each R⁷¹ is independently selected fromthe group consisting of

In some more specific embodiments, each R⁷¹ is independently selectedfrom the group consisting of hydroxyl,

In some embodiments, each R⁷² is independently selected from the groupconsisting of C₁₋₆ alkyl, hydroxyl, C₁₋₆ alkoxy, 3- to 6-memberedcycloalkyl, and C₁₋₆ alkylamino, wherein the C₁₋₆ alkyl, 3- to6-membered cycloalkyl, or C₁₋₆ alkylamino is optionally substituted byhalogen, and wherein the hydroxyl is substituted by: —C₁₋₆ alkyl-OH, 5-to 6-membered heterocycloalkyl, —C₁₋₆ alkyl-S(═O)₂R^(c), or —C₁₋₆alkyl-NR^(d)R^(e). In some embodiments, each R⁷² is independentlyselected from the group consisting of C₁₋₄ alkyl, hydroxyl, C₁₋₄ alkoxy,3- to 6-membered cycloalkyl, and C₁₋₄ alkylamino, wherein the C₁₋₄alkyl, 3- to 6-membered cycloalkyl, or C₁₋₄ alkylamino is optionallysubstituted by halogen, and wherein the hydroxyl is substituted by:—C₁₋₄ alkyl-OH. In some embodiments, each R⁷² is independently selectedfrom the group consisting of methyl, ethyl, hydroxyl, methoxy, ethoxy,cyclopropyl, and methylamino, wherein the methyl, ethyl, or cyclopropylis optionally substituted by fluoro; wherein the hydroxyl is substitutedby: -ethyl-OH. In some embodiments, each R⁷² is independently selectedfrom the group consisting of methyl, ethyl, cyclopropyl, hydroxyl,methoxy, ethoxy, difluoromethyl, difluoroethyl, and methylamino, whereinthe hydroxyl is substituted by: -ethyl-OH.

In some specific embodiments, each R⁷² is independently selected fromthe group consisting of methyl, ethyl, cyclopropyl, difluoromethyl,

ethoxy, ethoxy, methylamino, and

In some embodiments, the structural unit

is selected from the group consisting of

wherein each R⁷¹ is independently selected from hydroxyl, and thehydroxyl is substituted by: —C₁₋₁₂ alkyl-OH, 3- to 10-memberedheterocycloalkyl, —C₁₋₁₂ alkyl-S(═O)₂R, or —C₁₋₁₂ alkyl-NR^(d)R^(e); andeach R⁷² is independently selected from the group consisting of C₁₋₁₂alkyl, hydroxyl, 3- to 10-membered cycloalkyl, and C₁₋₁₂ alkylamino,wherein the hydroxyl is substituted by: —C₁₋₁₂ alkyl-OH, 3- to10-membered heterocycloalkyl, —C₁₋₁₂ alkyl-S(═O)₂R^(c), or —C₁₋₁₂alkyl-NR^(d)R^(e), wherein the C₁₋₁₂ alkyl, 3- to 10-memberedcycloalkyl, or C₁₋₁₂ alkylamino is optionally substituted by halogen.

In some embodiments, each R⁷¹ is independently selected from hydroxyl,and the hydroxyl is substituted by: —C₁₋₆ alkyl-OH, 3- to 6-memberedheterocycloalkyl, —C₁₋₆ alkyl-S(═O)₂R^(c), or —C₁₋₆ alkyl-NR^(d)R^(e).In some embodiments, each R⁷¹ is independently selected from hydroxyl,wherein the hydroxyl is substituted by: —C₁₋₄ alkyl-OH, 5- to 6-memberedheterocycloalkyl, —C₁₋₄ alkyl-S(═O)₂R^(c), or —C₁₋₄ alkyl-NR^(d)R^(e).In some embodiments, each R⁷¹ is independently selected from hydroxyl,wherein the hydroxyl is substituted by: -ethyl-OH, epoxyhexyl,-propyl-S(═O)₂R^(c), or -ethyl-NR^(d)R^(e). In some embodiments, eachR⁷¹ is independently selected from hydroxyl, wherein the hydroxyl issubstituted by: -ethyl-OH,

-propyl-S(═O)₂CH₃, or -ethyl-N(CH₃)₂.

In some specific embodiments, each R⁷¹ is independently selected fromthe group consisting of

In some embodiments, each R⁷² is independently selected from the groupconsisting of C₁₋₆ alkyl, hydroxyl, 3- to 6-membered cycloalkyl, andC₁₋₆ alkylamino, wherein the C₁₋₆ alkyl, 3- to 6-membered cycloalkyl, orC₁₋₆ alkylamino is optionally substituted by halogen, and wherein thehydroxyl is substituted by: —C₁₋₆ alkyl-OH, 5- to 6-memberedheterocycloalkyl, —C₁₋₆ alkyl-S(═O)₂R^(c), or —C₁₋₆ alkyl-NR^(d)R^(e).In some embodiments, each R⁷² is independently selected from the groupconsisting of C₁₋₄ alkyl, hydroxyl, 3- to 6-membered cycloalkyl, andC₁₋₄ alkylamino, wherein the C₁₋₄ alkyl, 3- to 6-membered cycloalkyl, orC₁₋₄ alkylamino is optionally substituted by halogen, wherein thehydroxyl is substituted by: —C₁₋₄ alkyl-OH. In some embodiments, eachR⁷² is independently selected from the group consisting of methyl,ethyl, hydroxyl, cyclopropyl, and methylamino, wherein the methyl,ethyl, or cyclopropyl is optionally substituted by fluoro; and whereinthe hydroxyl is substituted by: -ethyl-OH. In some embodiments, each R⁷²is independently selected from the group consisting of methyl, ethyl,cyclopropyl, hydroxyl, difluoromethyl, and methylamino, wherein thehydroxyl is substituted by: -ethyl-OH.

In some specific embodiments, each R⁷² is independently selected fromthe group consisting of methyl, ethyl, cyclopropyl, hydroxyl,difluoromethyl, methylamino, and

In some specific embodiments, the structural unit

is selected from the group consisting of

In some specific embodiments,

is selected from the group consisting

In some specific embodiments, the structural unit

is selected from the group consisting of

In some embodiments, Z⁸, Z⁹, Z¹⁰, and Z¹¹ are each independently groupconsisting of CH, C(═O), and N, and at least one of them is selectedfrom N; in some embodiments, at least one of them is selected fromC(═O), and at least one of them is selected from N; and in someembodiments, one of them is selected from C(═O), another one of them isselected from N, and the other two are each CH.

In some embodiments, the structural unit

wherein Z⁹, Z¹⁰, and Z¹¹ are each independently selected from the groupconsisting of CH, C(═O), and N; in some embodiments, the structural unit

wherein Z⁹ and Z¹⁰ are each independently selected from the groupconsisting of CH and N; in some embodiments, the structural unit

and in some embodiments, the structural unit

In some embodiments, j is 1 or 2.

In some embodiments, each R⁹ is independently selected from the groupconsisting of halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, and hydroxyl, whereinthe C₁₋₆ alkyl is optionally substituted by halogen or C₁₋₆ alkoxy, andwherein the hydroxyl is optionally substituted by: —C₁₋₆ alkyl-O—C₁₋₆alkyl, —C₁₋₆ alkyl-OH, or —C₁₋₆ alkyl-C(═O)NR^(f)R^(g). In someembodiments, each R⁹ is independently selected from the group consistingof halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, and hydroxyl, wherein the C₁₋₄alkyl is optionally substituted by halogen or C₁₋₄ alkoxy, and whereinthe hydroxyl is optionally substituted by: —C₁₋₄ alkyl-O—C₁₋₄ alkyl,—C₁₋₄ alkyl-OH, or —C₁₋₄ alkyl-C(═O)NR^(f)R^(g). In some embodiments,each R⁹ is independently selected from the group consisting of halogen,methyl, ethyl, methoxy, ethoxy, and hydroxyl, wherein the methyl orethyl is optionally substituted by halogen or methoxy, and wherein thehydroxyl is optionally substituted by: -ethyl-O-methyl, -ethyl-OH, or-methyl-C(═O)NR^(f)R^(g). In some embodiments, each R⁹ is independentlyselected from the group consisting of halogen, methyl, ethyl, methoxy,ethoxy, and hydroxyl, wherein the methyl or ethyl is optionallysubstituted by fluoro or methoxy, and wherein the hydroxyl is optionallysubstituted by: -ethyl-O-methyl, -ethyl-OH, —CH₂C(═O)NHCH₃, or—CH₂C(═O)NH₂.

In some specific embodiments, each R⁹ is independently selected from thegroup consisting of ethyl, hydroxyl, methoxy,

fluoro, ethoxy, difluoromethyl, and

In some embodiments, the structural unit

is selected from the group consisting of

wherein R⁹¹ is selected from the group consisting of C₁₋₁₂ alkyl, C₁₋₁₂alkoxy, and hydroxyl, wherein the C₁₋₁₂ alkyl is optionally substitutedby C₁₋₁₂ alkoxy or halogen, and wherein the hydroxyl is optionallysubstituted by —C₁₋₁₂ alkyl-OH, or —C₁₋₁₂ alkyl-O—C₁₋₁₂ alkyl; whereinR⁹² is selected from the group consisting of hydroxyl, —C₁₋₁₂ alkoxy,and halogen, wherein the hydroxyl is optionally substituted by —C₁₋₁₂alkyl-OH, —C₁₋₁₂ alkyl-O—C₁₋₁₂ alkyl, or —C₁₋₁₂ alkyl-C(═O)NR^(f)R^(g).

In some embodiments, R⁹¹ is selected from the group consisting of C₁₋₆alkyl, C₁₋₆ alkoxy, and hydroxyl, wherein the C₁₋₆ alkyl is optionallysubstituted by C₁₋₆ alkoxy or halogen, and wherein the hydroxyl isoptionally substituted by —C₁₋₆ alkyl-OH or —C₁₋₆ alkyl-O—C₁₋₆ alkyl. Insome embodiments, R⁹¹ is selected from the group consisting of C₁₋₄alkyl, C₁₋₄ alkoxy, and hydroxyl, wherein the C₁₋₄ alkyl is optionallysubstituted by C₁₋₄ alkoxy or halogen, and wherein the hydroxyl isoptionally substituted by —C₁₋₄ alkyl-OH or —C₁₋₄ alkyl-O—C₁₋₄ alkyl. Insome embodiments, R⁹¹ is selected from the group consisting of methyl,ethyl, methoxy, ethoxy, and hydroxyl, wherein the methyl or ethyl isoptionally substituted by halogen or methoxy, and wherein the hydroxylis optionally substituted by -ethyl-O-methyl or -ethyl-OH. In someembodiments, R⁹¹ is selected from the group consisting of methyl, ethyl,methoxy, ethoxy, and hydroxyl, wherein the methyl or ethyl is optionallysubstituted by fluoro or methoxy, and wherein the hydroxyl is optionallysubstituted by -ethyl-O-methyl or -ethyl-OH.

In some specific embodiments, R⁹¹ is selected from the group consistingof ethyl, methoxy, ethoxy, difluoromethyl,

In some embodiments, R⁹² is selected from the group consisting ofhydroxyl, C₁₋₆ alkoxy, and halogen, wherein the hydroxyl is optionallysubstituted by —C₁₋₆ alkyl-OH, —C₁₋₆ alkyl-O—C₁₋₆ alkyl, or —C₁₋₆alkyl-C(═O)NR^(f)R^(g). In some embodiments, R⁹² is selected from thegroup consisting of hydroxyl, C₁₋₄ alkoxy, and halogen, wherein thehydroxyl is optionally substituted by —C₁₋₄ alkyl-OH, —C₁₋₄ alkyl-O—C₁₋₄alkyl, or —C₁₋₄ alkyl-C(═O)NR^(f)R^(g). In some embodiments, R⁹² isselected from the group consisting of hydroxyl, methoxy, and halogen,wherein the hydroxyl is optionally substituted by -ethyl-OH,-ethyl-O-methyl, or -methyl-C(═O)NR^(f)R^(g). In some embodiments, R⁹²is selected from the group consisting of hydroxyl, methoxy, and halogen,wherein the hydroxyl is optionally substituted by -ethyl-OH,-ethyl-O-methyl, —CH₂C(═O)NHCH₃, or —CH₂C(═O)NH₂.

In some specific embodiments, R⁹² is selected from the group consistingof hydroxyl, methoxy,

and fluoro.

In some specific embodiments, the structural unit

is selected from the group consisting of

In some embodiments, two of X¹², X¹³, X¹⁴. X¹⁵, and X¹⁶ are NH andC(═O), respectively, and the others are CH₂ or O.

In some embodiments, the structural unit

and in some embodiments, the structural unit

In some embodiments, each R⁸ is independently selected from the groupconsisting of hydrogen, C₁₋₆ alkyl, hydroxyl, amino, 3- to 6-memberedcycloalkyl, C₁₋₆ alkoxy, 3- to 6-membered heterocycloalkyl, and C₁₋₆alkylamino; in some embodiments, each R⁸ is independently selected fromC₁₋₄ alkyl; and in some embodiments, each R⁸ is independently selectedfrom ethyl.

In some embodiments, q is 0, 1, or 2; in some embodiments, q is 1 or 2;and in some embodiments, q is 1.

In some embodiments, the structural unit

In some specific embodiments, the structural unit

In another aspect, the present application provides a compound ofFormula (II) or a pharmaceutically acceptable salt thereof:

-   -   wherein,    -   R² and R³ are selected from methyl, or R² and R³ are connected        to each other to form cyclobutyl together; and    -   the structural unit

and X⁵, X⁶, X⁷, T, and R⁵ are as defined in the compound of Formula (I).

In some embodiments of the present invention, T is selected from CH.

In still another aspect, the present application provides a compound ofFormula (III-1) or a compound of Formula (III-2) or a pharmaceuticallyacceptable salt thereof:

-   -   wherein,    -   R² and R³ are selected from methyl, or R² and R³ are connected        to each other to form cyclobutyl together; and    -   the structural units

and X⁸, X⁹, X¹⁰, X¹¹, Ys, Y⁹, Y¹⁰, Y¹, T, R⁵, R^(b), R⁷, and mare asdefined in the compound of Formula (I).

In yet another aspect, the present application provides a compound ofFormula (III-21) or a compound of Formula (III-22) or a pharmaceuticallyacceptable salt thereof:

-   -   wherein,    -   m is 1 or 2; R² and R³ are selected from methyl, or R² and R³        are connected to each other to form cyclobutyl together; and    -   the structural unit

and T, R⁵, and R⁷ are as defined in the compound of Formula (I).

In some embodiments, the structural unit

wherein the definition of the structural unit

is as mentioned above.

In still yet another aspect, the present application provides a compoundof Formula (IV) or a pharmaceutically acceptable salt thereof:

-   -   wherein,    -   q is 1 or 2; R² and R³ are selected from methyl, or R² and R³        are connected to each other to form cyclobutyl together; and    -   the structural unit

and T, X¹², X¹³, X¹⁴, X⁵, X¹⁶, R⁵, and R⁸ are as defined in the compoundof Formula (I).

In some embodiments of the present application, T is selected from CH.

In a further aspect, the present application provides a compound ofFormula (V) or a pharmaceutically acceptable salt thereof:

-   -   wherein the structural units

and T, R⁴, n, R⁵, and R⁶ are as defined in the compound of Formula (I).

In some embodiments of the present application, T is selected from CH.

Preferably, the present application provides a compound of Formula (VI)or a pharmaceutically acceptable salt thereof:

-   -   wherein    -   the structural unit

and T, R¹, R⁵, R⁹, Z⁸, Z⁹, Z¹⁰, Z¹¹, and j are as defined in thecompound of Formula (I); and

-   -   R² and R³ are selected from methyl, or R² and R³ are connected        to each other to form cyclobutyl together.

In some specific embodiments, R¹ is selected from the group consistingof fluoro, chloro, and trifluoromethyl.

Preferably, the present application provides a compound of Formula(VI-1) or a pharmaceutically acceptable salt thereof:

-   -   wherein,    -   T, R¹, R⁵, R⁹, and j are as defined in the compound of Formula        (I); and R² and R³ are selected from methyl, or R² and R³ are        connected to each other to form cyclobutyl together.

In some embodiments, the structural unit

wherein the definition of the structural unit

is as mentioned above.

In some specific embodiments, R¹ is selected from the group consistingof fluoro, chloro, and trifluoromethyl.

In another aspect, the present application provides a compound ofFormula (VII) or a pharmaceutically acceptable salt thereof:

-   -   wherein,    -   T, R¹, R⁴, and n are as defined in the compound of Formula (I);        and the ring B is selected from the group consisting of

wherein X⁸, X⁹, X¹⁰, X¹¹, Y⁸, Y⁹, Y¹⁰, Y¹¹, Z⁸, Z⁹, Z¹⁰, Z¹¹, R⁵, R⁶,R^(b), R⁷, R⁹, m, j, and the structural units

are as defined in the compound of Formula (I).

In still another aspect, the present application provides the followingcompounds or a pharmaceutically acceptable salt thereof:

In yet another aspect, the present application relates to apharmaceutical composition, comprising the compound of Formula (I),Formula (II), Formula (III-1), Formula (III-2), Formula (III-21),Formula (III-22), Formula (IV), Formula (V), Formula (VI), Formula(VI-1), or Formula (VII), or a pharmaceutically acceptable salt thereofaccording to the present application. In some embodiments, thepharmaceutical composition of the present application further comprisesa pharmaceutically acceptable excipient.

In still yet another aspect, the present application relates to a methodfor treating an androgen-mediated disease in a mammal, comprisingadministering to a mammal, preferably a human, in need of the treatmenta therapeutically effective amount of the compound of Formula (I),Formula (11), Formula (III-1), Formula (III-2), Formula (III-21),Formula (III-22), Formula (IV), Formula (V), Formula (VI), Formula(VI-1), or Formula (VII), or a pharmaceutically acceptable salt thereof,or the pharmaceutical composition thereof; and the disease includes, butis not limited to, cell proliferative diseases (e.g., cancer).

In a further aspect, the present application relates to use of thecompound of Formula (I), Formula (II), Formula (III-1), Formula (III-2),Formula (III-21), Formula (III-22), Formula (IV), Formula (V), Formula(VI), Formula (VI-1), or Formula (VII), or a pharmaceutically acceptablesalt thereof, or the pharmaceutical composition thereof in thepreparation of a medicament for the treatment of an androgen-mediateddisease, and the disease includes, but is not limited to, cellproliferative diseases (e.g., cancer).

In still a further aspect, the present application relates to use of thecompound of Formula (I), Formula (II), Formula (III-1), Formula (III-2),Formula (III-21), Formula (III-22), Formula (IV), Formula (V), Formula(VI), Formula (VI-1), or Formula (VII), or a pharmaceutically acceptablesalt thereof, or the pharmaceutical composition in the treatment of anandrogen-mediated disease, and the disease includes, but is not limitedto, cell proliferative diseases (e.g., cancer).

In yet a further aspect, the present application relates to the compoundof Formula (I), Formula (II), Formula (III-1), Formula (III-2), Formula(III-21), Formula (III-22), Formula (IV), Formula (V), Formula (VI),Formula (VI-1), or Formula (VII), or a pharmaceutically acceptable saltthereof, or the pharmaceutical composition thereof for use in preventingor treating an androgen-mediated disease, and the disease includes, butis not limited to, cell proliferative diseases (e.g., cancer).

Definitions

Unless specified otherwise, the following terms used herein have thefollowing meanings. If a particular term is not specifically defined, itcannot be considered to be indefinite or unclear, and shall beunderstood according to the ordinary meaning in the art. Where a tradename is cited herein, it is intended to indicate the correspondingproduct or its active ingredient.

The term “substituted” means that any one or more hydrogen atoms on aspecific atom are replaced by substituents, as long as the valence ofthe specific atom is normal and the substituted compound is stable. Whenthe substituent is oxo or keto (i.e., ═O), it means that two hydrogenatoms are substituted.

The term “optional” or “optionally” is intended to mean that thesubsequently described event or circumstance may or may not occur, andthat the description includes instances where said event or circumstanceoccurs and instances where said event or circumstance does not occur.For example, when ethyl is “optionally” substituted with fluoro orchloro, it is intended to mean that the ethyl may be unsubstituted(e.g., —CH₂CH₃), monosubstituted (e.g., —CH₂CH₂F, —CHFCH₃),polysubstituted (e.g., —CHFCH₂F, —CHClCH₂F, —CH₂CHCl₂, —CH₂CHF₂ and thelike), or completely substituted (—CFClCF₃, —CF₂CF₃). It will beunderstood by those skilled in the art, with respect to any groupscontaining one or more substituents, that such groups are not intendedto introduce any substitutions or substitution patterns which aresterically impractical and/or synthetically non-feasible. Unlessotherwise specified, the kinds and numbers of substituents may bearbitrary on the basis that they are chemically achievable.

When a substituent may be connected to more than one atom on a ring,such a substituent may be bound to any atom on the ring, for example,the structural unit

includes

but does not include

“C_(m-n)” as used herein means that this moiety has an integer number ofcarbon atoms in the given range. For example, “C₁₋₆” means that thegroup may have 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbonatoms, 5 carbon atoms, or 6 carbon atoms; and “C₃₋₆” means that thegroup may have 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6carbon atoms.

When any variable (e.g., R⁷) occurs in the composition or structure of acompound more than once, the variable at each occurrence is independentdefined. Therefore, for example, (R⁷)_(m) represents a group substitutedby m R⁷, and each R⁷ has independent options; and specifically, forexample, when m=2, one group is substituted by 2 R⁷, and each R⁷ hasindependent options.

The term “halo” or “halogen” refers to fluoro, chloro, bromo, and iodo.

The term “hydroxyl” refers to —OH group.

The term “amino” refers to —NH₂ group.

The term “trifluoromethyl” refers to —CF₃ group.

The term “alkyl” refers to a hydrocarbyl having a general formulaC_(n)H_(2n+1). The alkyl may be straight or branched. For example, theterm “C₁₋₆ alkyl”” refers to an alkyl containing 1 to 6 carbon atoms(e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl,tert-butyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl,neopentyl, hexyl, 2-methylpentyl and the like). Similarly, the alkylmoiety (i.e., an alkyl) of an alkoxy has the same definition as above;and the term “C₁₋₃ alkyl” refers to an alkyl containing 1 to 3 carbonatoms (e.g., methyl, ethyl, n-propyl, or isopropyl).

The term “alkoxy” refers to —O-alkyl.

The term “alkylamino” refers to —NH-alkyl.

The term “alkylaminocarbonyl” refers to —C(═O)—NH-alkyl.

The term “alkenyl” refers to a straight or branched unsaturatedaliphatic hydrocarbonyl consisting of carbon atoms and hydrogen atomsand having at least one double bond. Non-limiting examples of thealkenyl include, but are not limited to, ethenyl, 1-propenyl,2-propenyl, 1-butenyl, isobutenyl, 1,3-butadienyl, and the like. Forexample, the term “C₂₋₆ alkenyl” refers to an alkenyl containing 2 to 6carbon atoms; and the term “C₂-C₃ alkenyl” refers to an alkenylcontaining 2 to 3 carbon atoms (e.g., ethenyl, 1-propenyl, or2-propenyl).

The term “alkynyl” refers to a straight or branched unsaturatedaliphatic hydrocarbonyl consisting of carbon atoms and hydrogen atomsand having at least one triple bond. Non-limiting examples of thealkynyl include, but are not limited to, ethynyl (—C≡CH), 1-propynyl(—C≡C—CH₃), 2-propynyl (—CH₂—C≡CH), 1,3-butadiynyl (—C≡CC≡CH), and thelike.

The term “cycloalkyl” refers to a fully saturated carbon ring that mayexist as a monocyclic ring, a bridged ring, or a spiro ring. Unlessotherwise specified, the carbon ring is usually a 3- to 10-memberedring. Non-limiting examples of the cycloalkyl include, but are notlimited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl(bicyclo[2.2.1]heptyl), bicyclo[2.2.2]octyl, adamantyl, and the like.The cycloalkyl is preferably a monocyclic cycloalkyl having 3 to 6 ringatoms.

The term “heterocycloalkyl” refers to a fully saturated cyclic groupthat may exist as a monocyclic ring, a bicyclic ring, or a spiro ring.Unless otherwise indicated, the heterocyclic ring is usually a 3- to7-membered ring containing 1 to 3 heteroatoms (preferably 1 or 2heteroatoms) independently selected from the group consisting of sulfur,oxygen, and/or nitrogen. Examples of a 3-membered heterocycloalkylinclude, but are not limited to, epoxyethyl, cyclothioethyl, andazirdinyl; non-limiting examples of a 4-membered heterocycloalkylinclude, but are not limited to, azetidinyl, oxetanyl, and thietanyl;examples of a 5-membered heterocycloalkyl include, but are not limitedto, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, isooxazolidinyl,oxazolidinyl, isothiazolidinyl, thiazolidinyl, imidazolidinyl,tetrahydropyrazolyl, and pyrrolinyl; examples of a 6-memberedheterocycloalkyl include, but are not limited to, piperidinyl,tetrahydropyranyl, tetrahydrothiopyranyl, morpholinyl, piperazinyl,1,4-thioxanyl, 1,4-dioxanyl, thiomorpholinyl, 1,2-dithioalkyl,1,4-dithioalkyl, and tetrahydropyranyl; and examples of a 7-memberedheterocycloalkyl include, but are not limited to, azacycloheptyl,oxacycloheptyl, and thiacycloheptyl. The heterocycloalkyl is preferablya monocyclic heterocycloalkyl having 5 to 6 ring atoms.

The term “heteroaryl” refers to a monocyclic or fused polycyclic ringsystem containing at least one ring atom selected from the groupconsisting of N, O, and S, the other ring atoms being C, and having atleast one aromatic ring. A preferable heteroaryl has a single 4- to8-membered ring, and particularly a 5- to 8-membered ring, or aplurality of fused rings containing 6 to 14, and particularly 6 to 10,ring atoms. Non-limiting examples of the heteroaryl include, but are notlimited to, pyrrolyl, furanyl, thienyl, imidazolyl, oxazolyl, pyrazolyl,pyridinyl, pyrimidinyl, pyrazinyl, quinolyl, isoquinolyl, tetrazolyl,triazolyl, triazinyl, benzofuranyl, benzothienyl, indolyl, isoindolyl,and the like.

The “—C₁₋₁₂ alkyl-(3- to 10-membered cycloalkyl)” herein represents aC₁₋₁₂ alkyl substituted by a 3- to 10-membered cycloalkyl, and othersimilar expressions should be understood similarly.

Herein, the “—C₁₋₁₂ alkyl-(3- to 10-membered cycloalkyl) optionallysubstituted by halogen or hydroxyl” means that any hydrogen atom of the—C₁₋₁₂ alkyl-(3- to 10-membered cycloalkyl) may be substituted byhalogen or hydroxyl, and other similar expressions should be understoodsimilarly.

The structural unit

represents a benzoheterocyclic ring system. The bond “

” correspondingly represents a single bond or a double bond according toa specific option of X⁵, X⁶, X⁷, X⁸, X⁹, X¹⁰, X¹¹, Y⁸, Y⁹, Y¹⁰, or Y¹¹in the present application, and will not violate the valence bondtheory. For example, when X⁵ is CH, X⁶ is N (—R^(a)), and X⁷ is N, thestructural unit

For example, when X⁵ is CH, X⁶ is N, and X⁷ is N(—R^(a)), the structuralunit

For example, when X⁸ is N, X⁹ is CH, X¹⁰ is NH, and X¹¹ is C(═O), thestructural unit

For example, when Y⁸ is N, Y⁹ is CH, Y¹⁰ is N, and Y¹¹ is CH, thestructural unit

The structural unit

represents a pyridinoheterocyclic ring system. The bond “

” correspondingly represents a single bond or a double bond according toa specific option of Z⁸, Z⁹, Z¹⁰, or Z¹¹ in the present application, andwill not violate the valence bond theory.

Unless otherwise indicated, a wedge-shaped bond and a dotted bond (

) denote an absolute configuration of a stereocenter, while a wavy line

denotes one of the absolute configurations of a stereocenter (e.g., oneof

or

), and

and

denote a relative configuration of a stereocenter. When the compounds ofthe present application contain olefinic double bonds or othergeometrically asymmetric centers, they include E and Z geometricisomers, unless otherwise specified. Likewise, all tautomeric forms areincluded within the scope of the present application.

The compounds of the present application may exist in specificgeometrical isomers or stereoisomeric forms. All such compounds arecontemplated in the present application, including tautomers, cis- andtrans-isomers, (−)- and (+)-enantiomers, (R)- and (S)-enantiomers,diastereomers, (D)-isomers, (L)-isomers, and their racemic mixtures andother mixtures, such as enantiomer or diastereomer enriched mixtures.All such mixtures are included in the scope of the present application.Substituents such as an alkyl group may have additional unsymmetricalcarbon atoms. All such isomers and mixtures thereof are included withinthe scope of the present application.

The term “treating” or “treatment” means administering the compounds orpreparations according to the present application to prevent,ameliorate, or eliminate a disease or one or more symptoms associatedwith the disease, and includes:

-   -   (i) preventing the occurrence of a disease or condition in a        mammal, particularly when such an mammal is susceptible to the        condition, but has not yet been diagnosed as having the        condition;    -   (ii) inhibiting a disease or condition, i.e., arresting its        development; and    -   (iii) alleviating a disease or condition, i.e., causing        regression of the disease or condition.

The term “therapeutically effective amount” is intended to refer to anamount of the compound of the present application for (i) treating orpreventing a particular disease, condition, or disorder, (ii) relieving,ameliorating, or eliminating one or more symptoms of the particulardisease, condition, or disorder, or (iii) preventing or delaying onsetof one or more symptoms of the particular disease, condition, ordisorder described herein. The amount of the compound of the presentapplication constituting the “therapeutically effective amount” willvary depending on the compound, the disease condition and its severity,the administration method, and the age of the mammal to be treated, butmay be routinely determined by those skilled in the art based on theirown knowledge and the present disclosure.

The term “pharmaceutically acceptable” refers to those compounds,materials, compositions and/or dosage forms that are, within the scopeof sound medical judgment, suitable for use in contact with the tissuesof human being and animals without excessive toxicity, irritation,allergic response or other problems or complications, commensurate witha reasonable benefit/risk ratio.

As the pharmaceutically acceptable salts, for example, metal salts,ammonium salts, salts of organic bases, salts of inorganic acids, saltsof organic acids, salts of alkaline or acidic amino acids may bementioned.

The term “pharmaceutical composition” refers to a mixture of one or moreof the compounds or salts thereof of the present application and apharmaceutically acceptable excipient. An object of the pharmaceuticalcomposition is to facilitate administering the compound of the presentapplication to an organism.

The term “pharmaceutically acceptable excipient” refer to the excipientsthat neither have obvious irritation effects on an organism, nor willimpair the bioactivity and properties of the active compound.Appropriate excipients are well known to those skilled in the art, suchas carbohydrates, waxes, water-soluble and/or water-swellable polymers,hydrophilic or hydrophobic materials, gelatin, oils, solvents, water andthe like.

The wording “comprise” and English variations thereof (such as“comprises” and “comprising”) should be understood as open andnon-exclusive meanings, i.e. “include but not limited to”.

The intermediates and compounds according to the present application mayalso exist in the form of different tautomers, and all such forms areincluded in the scope of the present application. The term “tautomer” or“tautomeric form” refers to structural isomers of different energieswhich are interconvertible via a low energy barrier. For example, protontautomers (also known as prototropic tautomers) include interconversionsvia migration of a proton, such as keto-enol and imine-enamineisomerizations. A specific example of proton tautomers is an imidazolemoiety, wherein a proton can migrate between the two nitrogen atoms ofthe ring. Valence tautomers include interconversions by reorganizationof some of the bond-forming electrons.

The present application also includes isotopically-labeled compounds ofthe present application that are identical to those described herein,but in which one or more atoms are replaced with atoms having an atomicweight or mass number different from that normally found in nature.Examples of the isotopes that can be incorporated into the compounds ofthe present application include isotopes of hydrogen, carbon, nitrogen,oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine. For example,the isotopes are ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹³N, ¹⁵N, ¹⁵O, ¹⁷O, ¹⁸O, ³¹P,³²P, ³⁵S, ¹⁸F, ¹²³I, ¹²⁵I, and ³⁶Cl, respectively.

Certain isotopically-labeled compounds of the present application (e.g.,those labeled with ³H and ¹⁴C) can be used in compound and/or substratetissue distribution assays. Tritium (i.e., ³H) and carbon-14 (i.e., ¹⁴C)isotopes are particularly preferred due to their ease of preparation anddetectability. Positron emitting isotopes, such as ¹⁵O, ¹³N, ¹¹C, and¹⁸F, can be used in Positron Emission Topography (PET) studies todetermine substrate occupancy. Isotopically-labeled compounds of thepresent application can generally be prepared by the procedures similarto those disclosed in the schemes and/or examples below, by replacingnon-isotopically-labeled reagents with isotopically-labeled reagents.

Furthermore, the substitution with heavier isotopes (such as deuterium,i.e. ²H) may afford certain therapeutic advantages resulting fromgreater metabolic stability, for example, increased in vivo half-life orreduced dosage requirements, and thus may be preferable in somecircumstances, wherein the deuterium substitution may be partial orcomplete, and the partial deuterium substitution means that at least onehydrogen is substituted with at least one deuterium.

The compounds of the present application may be asymmetric, for example,having one or more stereoisomers. Unless otherwise stated, all thestereoisomers are included, such as enantiomers and diastereoisomers.The compounds containing asymmetric carbon atoms of the presentapplication can be isolated in optically active pure forms or racemicforms. Optically active pure forms can be resolved from racemic mixturesor synthesized by using chiral starting materials or chiral reagents.

The pharmaceutical composition of the present application can beprepared by combining the compound of the present application with asuitable pharmaceutically acceptable excipient, and for example, it canbe formulated into solid, semi-solid, liquid or gaseous preparations,such as tablets, pills, capsules, powders, granules, ointments,emulsions, suspensions, suppositories, injections, inhalants, gels,microparticles, aerosols and the like.

Typical routes for administering the compound or a pharmaceuticallyacceptable salt thereof, or the pharmaceutical composition thereof ofthe present application include, but are not limited to, oral, rectal,topical, inhalational, parenteral, sublingual, intravaginal, intranasal,intraocular, intraperitoneal, intramuscular, subcutaneous, andintravenous administration.

The pharmaceutical composition of the present application can bemanufactured by using well-known methods in the art, such as aconventional mixing method, a dissolution method, a granulation method,a method for preparing sugar-coated pills, a grinding method, aemulsification method, lyophilization and the like.

In some embodiments, the pharmaceutical composition is in an oral form.For the oral administration, the pharmaceutical composition can beformulated by mixing an active compound with a pharmaceuticallyacceptable excipient well known in the art. These excipients enable thecompound of the present application to be formulated into tablets,pills, pastilles, dragees, capsules, liquids, gels, slurries,suspensions, and the like, for oral administration to a patient.

A solid oral composition can be prepared by conventional mixing, fillingor tableting methods. For example, it can be obtained by the followingmethod: mixing the active compound with a solid excipient, optionallygrinding the resulting mixture, adding other suitable excipients, ifnecessary, and then processing the mixture into granules to obtain acore of a tablet or a dragee. Suitable excipients include, but are notlimited to: binders, diluents, disintegrants, lubricants, glidants,sweeteners, or flavoring agents.

The pharmaceutical composition may also be suitable for parenteraladministration, such as sterile solutions, suspensions or lyophilizedproducts in suitable unit dosage forms.

In all the administration methods for the compounds of Formula (I),Formula (II), Formula (III-1), Formula (III-2), Formula (III-21),Formula (III-22), Formula (IV), Formula (V), Formula (VI), Formula(VI-1), or Formula (VII) according to the present application, the dailydose is 0.01 to 200 mg/kg body weight, in the form of separate ordivided doses.

The compounds of the present application can be prepared by a variety ofsynthetic methods well known to those skilled in the art, including thespecific embodiments listed below, the embodiments obtained by combiningthe specific embodiments listed below with other chemical synthesismethods, and equivalents well known to those skilled in the art. Thepreferred embodiments include, but are not limited to, the examples ofthe present application.

The chemical reactions in the specific embodiments of the presentapplication are carried out in suitable solvents which are suitable forthe chemical changes of the present application and the requiredreagents and materials thereof. In order to obtain the compounds of thepresent application, it is sometimes necessary for those skilled in theart to modify or select the synthetic steps or reaction schemes based onthe existing embodiments.

It is one important consideration factor for planning a synthesis schemein the art to select appropriate protecting groups for the reactivefunctional groups (such as the hydroxyl group in the presentapplication). For example, reference may be made to Greene's ProtectiveGroups in Organic Synthesis (4th Ed). Hoboken, New Jersey: John Wiley &Sons, Inc. All references cited in the present application areincorporated herein by reference in their entirety.

In some embodiments, the compounds of Formula (I) of the presentapplication may be prepared by those skilled in the field of organicsynthesis through the following steps and routes:

Intermediate Synthesis (I):

Step 1:

Step 2:

Scheme I of Step 3:

Scheme II of Step 3:

Scheme III of Step 3:

Scheme IV of Step 3:

Intermediate Synthesis (II):Step 1:

Scheme I of Step 2:

Scheme II of Step 2:

Preparation for the Target Compound (I)Route I:

Route II:

Route III:

Route IV:

Route V:

Preparation for the Target Compound (II)Route I:

Route II:

In the above routes,

-   -   each R⁷¹ is independently selected from the group consisting of        hydroxyl and 5- to 10-membered heteroaryl, and the hydroxyl is        optionally substituted by: —C₁₋₁₂ alkyl-(3- to 10-membered        heterocycloalkyl), —C₁₋₁₂ alkyl-S(═O)₂R^(c), —C₁₋₁₂        alkyl-NR^(d)R^(e), —C₁₋₁₂ alkyl-C(═O)NR^(f)R^(g), —C₁₋₁₂        alkyl-(3- to 10-membered cycloalkyl) optionally substituted by        halogen or hydroxyl, or 3- to 10-membered heterocycloalkyl        optionally substituted by halogen or hydroxyl; or each R⁷¹ is        independently selected from hydroxyl, and the hydroxyl is        optionally substituted by: heterocycloalkyl, -alkyl-S(═O)₂R^(c),        or -alkyl-NR^(d)R^(e), wherein R^(c), R^(d) and R^(e) are as        defined in the present application; and    -   R¹⁰ is selected from the group consisting of R⁷² and H, and j,        T, R¹, R⁵, R⁹, and R⁷² are as defined in the present        application.

The following abbreviations are used in the present application:

DMF represents N,N-dimethylformamide, DMSO represents dimethylsulfoxide, LCMS represents liquid chromatography-mass spectrometry, TLCrepresents thin layer chromatography, HPLC represents high performanceliquid chromatography, Boc represents tert-butoxycarbonyl, TMSCHN₂represents trimethylsilyldiazomethane, TMSCN represents trimethylsilylcyanide, diBoc represents di-tert-butyl dicarbonate, NBS representsN-bromosuccinimide, CDI represents 1,1′-carbonyldiimidazole, Boc-NH₂represents tert-butyl carbamate, Boc₂O represents di-tert-butyldicarbonate, EDTA-K2 represents dipotassium ethylenediaminetetraacetate, DAST represents diethylaminosulfur trifluoride, NMPrepresents 1-methyl-2-pyrrolidone, CMC represents carboxymethylcellulose, HATU represents2-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate; v/v represents a volume ratio; RLU represents arelative luminous intensity; Solutol represents polyethylene glycol-15hydroxystearate; PEG400 represents polyethylene glycol 400; POrepresents oral administation; QD represents the frequency ofadministration; PMB represents p-methoxybenzyl; and DPPF represents1,1′-bis(diphenylphosphino)ferrocene.

Detailed Description of Embodiments

The present application will be described below in detail in conjunctionwith examples, but it is not intended to impose any unfavorablelimitation to the present invention. The present application has beendescribed in detail herein, and specific embodiments thereof are alsodisclosed. It will be apparent for those skilled in the art to makevarious modifications and improvements of the specific embodiments ofthe present application without departing from the spirit and scope ofthe present application. All solvents used in the present applicationare commercially available, and can be used without furtherpurification. The starting compound materials used for synthesis in thepresent application are commercially available, or may be prepared bymethods in the prior art.

The nuclear magnetic resonance chromatography (NMR) in the presentapplication is determined by using BRUKER 400 nuclear magnetic resonancespectrometer with tetramethylsilane (TMS=δ 0.00) as the internalstandard of the chemical shift. The nuclear magnetic resonance hydrogenspectrum data are recorded in the format of peak pattern (s: singlet; d:doublet; t: triplet; q: quartet; m: multiplet), coupling constant (unit:Hertz Hz), and the number of protons. SHIMADUZU LCMS-2010 is used as theinstrument for mass spectrometry.

Example 1 Synthesis of Compound 1

1) Synthesis of Compound 1-2

0.5 mL of dichlorosulfoxide was added dropwise to a solution of Compound1-1 (300 mg, 1.33 mmol) in 5 mL of DMF. The reaction mixture was heatedto 80° C., and stirred at this temperature for 6 h. The reaction mixturewas spin-dried under reduced pressure. The resulting solid was dissolvedin 30 mL of ethyl acetate, washed with 20 mL of water and 20 mL ofsaturated brine respectively, dried over anhydrous sodium sulfate,filtered, and concentrated, to obtain Compound 1-2. LCMS (ESI) m/z: 245(M+3).

2) Synthesis of Compound 1-3

In a microwave tube, Compound 1-2 (150 mg, 616.04 μmol) and a solutionof methylamine in ethanol (750 μL, 20-30% purity) were dissolved intert-butanol (4 mL). The reaction mixture was kept at 90° C. formicrowave reaction for 0.5 h, and then concentrated under reducedpressure. The resulting residue was dissolved in 20 mL of ethyl acetate,washed with 10 mL of water and 20 mL of saturated brine respectively,dried over anhydrous sodium sulfate, filtered, and concentrated, toobtain Compound 1-3. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.45 (s, 1H), 7.85(d, J=3.2 Hz, 2H), 7.67 (s, 1H), 3.07 (s, 3H); LCMS (ESI) m/z: 240(M+3).

3) Synthesis of Compound 1-5

In a microwave tube, Compound 1-3 (250 mg, 961.86 μmol), Compound 1-4(149 mg, 1.44 mmol), potassium carbonate (332 mg, 2.40 mmol), cuprouschloride (19 mg, 192.37 μmol) and 2-acetylcyclohexanone (27 mg, 192.37μmol) were dissolved in a mixed solution of DMF (5 mL) and water (0.5mL), and the resulting mixture was kept at 130° C. for microwavereaction for 1.5 h. The reaction mixture was cooled, and then filtered.12 mL of water was added to the filtrate, and the resulting mixture wasthen extracted with ethyl acetate (20 mL×3), and the aqueous phase wasconcentrated under reduced pressure to obtain Compound 1-5. LCMS (ESI)m/z: 261 (M+1).

4) Synthesis of Compound 1-6

Dichlorosulfoxide (500 μL) was added dropwise to a solution of Compound1-5 (300 mg, 1.15 mmol) in methanol (4 mL) in an ice bath. Then, theresulting mixture was heated to 26° C., and stirred at this temperaturefor 6 h. The reaction mixture was concentrated under reduced pressure,and 10 mL of water was added to the residue. The resulting mixture wasextracted with ethyl acetate (15 mL×3), and the aqueous phase wasadjusted to pH=10 with a saturated sodium bicarbonate solution. A brownsolid precipitated, and was filtered. The filter cake was collected toobtain Compound 1-6. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.22 (s, 1H),7.80-7.78 (dd, J=4.4, 8.8 Hz, 2H), 6.78-6.76 (d, J=9.2 Hz, 1H), 6.71 (s,1H), 6.25 (s, 1H), 3.59 (s, 3H), 2.91 (s, 3H), 1.49 (s, 6H).

5) Synthesis of Compound 1

Compound 1-6 (150 mg, 546.81 μmol) and Compound 1-7 (250 mg, 1.09 mmol)were dissolved in a mixed solution of DMF (500 μL) and methylbenzene (2mL), and the resulting mixture was heated to 90° C., and stirred at thistemperature in a nitrogen atmosphere for 48 h. 3 mL of methanol wasadded dropwise to the reaction mixture, and the resulting mixture wasstirred at room temperature for 0.5 h. Then, the reaction mixture wasspin-dried under reduced pressure. The resulting solid was dissolved in15 mL of ethyl acetate, then washed with 15 mL of water and 30 mL ofsaturated brine respectively, dried over anhydrous sodium sulfate,filtered, and spin-dried. The crude product was purified by apreparative TLC plate and preparative HPLC method to obtain Compound 1.¹H NMR (400 MHz, CDCl₃) δ ppm 8.76 (s, 1H), 8.02 (d, J=8 Hz, 2H),7.83-7.91 (m, 3H), 7.44 (dd, J=2, 2.2 Hz, 1H), 5.89 (d, J=4.4 Hz, 1H),3.27 (d, J=4.8 Hz, 3H), 1.70 (s, 6H); LCMS (ESI) m/z: 471 (M+1).

Example 2 Synthesis of Compound 2

1) Synthesis of Compound 2-2

Dichlorosulfoxide (1.96 g, 16.44 mmol) was added dropwise to a solutionof Compound 2-1 (850 mg, 5.48 mmol) in methanol (10 mL) at 0° C. Afterthe completion of the dropwise addition, the resulting mixture wasstirred at 25° C. for 12 h. The reaction mixture was concentrated, andthe resulting residue was basified with a saturated sodium bicarbonatesolution (30 mL), and extracted with dichloromethane (20 mL×2). Thecombined organic phase was washed with water (50 mL), dried overanhydrous sodium sulfate, filtered, and concentrated to obtain Compound2-2. LCMS (ESI) m/z: 170 (M+1).

2) Synthesis of Compound 2-4

Compound 2-2 (300 mg, 1.77 mmol), Compound 2-3 (637 mg, 2.66 mmol),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (103 mg, 177.36 μmol),bis(dibenzylideneacetone) palladium (102 mg, 177.36 μmol), and cesiumcarbonate (1.16 g, 3.55 mmol) were added to a microwave tube filled withmethylbenzene (5 mL). Then, the resulting mixture was kept at 120° C.for microwave reaction for 2 h. The reaction mixture was diluted withdichloromethane (5 mL), and filtered. The filtrate was concentrated. Theresulting crude product was purified by a chromatographic column toobtain Compound 2-4. LCMS (ESI) m/z: 281 (M+1).

3) Synthesis of Compound 2-6

Compound 2-4 (200 mg, 712.56 μmol), Compound 2-5 (159 mg, 855.07 μmol),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (41 mg, 71.26 μmol),cesium carbonate (464 mg, 1.43 mmol), andbis(dibenzylideneacetone)palladium (41 mg, 71.26 μmol) were added to amicrowave tube filled with methylbenzene (5 mL). Then, the resultingmixture was kept at 120° C. for microwave reaction for 2 h. The reactionmixture was diluted with dichloromethane (20 mL), and filtered. Thefiltrate was concentrated. The resulting crude product was purified by apreparative chromatoplate to obtain Compound 2-6. LCMS (ESI) m/z: 431(M+1).

4) Synthesis of Compound 2-7

Thiophosgene (107 mg, 929.48 μmol) was added dropwise to a solution ofCompound 2-6 (200 mg, 464.74 μmol) and sodium tert-butoxide (223 mg,2.32 mmol) in tetrahydrofuran (2 mL) at 0° C. After the completion ofthe dropwise addition, the resulting mixture was stirred at 60° C. for12 h. The reaction mixture was cooled to 20° C. and then water (10 mL)was added to quench the reaction. The resulting mixture was diluted withdichloromethane (10 mL), and extracted with dichloromethane (10 mL×2).The combined organic phase was washed with saturated brine (20 mL),dried over anhydrous sodium sulfate, filtered, and concentrated. Theresulting crude product was purified by a preparative chromatoplate toobtain Compound 2-7. LCMS (ESI) m/z: 473 (M+1).

5) Synthesis of Compound 2-8

An aqueous solution of lithium hydroxide (1 M, 1 mL) was added dropwiseto a solution of Compound 2-7 (40 mg, 84.67 μmol) in tetrahydrofuran (4mL) at room temperature (20° C.). After the completion of the dropwiseaddition, the resulting mixture was heated to 80° C., and stirred for 2h. The reaction mixture was acidified to pH=5-6 with 1M dilutehydrochloric acid, and extracted with dichloromethane (10 mL×3). Thecombined organic phase was washed with saturated brine (20 mL), driedover anhydrous sodium sulfate, filtered, and concentrated to obtainCompound 2-8. LCMS (ESI) m/z: 459 (M+1).

6) Synthesis of Compound 2

At room temperature (20° C.), methylamine hydrochloride (5 mg, 78.54μmol), triethylamine (20 mg, 196.35 μmol), andO-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (30 mg, 78.54 μmol) were added to a solution ofCompound 2-8 (30 mg, 65.45 μmol) in dichloromethane (2 mL). Theresulting mixture was stirred at 20° C. for 1 h. Water (10 mL) was addedto the reaction mixture, and then the resulting mixture was diluted withdichloromethane (10 mL), and extracted with dichloromethane (10 mL×2).The combined organic phase was washed with saturated brine (20 mL),dried over anhydrous sodium sulfate, filtered, and concentrated. Theresulting crude product was purified by a preparative TLC plate andpreparative HPLC method to obtain Compound 2. ¹H NMR (400 MHz, CDCl₃) δppm 8.40-8.38 (m, 1H), 8.27-8.24 (m, 2H), 8.18-8.16 (m, 1H), 8.10-8.09(m, 1H), 7.53-7.49 (m, 2H), 7.38-7.36 (m, 1H), 7.28-7.27 (m, 1H), 3.11(d, J=4.8 Hz, 3H); LCMS (ESI) m/z: 472 (M+1).

Example 3 Synthesis of Compound 3

1) Synthesis of Compound 3-2

Zinc powder (3.98 g, 60.84 mmol) and ammonium chloride (3.25 g, 60.84mmol) were added to a solution of Compound 3-1 (2.10 g, 12.17 mmol) inmethanol (20 mL) and dichloromethane (10 mL). The resulting reactionmixture was stirred at 15° C. for 24 h. The reaction mixture wasfiltered, and the filter cake was washed with dichlorometahne (40 mL).The resulting filtrate was concentrated under reduced pressure to obtainCompound 3-2. LCMS (ESI) m/z: 143 (M+1).

2) Synthesis of Compound 3-3

Dichlorosulfoxide (13.12 g, 110.31 mmol) was added to a solution ofCompound 3-9 (4.00 g, 18.26 mmol) in anhydrous methanol (40 mL) at 0° C.The resulting reaction mixture was stirred at 15° C. for 16 h. Thereaction mixture was concentrated under reduced pressure, and theresidue obtained from the concentration was purified by a silica gelcolumn to obtain Compound 3-3.

3) Synthesis of Compound 3-4

A mixture of Compound 3-3 (1.08 g, 4.63 mmol), Compound 3-2 (600 mg,4.21 mmol), bis(dibenzylideneacetone)palladium (242 mg, 420.79 μmol),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (244 mg, 420.79 μmol),cesium carbonate (2.74 g, 8.42 mmol), and methylbenzene (15 mL) wasadded to a microwave tube. The microwave tube was sealed, and thenheated to 130° C. for microwave reaction for 2 h. The reaction mixturewas filtered and concentrated under reduced pressure. The residueobtained from the concentration was purified by a silica gel column toobtain Compound 3-4. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.23 (d, J=5.0 Hz,1H), 7.85 (t, J=8.4 Hz, 1H), 7.22 (d, J=5.0 Hz, 1H), 6.42 (dd, J=2.3,8.5 Hz, 1H), 6.21 (dd, J=2.3, 12.8 Hz, 1H), 5.94 (s, 1H), 3.90 (s, 3H),2.28 (s, 3H); LCMS (ESI) m/z: 295 (M+1).

4) Synthesis of Compound 3-5

Compound 3-4 (500 mg, 1.70 mmol), Compound 2-5 (348 mg, 1.87 mmol),bis(dibenzylideneacetone)palladium (98 mg, 170.00 μmol),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (98 mg, 170.00 μmol),cesium carbonate (1.11 g, 3.40 mmol), and methylbenzene (8 mL) wereadded to a microwave tube. The microwave tube was sealed, and thenheated to 130° C. for microwave reaction for 2 h. The reaction mixturewas filtered and concentrated under reduced pressure. The residueobtained from the concentration was purified by a silica gel column toobtain Compound 3-5. LCMS (ESI) m/z: 445 (M+1).

5) Synthesis of Compound 3-6

Potassium tert-butoxide (216 mg, 2.25 mmol) and thiophosgene (104 mg,900.12 μmol) were added to a solution of Compound 3-5 (100 mg, 225.03μmol) in tetrahydrofuran (2 mL) and methylbenzene (2 mL). The resultingreaction mixture was heated to 100° C., and stirred for 16 h. Ethylacetate (20 mL) and water (20 mL) were added to the reaction mixture forliquid separation. The organic phase was washed with saturated brine (20mL), dried over anhydrous sodium sulfate, filtered, and concentratedunder reduced pressure. The residue obtained from the concentration waspurified by a preparative TLC plate to obtain Compound 3-6. ¹H NMR (400MHz, CDCl₃) δ ppm 8.27 (d, J=1.5 Hz, 1H), 8.21 (t, J=7.9 Hz, 1H),8.17-8.10 (m, 2H), 8.09-8.04 (m, 1H), 7.43-7.32 (m, 2H), 7.02 (d, J=5.0Hz, 1H), 4.01 (s, 3H), 1.98 (s, 3H); LCMS (ESI) m/z: 487 (M+1)

6) Synthesis of Compound 3-7

Lithium hydroxide (9 mg, 205.58 μmol) was added to a solution ofCompound 3-6 (50 mg, 102.79 μmol) in tetrahydrofuran (1.2 mL) and water(0.3 mL). The resulting reaction mixture was stirred at 5° C. for 16 h.1M hydrochloric acid solution (10 mL) and ethyl acetate (20 mL) wereadded to the reaction mixture for liquid separation. The organic phasewas washed with saturated brine (15 mL), dried over anhydrous sodiumsulfate, filtered, and concentrated under reduced pressure to obtain thetarget compound 3-7. LCMS (ESI) m/z: 473 (M+1). 7) Synthesis of Compound3

O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (39 mg, 101.60 μmol), triethylamine (26 mg, 254.01μmol), and methylamine hydrochloride (9 mg, 127.01 μmol) were added to asolution of Compound 3-7 (40 mg, 84.67 μmol) in dichloromethane (1 mL).The resulting reaction mixture was stirred at 5° C. for 16 h.Dichloromethane (15 mL) and water (10 mL) were added to the reactionmixture for liquid separation. The organic phase was washed withsaturated brine (10 mL), dried over anhydrous sodium sulfate, filtered,and concentrated under reduced pressure. The residue obtained from theconcentration was purified by preparative HPLC to obtain the Compound 3.¹H NMR (400 MHz, CDCl3) δ ppm 8.37 (t, J=8.3 Hz, 1H), 8.27 (s, 1H),8.18-8.10 (m, 2H), 8.10-8.04 (m, 1H), 7.45-7.33 (m, 2H), 7.01 (d, J=5.0Hz, 1H), 6.76 (br s, 1H), 3.10 (d, J=4.5 Hz, 3H), 1.97 (s, 3H); LCMS(ESI) m/z: 486 (M+1).

Example 4 Synthesis of Compound 4

1) Synthesis of Compound 4-2

Triethylamine (1.34 g, 13.22 mmol) and hydroxylamine hydrochloride (918mg, 13.22 mmol) were added to a solution of Compound 4-1 (2.00 g, 8.81mmol) in methanol (30 mL). The resulting reaction mixture was stirred at10° C. for 16 h, heated to 30° C. and stirred for 16 h. The reactionmixture was concentrated under reduced pressure, and then ethyl acetate(50 mL) and water (40 mL) were added. The organic phase was washed withsaturated brine (40 mL), dried over anhydrous sodium sulfate, andconcentrated under reduced pressure to obtain Compound 4-2. LCMS (ESI)m/z: 242 (M+1).

2) Synthesis of Compound 4-3

A mixture of Compound 4-2 (2.00 g, 8.26 mmol) and polyphosphoric acid(20 mL) was heated to 95° C. and stirred for 3 h. 150 mL of water wasadded to the reaction mixture, and then the resulting mixture wasstirred for 30 min, and extracted with ethyl acetate (100 mL×3). Theorganic phase was washed with saturated brine (150 mL), dried overanhydrous sodium sulfate, and concentrated under reduced pressure. Theresidue obtained from the concentration was purified by a preparativeTLC plate to obtain Compound 4-3. LCMS (ESI) m/z: 242 (M+1). 3)Synthesis of Compound 4-4

60% Sodium hydride (50 mg, 1.25 mmol) was added to a solution ofCompound 4-3 (200 mg, 826.21 μmol) in DMF (4 mL), and the resultingmixture was stirred at 10° C. for 10 min. Then, iodoethane (155 mg,993.78 μmol) was added. The resulting reaction mixture was stirred at10° C. for 30 min. The reaction mixture was slowly poured into water (30mL), and extracted with ethyl acetate (20 mL×3). The organic phase waswashed with saturated brine (40 mL), dried over anhydrous sodiumsulfate, and concentrated under reduced pressure. The residue obtainedfrom the concentration was purified by preparative TLC to obtainCompound 4-4. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.70 (d, J=8.3 Hz, 1H), 7.26(dd, J=1.8, 8.3 Hz, 1H), 7.16 (d, J=1.8 Hz, 1H), 4.38 (t, J=5.0 Hz, 2H),3.64 (q, J=7.3 Hz, 2H), 3.50 (t, J=5.0 Hz, 2H), 1.23 (t, J=7.2 Hz, 3H).

4) Synthesis of Compound 4-5

A turbid liquid of Compound 4-4 (100 mg, 370.21 μmol), Compound 1-4 (57mg, 555.32 μmol), cuprous chloride (7 mg, 74.04 μmol),2-acetylcyclohexanone (10 mg, 74.04 μmol), and potassium carbonate (128mg, 925.53 μmol) in DMF (1.5 mL) and water (0.08 mL) was added to amicrowave tube, and kept at 130° C. for microwave reaction for 1 h. Thereaction mixture was filtered through Celite, washed with ethyl acetate(5 mL), and concentrated under reduced pressure. The residue obtainedfrom the concentration was dissolved in water (10 mL), and extractedwith ethyl acetate (5 mL). Concentrated hydrochloric acid (0.5 mL) wasadded to the aqueous phase, and the resulting turbid aqueous solutionwas concentrated under reduced pressure. The residue obtained from theconcentration was slurried with dichloromethane/methanol (10/1, 20 mL),and filtered. The filtrate was concentrated under reduced pressure toobtain Compound 4-5. LCMS (ESI) m/z: 293 (M+1).

5) Synthesis of Compound 4-6

Dichlorosulfoxide (407 mg, 3.42 mmol) was carefully added dropwise(exothermic) to a turbid liquid of Compound 4-5 (100 mg, 342.08 μmol) inmethanol (4 mL). The resulting yellow clear solution was stirred at 40°C. for 16 h. The reaction mixture was concentrated under reducedpressure. The residue obtained from the concentration was purified by apreparative TLC plate to obtain Compound 4-6. LCMS (ESI) m/z: 307 (M+1).

6) Synthesis of Compound 4

Compound 1-7 (186 mg, 816.05 μmol) was added to a solution of Compound4-6 (50 mg, 163.21 μmol) in methylbenzene (1 mL) and DMF (0.02 mL). Theresulting reaction mixture was heated to 100° C., and stirred for 24 h.Methanol (2 mL) was added to the reaction mixture, and the resultingmixture was stirred for 5 min, and then concentrated under reducedpressure. The residue obtained from the concentration was purified by apreparative TLC plate, and then purified by preparative HPLC to obtainCompound 4. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.98 (d, J=8.3 Hz, 1H),7.95-7.84 (m, 2H), 7.77 (dd, J=1.9, 8.2 Hz, 1H), 7.01 (dd, J=2.0, 8.5Hz, 1H), 6.89 (d, J=2.0 Hz, 1H), 4.40 (t, J=4.8 Hz, 2H), 3.62 (q, J=7.2Hz, 2H), 3.56 (t, J=4.9 Hz, 2H), 1.52 (s, 6H), 1.20 (t, J=7.2 Hz, 3H);LCMS (ESI) m/z: 503 (M+1).

Example 5 Synthesis of Compound 5

1) Synthesis of Compound 5-1

Cesium carbonate (869 mg, 2.66 mmol) and 1,1,1-trifluoro-2-iodoethane(933 mg, 4.44 mmol) were added to a solution of Compound 1-1 (500 mg,2.22 mmol) in DMF (10 mL). The resulting reaction mixture was stirred at100° C. for 16 h. The reaction mixture was cooled, and then filtered toremove cesium carbonate. The filtrate was poured into water (40 mL), andextracted with ethyl acetate (30 mL×3). The organic phase was washedwith saturated brine (50 mL), dried over anhydrous sodium sulfate, andconcentrated under reduced pressure. The residue obtained from theconcentration was slurried with petroleum ether/ethyl acetate (10 mL,10/1), and filtered to obtain Compound 5-1. ¹H NMR (400 MHz, CDCl₃) δppm 8.11 (d, J=8.5 Hz, 1H), 7.96 (s, 1H), 7.85 (d, J=1.8 Hz, 1H), 7.60(dd, J=1.8, 8.5 Hz, 1H), 4.59 (q, J=8.4 Hz, 2H).

2) Synthesis of Compound 5-2

A turbid liquid of Compound 5-1 (300 mg, 976.98 μmol), Compound 1-4 (151mg, 1.47 mmol), cuprous chloride (19 mg, 195.40 μmol),2-acetylcyclohexanone (27 mg, 195.40 μmol), and potassium carbonate (338mg, 2.44 mmol) in DMF (3 mL) and water (0.15 mL) was added to amicrowave tube, and kept at 130° C. for microwave reaction for 1 h. Thereaction mixture was filtered through Celite, washed with ethyl acetate(10 mL), and concentrated under reduced pressure. The residue obtainedfrom the concentration was dissolved in water (30 mL), and extractedwith ethyl acetate (5 mL). Concentrated hydrochloric acid (1 mL) wasadded to the aqueous phase, and the resulting turbid aqueous solutionwas concentrated under reduced pressure. The residue obtained from theconcentration was slurried with dichloromethane/methanol (10/1, 20 mL),and filtered. The filtrate was concentrated under reduced pressure toobtain Compound 5-2. LCMS (ESI) m/z: 330 (M+1).

3) Synthesis of Compound 5-3

Dichlorosulfoxide (1.15 g, 9.65 mmol, 0.7 mL) was carefully addeddropwise (exothermic) to a turbid liquid of Compound 5-2 (500 mg, 945.42μmol) in methanol (5 mL). The resulting yellow clear solution wasstirred at 40° C. for 16 h. The reaction mixture was concentrated underreduced pressure. The residue obtained from the concentration waspurified by a preparative TLC plate to obtain Compound 5-3. LCMS (ESI)m/z: 344 (M+1). 4) Synthesis of Compound 5

Compound 1-7 (166 mg, 728.25 μmol) was added to a solution of Compound5-3 (50 mg, 145.65 μmol) in methylbenzene (1 mL) and DMF (0.05 mL). Theresulting reaction mixture was heated to 120° C., and stirred for 48 h.Methanol (2 mL) was added to the reaction mixture, and the resultingmixture was stirred for 5 min, and then concentrated under reducedpressure. The residue obtained from the concentration was purified bypreparative HPLC to obtain Compound 5. ¹H NMR (400 MHz, CDCl₃) δ ppm8.42 (d, J=8.5 Hz, 1H), 8.03 (s, 1H), 7.95-7.89 (m, 2H), 7.79 (dd,J=2.0, 8.3 Hz, 1H), 7.65 (d, J=1.8 Hz, 1H), 7.43 (dd, J=2.0, 8.5 Hz,1H), 4.64 (q, J=8.3 Hz, 2H), 1.58 (s, 6H); LCMS (ESI) m/z: 540 (M+1).

Example 6 Synthesis of Compound 6

1) Synthesis of Compound 6-2

1,1,1-Trifluoro-2-iodoethane (933 mg, 4.44 mmol) was added to a solutionof Compound 6-1 (500 mg, 2.22 mmol) and cesium carbonate (869 mg, 2.66mmol) in DMF (8 mL). The reaction mixture was stirred at 100° C. for 16h. The reaction mixture was cooled, and then filtered to remove cesiumcarbonate. The filtrate was poured into water (10 mL), and extractedwith ethyl acetate (10 mL×3). The organic phase was washed withsaturated brine (15 mL), dried over anhydrous sodium sulfate, andconcentrated under reduced pressure. The residue obtained from theconcentration was slurried with petroleum ether/ethyl acetate (10 mL,10/1), and filtered to obtain Compound 6-2. ¹H NMR (400 MHz, CDCl₃) δppm 8.32 (d, J=8.3 Hz, 1H), 8.14 (s, 1H), 7.95-7.89 (m, 2H), 4.87 (q,J=8.3 Hz, 2H).

2) Synthesis of Compound 6-3

A turbid liquid of Compound 6-2 (300 mg, 976.98 μmol), Compound 1-4 (151mg, 1.47 mmol), cuprous chloride (19 mg, 195.40 μmol),2-acetylcyclohexanone (27 mg, 195.40 μmol), and potassium carbonate (338mg, 2.44 mmol) in DMF (3 mL) and water (0.15 mL) was added to amicrowave tube, and kept at 130° C. for microwave reaction for 1 h. Thereaction mixture was filtered through Celite, washed with ethyl acetate(10 mL), and concentrated under reduced pressure. The residue obtainedfrom the concentration was dissolved in water (10 mL), and extractedwith ethyl acetate (5 mL). Concentrated hydrochloric acid (0.5 mL) wasadded to the aqueous phase, and the resulting turbid aqueous solutionwas concentrated under reduced pressure. The residue obtained from theconcentration was slurried with dichloromethane/methanol (10/1, 40 mL),and filtered. The filtrate was concentrated under reduced pressure toobtain Compound 6-3. LCMS (ESI) m/z: 330 (M+1).

3) Synthesis of Compound 6-4

Dichlorosulfoxide (1.31 g, 11.03 mmol, 0.8 mL) was carefully addeddropwise (exothermic) to a turbid liquid of Compound 6-3 (500 mg, 1.17mmol) in methanol (5 mL). The resulting yellow clear solution wasstirred at 40° C. for 16 h. The reaction mixture was concentrated underreduced pressure. The residue obtained from the concentration waspurified by a preparative TLC plate to obtain Compound 6-4. LCMS (ESI)m/z: 344 (M+1).

4) Synthesis of Compound 6

Compound 1-7 (299 mg, 1.31 mmol) was added to a solution of Compound 6-4(90 mg, 262.16 μmol) in methylbenzene (2 mL) and DMF (0.1 mL). Theresulting reaction mixture was heated to 120° C., and stirred for 48 h.Methanol (2 mL) was added to the reaction mixture, and the resultingmixture was stirred for 5 min, and then concentrated under reducedpressure. The residue obtained from the concentration was purified by apreparative TLC plate, and then purified by preparative HPLC to obtainCompound 6. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.56 (d, J=8.3 Hz, 1H), 8.17(s, 1H), 7.94 (d, J=8.3 Hz, 1H), 7.90 (s, 1H), 7.77 (dd, J=1.8, 8.3 Hz,1H), 7.69-7.62 (m, 2H), 4.82 (q, J=8.5 Hz, 2H), 1.59 (s, 6H); LCMS (ESI)m/z: 540 (M+1).

Example 7 Synthesis of Compound 7 and Compound 8

1) Synthesis of Compound 7-2

In a microwave tube, Compound 7-1 (1.00 g, 5.08 mmol), Compound 1-4 (785mg, 7.61 mmol), 2-acetylcyclohexanone (142 mg, 1.02 mmol), cuprouschloride (100 mg, 1.02 mmol), and potassium carbonate (1.75 g, 12.69mmol) were dissolved in DMF (5 mL) and water (90 μL) at 15° C. Then, theresulting mixture was microwave-heated to 130° C., and stirred at thistemperature for 1.2 h. The reaction mixture was directly filtered, andspin-dried. 15 mL of water was added, and then the resulting mixture wasextracted with ethyl acetate (15 mL×2). Then, the aqueous phase wasconcentrated to obtain Compound 7-2. LCMS (ESI) m/z: 220 (M+1). 2)Synthesis of Compound 7-3

Dichlorosulfoxide (5.84 g, 49.08 mmol) was added dropwise to a solutionof Compound 7-2 (800 mg, 3.65 mmol) in methanol (10 mL) in an ice waterbath. After the completion of the dropwise addition, the resultingmixture was stirred at 50° C. for 12 h. The reaction mixture wasdirectly concentrated to obtain Compound 7-3. LCMS (ESI) m/z: 234 (M+1).

3) Synthesis of Compound 7-4

Compound 7-3 (400 mg, 1.71 mmol) and Compound 1-7 (1.17 g, 5.14 mmol)were dissolved in DMF (1.5 mL) and methylbenzene (6 mL) at 15° C. Afterthree times of nitrogen displacement, the mixture was heated to 100° C.and stirred for 12 h under nitrogen protection. 5 mL of methanol wasadded to the reaction mixture, and then the resulting mixture wasstirred for 20 min, and concentrated under reduced pressure. The crudeproduct was purified by flash column chromatography to obtain Compound7-4. LCMS (ESI) m/z: 430 (M+1).

4) Synthesis of Compound 7 and Compound 8

Compound 7-4 (100 mg, 233 μmol), Compound 7-5 (24 mg, 279.44 μmol), andcesium carbonate (114 mg, 349.30 μmol) were put intoN,N-dimethylacetamide (5 mL) at 15° C., and the resulting mixture washeated to 120° C., and stirred for 2.5 h. The reaction mixture wasfiltered. 10 mL of water was added to the filtrate, and the resultingmixture was then extracted with ethyl acetate (10 mL×2). The organicphase was washed with 20 mL of saturated brine, dried over anhydroussodium sulfate, filtered, and spin-dried. The crude product was purifiedby a preparative chromatoplate and preparative HPLC to obtain Compound 7and Compound 8.

¹H NMR (400 MHz, CDCl₃) δ ppm 8.14 (s, 1H), 8.04-7.99 (m, 2H), 7.89 (brd, J=8.28 Hz, 1H), 7.74-7.69 (m, 2H), 7.34 (br d, J=8.78 Hz, 1H), 5.14(br s, 1H), 4.81 (br s, 1H), 4.55-4.49 (m, 1H), 4.40-4.29 (m, 2H), 3.97(br d, J=7.03 Hz, 1H), 2.15 (br d, J=5.27 Hz, 1H), 1.65 (s, 6H); LCMS(ESI) m/z: 516 (M+1) (Compound 7).

¹H NMR (400 MHz, CDCl₃) δ ppm 8.17 (s, 1H), 7.97-8.02 (m, 2H), 7.89-7.83(m, 2H) 7.64 (s, 1H), 7.16 (dd, J=9.03, 2.01 Hz, 1H), 5.09 (br s, 1H),4.75 (br s, 1H), 4.48 (dd, J=10.16, 6.15 Hz, 1H), 4.39-4.31 (m, 2H),4.00-3.86 (m, 1H), 2.51 (br s, 1H), 1.63 (s, 6H); LCMS (ESI) m/z: 516(M+1) (Compound 8).

Example 8 Synthesis of Compound 9

1) Synthesis of Compound 9-2

A mixture of Compound 9-1 (2.00 g, 9.26 mmol), triethyl orthoacetate(3.00 g, 25.00 mmol), and aminomethanol (20 mL) (15% wt.) was added toan airtight jar, and stirred at 110° C. for 4 h. The reaction mixturewas concentrated under reduced pressure. The residue obtained from theconcentration was slurried with methanol (30 mL), and filtered to obtaina white solid. The filtrate was concentrated under reduced pressure,re-slurried with methanol (15 mL), and filtered to obtain a white solid.The two batches of white solids were combined to obtain Compound 9-2. ¹HNMR (400 MHz, DMSO-d6) δ ppm 12.38 (br s, 1H), 8.14 (d, J=2.3 Hz, 1H),7.91 (dd, J=2.4, 8.7 Hz, 1H), 7.53 (d, J=8.8 Hz, 1H), 2.34 (s, 3H).

2) Synthesis of Compound 9-3

Compound 9-2 (600 mg, 2.51 mmol), Compound 1-4 (388 mg, 3.76 mmol),potassium carbonate (867 mg, 6.28 mmol), cuprous chloride (50 mg, 502.00μmol), 2-acetylcyclohexanone (70 mg, 502.00 μmol), DMF (7 mL), and water(350 μL) were added to a 20 mL microwave tube. The resulting mixture waskept at 130° C. for microwave reaction for 1 h. The reaction mixture wasfiltered, and the filtrate was concentrated to dryness under reducedpressure. The residue obtained from the concentration was dissolved inwater (50 mL), and washed with dichloromethane (30 mL×3). Concentratedhydrochloric acid (1.5 mL) was added to the aqueous phase, such that theaqueous phase was acidic (pH about 6), and then the aqueous phase wasconcentrated under reduced pressure. The residue obtained from theconcentration was slurried with dichloromethane/methanol (30 mL/30 mL)at 29° C. for 2 min, filtered, and concentrated under reduced pressureto obtain Compound 9-3. LCMS (ESI) m/z: 262 (M+1).

3) Synthesis of Compound 9-4

Compound 9-3 (1.18 g, 2.58 mmol) was dissolved in anhydrous methanol (20mL), and dichlorosulfoxide (3.28 g, 27.58 mmol, 2.00 mL) was addeddropwise at 0° C. The resulting mixture was heated to 50° C., andstirred for 18 h. The reaction mixture was concentrated under reducedpressure, a saturated sodium bicarbonate solution (50 mL) was added, andthe resulting mixture was extracted with dichloromethane (30 mL×3). Theorganic phases were combined, washed with saturated brine (50 mL), driedover anhydrous sodium sulfate, and filtered. The filtrate wasconcentrated to dryness under reduced pressure. The residue obtainedfrom the concentration was slurried with dichloromethane/ethyl acetate(10 mL/10 mL) at 29° C. for 0.5 h, and filtered. The resulting filtercake was Compound 9-4. ¹H NMR (400 MHz, CDCl₃) δ ppm 10.94 (s, 1H),7.52-7.50 (d, J=9.2 Hz, 1H), 7.30-7.29 (d, J=2.8 Hz, 1H), 7.06-7.04 (m,1H), 4.45 (s, 1H), 3.76 (s, 3H), 2.52 (s, 3H), 1.65 (s, 6H); LCMS (ESI)m/z: 276 (M+1).

4) Synthesis of Compound 9-5

Compound 9-4 (300 mg, 933.89 μmol) and Compound 1-7 (864 mg, 3.79 mmol)were dissolved in DMF (1.5 mL) and methylbenzene (6 mL). The resultingmixture was heated to 120° C., and stirred for 18 h. The reactionmixture was concentrated to dryness under reduced pressure. The residueobtained from the concentration was purified by a preparativechromatoplate to obtain Compound 9-5. LCMS (ESI) m/z: 472 (M+1).

5) Synthesis of Compound 9

A turbid liquid of Compound 9-5 (130 mg, 275.74 μmol), 2-bromoethanol(83 mg, 661.78 μmol), and potassium carbonate (100 mg, 722.44 μmol) inDMF (3 mL) was stirred at 29° C. for 67 h. The reaction mixture wasfiltered directly. The filtrate was separated and purified bypreparative HPLC to obtain Compound 9. ¹HNMR (400 MHz, CDCl₃) δ ppm 8.04(d, J=2.4 Hz, 1H), 7.96-7.92 (m, 3H), 7.91-7.80 (dd, J=45.6 Hz, 1H),7.65-7.64 (dd, J=2.8 Hz, 1H), 4.721-4.71 (m, 2H), 4.70 (s, 2H), 2.69 (s,3H), 1.59 (s, 6H); LCMS (ESI) m/z: 516 (M+1).

Example 9 Synthesis of Compound 10

1) Synthesis of Compound 10-2

Compound 10-1 (20.00 g, 128.92 mmol) was dissolved in dichloromethane(200 mL), and NBS (22.95 g, 128.92 mmol) was added. The resultingmixture was stirred at 20° C. for 2 h. The reaction mixture wasfiltered, and the filter cake was washed with dichloromethane (75 mL×3).The resulting filter cake was dried under reduced pressure to obtainCompound 10-2. ¹H NMR (400 MHz, DMSO-d6) δ ppm 7.66-7.61 (m, 1H), 7.52(dd, J=2.3, 10.8 Hz, 1H); LCMS (ESI) m/z: 234 (M+1).

2) Synthesis of Compound 10-3

Ammonia water (51.52 g, 396.90 mmol) (purity: 27%) was added to asolution of Compound 10-2 (30.96 g, 132.30 μmmol),0-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (70.42 g, 185.22 mmol), and triethylamine (26.77 g,264.60 mmol) in DMF (500 mL). The resulting mixture was stirred at 20°C. for 4 h. 2000 mL of water was added to the reaction mixture, and theresulting mixture was stirred for 1 h, and filtered. The filter cake waswashed with water (50 mL×3), and the resulting white solid was dried inan infrared oven. The filtrate was extracted with dichloromethane (100mL×3). The resulting organic phase was concentrated under reducedpressure. The residue obtained from the concentration was slurried withwater (500 mL) at 20° C. for 20 min, and filtered. The filter cake wasdried in the infrared oven. The two dried white solids were combined toobtain Compound 10-3. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.35 (br d, J=7.0Hz, 1H), 7.18-7.08 (m, 1H); LCMS (ESI) m/z: 235 (M+3).

3) Synthesis of Compound 10-4

Propionyl chloride (28.39 g, 306.80 mmol) was added to a turbid liquidof Compound 10-3 (14.30 g, 61.36 mmol) in trichloromethane (200 mL). Theresulting mixture was stirred at 70° C. for 16 h. The reaction mixturewas cooled to 15° C., methanol (5 mL) was added, and then the resultingmixture was concentrated to dryness under reduced pressure. The residueobtained from the concentration was dissolved in a saturated sodiumbicarbonate solution (100 mL), and extracted withdichloromethane/methanol (10/1, 200 mL×3). The organic phases werecombined, washed with saturated brine (100 mL), dried over anhydroussodium sulfate, and filtered. The filtrate was concentrated to drynessunder reduced pressure. The residue obtained from the concentration wasslurried with ethyl acetate (100 mL) at 15° C. for 30 min, and filtered.The filter cake was washed with ethyl acetate (10 mL×3), and then driedin an infrared oven to obtain Compound 10-4. ¹H NMR (400 MHz, CDCl₃) δppm 8.00 (br d, J=1.3 Hz, 1H), 7.57-7.48 (m, 1H), 2.95 (s, 1H), 2.62 (q,J=7.5 Hz, 2H), 1.33-1.22 (m, 3H); LCMS (ESI) m/z: 273 (M+3).

4) Synthesis of Compound 10-5

Compound 10-4 (1.50 g, 5.53 mmol), Compound 1-4 (855 mg, 8.30 mmol),cuprous chloride (220 mg, 2.22 mmol), 2-acetylcyclohexanone (310 mg,2.22 mmol), potassium carbonate (1.91 g, 13.83 mmol), DMF (10 mL), andwater (500 μL) were added to a 30 mL microwave tube, respectively. Theresulting mixture was kept at 130° C. for microwave reaction for 80 min.The reaction mixture was filtered, and the filter cake was washed withDMF (10 mL×3). The resulting aqueous phase was acidified to a pH ofabout 6 with dilute hydrochloric acid (2 mol/L). The aqueous phase wasconcentrated to dryness under reduced pressure. The residue obtainedfrom the concentration was slurried with dichloromethane/methanol (10/1,30 mL) at 15° C. for 2 min, and filtered. The filtrate was concentratedunder reduced pressure to obtain Compound 10-5. LCMS (ESI) m/z: 294(M+1).

5) Synthesis of Compound 10-6

Dichlorosulfoxide (29.94 g, 251.64 mmol) was added dropwise to asolution of Compound 10-5 (7.30 g, 24.89 mmol) in methanol (80 mL) at 0°C. After the completion of the dropwise addition, the resulting mixturewas heated to 50° C., and stirred for 18 h. The reaction mixture wascooled to 15° C., and concentrated to dryness under reduced pressure.The residue obtained from the concentration was dissolved in a saturatedsodium bicarbonate solution (40 mL), and extracted withdichloromethane/methanol (10/1, 60 mL×4). The organic phases werecombined, washed with saturated brine (50 mL), dried over anhydroussodium sulfate, and filtered. The filtrate was concentrated to drynessunder reduced pressure. The residue obtained from the concentration waspurified by a silica gel column to obtain Compound 10-6. ¹H NMR (400MHz, CDCl₃) δ ppm 7.01 (d, J=2.5 Hz, 1H), 6.72 (dd, J=2.5, 12.3 Hz, 1H),3.68 (s, 3H), 2.72 (q, J=7.6 Hz, 2H), 1.56 (s, 6H), 1.36-1.31 (m, 3H);LCMS (ESI) m/z: 308 (M+1).

6) Synthesis of Compound 10-7

Under nitrogen protection, Compound 10-6 (2.10 g, 6.83 mmol) andCompound 1-7 (6.23 g, 27.32 mmol) were dissolved in DMF (5 mL) andmethylbenzene (50 mL), and the resulting mixture was heated to 120° C.,and stirred for 18 h. The reaction mixture was concentrated to drynessunder reduced pressure. The residue obtained from the concentration waspurified by a silica gel column to obtain Compound 10-7. ¹H NMR (400MHz, CDCl₃) δ ppm 7.99-7.93 (m, 2H), 7.78 (dd, J=1.6, 8.2 Hz, 1H), 7.58(d, J=8.3 Hz, 1H), 7.40 (dd, J=2.1, 9.9 Hz, 1H), 2.86-2.77 (m, 3H), 1.59(s, 6H), 1.44-1.33 (m, 3H); LCMS (ESI) m/z: 504 (M+1).

7) Synthesis of Compound 10

Under nitrogen protection, a turbid liquid of Compound 10-7 (1.32 g,2.62 mmol), 2-bromoethanol (4.10 g, 32.75 mmol), potassium carbonate(1.45 g, 10.48 mmol), and DMF (50 mL) was stirred at 40° C. for 78 h.The reaction mixture was filtered directly. The filtrate was separatedand purified by preparative HPLC and preparative chromatography toobtain Compound 10. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.94 (d, J=8.0 Hz,1H), 7.90 (d, J=1.5 Hz, 1H), 7.85 (s, 1H), 7.78 (dd, J=1.8, 8.3 Hz, 1H),7.39 (dd, J=2.1, 9.9 Hz, 1H), 4.76-4.71 (m, 2H), 4.03 (br d, J=3.8 Hz,2H), 2.98 (q, J=7.5 Hz, 2H), 2.72 (br s, 1H), 1.60 (s, 6H), 1.35 (t,J=7.7 Hz, 3H); LCMS (ESI) m/z: 548 (M+1).

Example 10 Synthesis of Compound 11

1) Synthesis of Compound 11-2

Cyclopropylformyl chloride (8.55 g, 81.84 mmol) was added dropwise to asolution of Compound 11-1 (4.40 g, 20.46 mmol) in trichloromethane (100mL) at 20° C. The reaction mixture was heated to 65° C. and reacted for12 h. The reaction mixture was cooled to room temperature, andconcentrated to obtain Compound 11-2. LCMS (ESI) m/z: 285 (M+3).

2) Synthesis of Compound 11-3

Sodium methoxide (4.12 g, 76.28 mmol) was added to a solution ofCompound 11-2 (5.40 g, 19.07 mmol) in methanol (100 mL) at 20° C. Thereaction mixture reacted at 20° C. for 12 h. The reaction mixture wascooled to room temperature, and concentrated to obtain a crude product.The crude product was added in water (100 mL), and neutralized with 1Maqueous solution of hydrochloric acid to pH=7. A large amount of graysolids precipitated. After filtration, the filter cake was collected anddried to obtain Compound 11-3. ¹H NMR (400 MHz, DMSO-d6) δ ppm 8.09 (d,J=2.26 Hz, 1H), 7.68 (d, J=2.26 Hz, 1H), 7.41 (d, J=8.78 Hz, 1H), 7.24(dd, J=8.78, 2.26 Hz, 1H), 2.00-1.86 (m, 1H), 1.13-0.97 (m, 4H); LCMS(ESI) m/z: 267 (M+3).

3) Synthesis of Compound 11-4

DMF (414 mg, 5.66 mmol) was added dropwise to a solution of Compound11-3 (1.50 g, 5.66 mmol) and dichlorosulfoxide (20 mL), and theresulting mixture was stirred at 80° C. for 3 h. The reaction mixturewas concentrated to dryness under reduced pressure, and the residue wasdissolved in ethanediol (20 mL). Triethylamine (344 mg, 3.40 mmol) wasadded, and the resulting mixture was further stirred at 80° C. for 1 h.The reaction mixture was cooled to 20° C. Dichloromethane (80 mL) wasadded to the resulting mixture, which was washed with water (50 mL×3).The organic phase was dried over anhydrous sodium sulfate, and filtered.The filtrate was concentrated to dryness under reduced pressure. Theresidue obtained from the concentration was purified by a silica gelcolumn to obtain Compound 11-4. LCMS (ESI) m/z: 309 (M+1).

4) Synthesis of Compound 11-5

Triethylamine (275 mg, 2.72 mmol), 4-dimethylaminopyridine (22 mg,181.14 μmol), and diBoc (495 mg, 2.72 mmol) were added dropwise to asolution of Compound 11-4 (280 mg, 905.68 μmol) in dichloromethane (10mL). The resulting mixture was stirred at 15° C. for 17 h. The reactionmixture was diluted with dichlorometahne (20 mL). Water (20 mL) wasadded to the resulting mixture, then 2 mol/L dilute hydrochloric acid (5drops) was added dropwise, and the resulting mixture was washed threetimes. The organic phase was washed with a saturated sodium carbonatesolution (20 mL), dried over anhydrous sodium sulfate, and filtered. Thefiltrate was concentrated under reduced pressure to obtain Compound11-5. LCMS (ESI) m/z: 411 (M+3).

5) Synthesis of Compound 11-6

Compound 11-5 (250 mg, 610.84 μmol), Compound 1-4 (95 mg, 916.27 μmol),potassium carbonate (338 mg, 2.44 mmol), cuprous chloride (12 mg, 122.17μmol), 2-acetylcyclohexanone (17 mg, 122.17 μmol), DMF (5 mL), and water(0.1 mL) were added to a 10 mL microwave tube. The resulting mixture waskept at 130° C. for microwave reaction for 1 h. The reaction mixture wasfiltered, and the filter cake was washed with DMF (5 mL×2). The filtratewas concentrated to dryness under reduced pressure. The residue obtainedfrom the concentration was slurried with dichloromethane (20 mL) at 15°C. for 2 min, and filtered. The filtrate was concentrated under reducedpressure to obtain Compound 11-6. LCMS (ESI) m/z: 432 (M+1).

6) Synthesis of Compound 11-7

A solution of TMSCHN₂ in n-hexane (2M, 1.74 mL, 3.48 mmol) was addeddropwise to a solution of Compound 11-6 (500 mg, 1.16 mmol) indichloromethane (5 mL) and methanol (500 μL). The resulting mixture wasstirred at 20° C. for 1.5 h. The reaction mixture was concentrated todryness under reduced pressure. The residue obtained from theconcentration was purified by a preparative chromatoplate to obtainCompound 11-7. LCMS (ESI) m/z: 446 (M+1).

7) Synthesis of Compound 11-8

Compound 11-7 (85 mg, 190.79 μmol) and Compound 1-7 (131 mg, 572.38μmol) were dissolved in DMF (500 μL) and methylbenzene (3 mL). Theresulting mixture was stirred at 120° C. for 16 h under nitrogenprotection. The reaction mixture was cooled to room temperature, andthen concentrated under reduced pressure. The residue obtained from theconcentration was purified by a preparative chromatoplate to obtainCompound 11-8. LCMS (ESI) m/z: 642 (M+1).

8) Synthesis of Compound 11

Trifluoroacetic acid (2 mL) was added to a solution of Compound 11-8 (50mg, 77.92 μmol) in dichloromethane (6 mL), and then the resultingmixture was stirred at 15° C. for 3 h. The reaction mixture was dilutedwith dichloromethane (10 mL), and washed with a saturated aqueoussolution of sodium bicarbonate (20 mL×3) and water (20 mL),respectively. The combined organic phase was washed with saturated brine(20 mL), dried over anhydrous sodium sulfate, filtered, and concentratedto obtain a crude product. The crude product was purified by preparativeHPLC to obtain Compound 11. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.02-7.97 (m,1H), 7.95-7.88 (m, 3H), 7.79 (dd, J=8.28, 1.76 Hz, 1H), 7.59 (dd,J=8.91, 2.38 Hz, 1H), 4.66-4.62 (m, 2H), 4.00 (br s, 2H), 2.52 (br s,1H), 2.26-2.17 (m, 1H), 1.58 (s, 6H), 1.19-1.12 (m, 2H), 1.09-1.01 (m,2H); LCMS (ESI) m/z: 542 (M+1).

Example 11 Synthesis of Compound 12

1) Synthesis of Compound 12-1

P-methylbenzenesulfonic acid (218 mg, 1.40 mmol) and Compound 11-1 (3.00g, 13.95 mmol) were added to trimethyl orthoformate (29.10 g, 274.22mmol) at room temperature (10° C.). The reaction mixture was heated to110° C., and reacted for 1 h. The reaction mixture was cooled to roomtemperature, and directly concentrated to obtain Compound 12-1. LCMS(ESI) m/z: 225 (M+1).

2) Synthesis of Compound 12-2

DMF (578 mg, 7.90 mmol) was added to a solution of Compound 12-1 (2.00g, 8.89 mmol) in dichlorosulfoxide (10 mL) at 20° C. The reactionmixture was heated to 80° C., and reacted for 2 h, and thenconcentrated. The resulting yellow solid was dissolved in ethanediol (10mL), triethylamine (4.00 g, 39.50 mmol) was added, and the resultingmixture was stirred at 80° C. for 1 h. The reaction mixture was dilutedwith water (50 mL), and extracted with dichloromethane (50 mL×3). Theorganic phase was dried over anhydrous sodium sulfate, filtered, andconcentrated to obtain Compound 12-2. LCMS (ESI) m/z: 269 (M+1). 3)Synthesis of Compound 12-3

Triethylamine (4.51 g, 44.58 mmol) and diBoc (8.10 g, 37.15 mmol) wereadded dropwise to a solution of Compound 12-2 (4.00 g, 14.86 mmol) and4-dimethylaminopyridine (363 mg, 2.97 mmol) in dichloromethane (30 mL).The resulting mixture was stirred at 15° C. for 3 h. The reactionmixture was diluted with dichloromethane (20 mL). The resulting mixturewas washed with dilute hydrochloric acid (30 mL×4) (the dilutehydrochloric acid was obtained by diluting 2 mol/L dilute hydrochloricacid (4 mL) with water (120 mL)). The organic phase was washed with asaturated sodium carbonate solution (30 mL), dried over anhydrous sodiumsulfate, and filtered. The filtrate was concentrated to dryness underreduced pressure. The residue obtained from the concentration waspurified by a silica gel column to obtain Compound 12-3. ¹H NMR (400MHz, CDCl₃) δ ppm 8.78 (s, 1H), 8.42-8.20 (m, 1H), 7.98-7.75 (m, 2H),4.80 (br d, J=3.5 Hz, 2H), 4.63-4.45 (m, 2H), 1.50 (s, 9H); LCMS (ESI)m/z: 369 (M+1).

4) Synthesis of Compound 12-4

Compound 12-3 (1.00 g, 2.71 mmol), Compound 1-4 (419 mg, 4.07 mmol),potassium carbonate (562 mg, 4.07 mmol), cuprous chloride (107 mg, 1.08mmol), 2-acetylcyclohexanone (152 mg, 1.08 mmol), DMF (8 mL), and water(800 μL) were added to a 30 mL microwave tube. The resulting mixture waskept at 130° C. for microwave reaction for 40 min. The reaction mixturewas filtered, and the filter cake was washed with DMF (3 mL×3). Dilutehydrochloric acid (2 mol/L) was added dropwise to the filtrate to adjustthe pH to about 7, and then the resulting mixture was concentrated todryness under reduced pressure. The residue obtained from theconcentration was slurried with dichloromethane/methanol (10/1, 20 mL)at 15° C. for 2 min, and filtered. The filtrate was concentrated underreduced pressure to obtain Compound 12-4. LCMS (ESI) m/z: 392 (M+1).

5) Synthesis of Compound 12-5

With reference to the synthesis method of Compound 11-7, Compound 12-5was prepared with Compound 12-4 as the starting material. LCMS (ESI)m/z: 406 (M+1). 6) Synthesis of Compound 12-6

With reference to the synthesis of Compound 11-8, Compound 12-6 wasprepared with Compound 12-5 as the starting material. LCMS (ESI) m/z:602 (M+1).

7) Synthesis of Compound 12

With reference to the synthesis of Compound 11, Compound 12 was preparedwith Compound 12-6 as the starting material. ¹H NMR (400 MHz, CDCl₃) δppm 8.90 (s, 1H), 8.19 (d, J=2.3 Hz, 1H), 8.15 (d, J=8.8 Hz, 1H),8.05-7.99 (m, 2H), 7.88 (dd, J=2.0, 8.3 Hz, 1H), 7.79 (dd, J=2.4, 8.9Hz, 1H), 4.85-4.79 (m, 2H), 4.15-4.08 (m, 2H), 2.74 (br s, 1H), 1.69 (s,6H); LCMS (ESI) m/z: 502 (M+1).

Example 12 Synthesis of Compound 13

1) Synthesis of Compound 13-1

P-methylbenzenesulfonic acid (245 mg, 1.29 mmol) was added to a solutionof Compound 10-3 (3.00 g, 12.87 mmol) and trimethyl orthoformate (30mL). The resulting white turbid liquid was heated to 110° C., andstirred for 16 h. The reaction mixture was concentrated under reducedpressure to obtain a white solid. Ethyl acetate (50 mL) was added to thewhite solid, and the resulting mixture was stirred for 30 min, and thenfiltered. The resulting white filter cake was dried under reducedpressure to obtain Compound 13-1. ¹H NMR (400 MHz, DMSO-d6) δ ppm 12.65(brs, 1H), 8.19 (s, 1H), 8.07-7.98 (m, 2H).

2) Synthesis of Compound 13-2

DMF (15 mg, 206.0 μmol) was added to a mixed solution of Compound 13-1(500 mg, 2.06 mmol) and dichlorosulfoxide (4.92 g, 41.36 mmol, 3 mL).The resulting reaction mixture was heated to 80° C., and stirred for 2h. The reaction mixture was concentrated under reduced pressure.Dichloromethane (3 mL), ethanediol (1.11 g, 17.88 mmol, 1 mL), andtriethylamine (657 mg, 6.49 mmol, 0.9 mL) were added to the residue(light yellow solid) obtained from the concentration. The resultingreaction mixture was heated to 80° C., and stirred for 1 h. The reactionmixture was filtered. The filtrate was poured into water (40 mL), andextracted with ethyl acetate (30 mL). The organic phase was washed withsaturated brine (20 mL), dried over anhydrous sodium sulfate, andconcentrated under reduced pressure to obtain Compound 13-2. LCMS (ESI)m/z: 289 (M+3).

3) Synthesis of Compound 13-3

diBoc (570 mg, 2.61 mmol, 0.6 mL), triethylamine (475 mg, 4.69 mmol,0.65 mL), and 4-dimethylaminopyridine (27 mg, 221.00 μmol) were added toa mixed solution of Compound 13-2 (630 mg, 2.19 mmol) in dichloromethane(10 mL). The resulting reaction mixture was stirred at 10° C. for 1 h.The reaction mixture was concentrated under reduced pressure, and theresidue obtained from the concentration was purified by a silica gelcolumn to obtain Compound 13-3. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.84 (s,1H), 8.15 (t, J=1.5 Hz, 1H), 7.68 (dd, J=2.0, 9.3 Hz, 1H), 4.86-4.78 (m,2H), 4.59-4.52 (m, 2H), 1.51 (s, 9H).

4) Synthesis of Compound 13-4

Compound 13-3 (300 mg, 774.79 μmol), Compound 1-4 (120 mg, 1.16 mmol),potassium carbonate (268 mg, 1.94 mmol), cuprous chloride (15 mg, 151.52μmol), 2-acetylcyclohexanone (22 mg, 156.94 μmol), DMF (2 mL), and water(0.1 mL) were added to a microwave tube. The microwave tube was sealed,and kept at 130° C. for microwave reaction for 40 min. The reactionmixture was filtered, and washed with ethyl acetate (20 mL). Thefiltrate was concentrated under reduced pressure. 1M hydrochloric acidwas added to the residue obtained from the concentration (pH=6-7), andthe resulting mixture was extracted with ethyl acetate (30 mL). Theorganic phase was washed with saturated brine (30 mL), dried overanhydrous sodium sulfate, and concentrated under reduced pressure toobtain Compound 13-4. LCMS (ESI) m/z: 410 (M+1).

5) Synthesis of Compound 13-5

A solution of TMSCHN₂ in n-hexane (2M, 1 mL) was added to a solution ofCompound 13-4 (290 mg, 708.34 μmol) in dichloromethane (5 mL) andmethanol (0.5 mL). The resulting reaction mixture was stirred at 10° C.for 1 h. The reaction mixture was concentrated under reduced pressure.The residue obtained from the concentration was purified by apreparative TLC plate to obtain Compound 13-5. LCMS (ESI) m/z: 424(M+1). 6) Synthesis of Compound 13-6

A mixed solution of Compound 13-5 (100 mg, 236.17 μmol), Compound 1-7(270 mg, 1.18 mmol), methylbenzene (2 mL), and DMF (0.5 mL) was heatedto 110° C., and stirred for 16 h. Compound 1-7 (270 mg, 1.18 mmol) wassupplemented to the reaction mixture. The reaction mixture was furtherstirred at 110° C. for 16 h. Methanol (2 mL) was added to the reactionmixture, which was stirred for 30 min, and then concentrated underreduced pressure. The residue obtained from the concentration waspurified by a preparative TLC plate to obtain Compound 13-6. LCMS (ESI)m/z: 620 (M+1).

7) Synthesis of Compound 13

Trifluoroacetic acid (0.4 mL) was added to a solution of Compound 13-6(100 mg, 161.40 μmol) in dichloromethane (2 mL). The resulting reactionmixture was stirred at 10° C. for 2 h. A saturated aqueous solution ofsodium bicarbonate was added to the reaction mixture (pH about 7), whichwas extracted with dichloromethane (30 mL). The organic phase was washedwith saturated brine (30 mL), dried over anhydrous sodium sulfate, andconcentrated under reduced pressure. The residue obtained from theconcentration was purified by a preparative TLC plate, and then purifiedby preparative HPLC to obtain Compound 13. ¹H NMR (400 MHz, CDCl₃) δ ppm8.94 (s, 1H), 8.06-7.94 (m, 3H), 7.86 (dd, J=1.9, 8.2 Hz, 1H), 7.53 (dd,J=2.1, 9.9 Hz, 1H), 4.86-4.76 (m, 2H), 4.17-4.07 (m, 2H), 2.47 (br t,J=5.5 Hz, 1H), 1.69 (s, 6H); LCMS (ESI) m/z: 520 (M+1).

Example 13 Synthesis of Compound 14

1) Synthesis of Compound 14-2

Phosphorus oxychloride (182 mg, 1.18 μmmol, 0.11 mL) andN,N-diisopropylethylamine (29 mg, 224.40 μmol) were added to a mixedsolution of Compound 14-1 (50 mg, 222.18 μmol) and anhydrousmethylbenzene (1 mL). The resulting reaction mixture was stirred at 10°C. for 0.5 h, heated to 110° C., and stirred for 5 h. The reactionmixture was concentrated under reduced pressure. Ethanediol (138 mg,2.22 mmol) and triethylamine (73 mg, 722.08 μmol, 0.1 mL) were added tothe residue obtained from the concentration. The resulting mixedsolution was stirred at 110° C. for 16 h. The reaction mixture wasconcentrated under reduced pressure. The residue obtained from theconcentration was diluted with dichloromethane (20 mL), and washed withwater (10 mL) and saturated brine (15 mL). The organic phase was driedover anhydrous sodium sulfate, and concentrated under reduced pressureto obtain Compound 14-2. LCMS (ESI) m/z: 269 (M+1).

2) Synthesis of Compound 14-3

diBoc (30 mg, 137.46 μmol), triethylamine (23 mg, 227.30 μmol), and4-dimethylaminopyridine (2 mg, 16.37 μmol) were added to a mixedsolution of Compound 14-2 (30 mg, 111.49 μmol) in dichloromethane (1mL). The resulting reaction mixture was stirred at 10° C. for 1 h. Thereaction mixture was concentrated under reduced pressure. The residueobtained from the concentration was purified by a preparative TLC plateto obtain Compound 14-3. LCMS (ESI) m/z: 391 (M+23).

3) Synthesis of Compound 14-4

Compound 14-3 (20 mg, 54.17 μmol), Compound 1-4 (9 mg, 87.28 μmol),potassium carbonate (20 mg, 144.63 μmol), cuprous chloride (2 mg, 20.20μmol), 2-acetylcyclohexanone (2 mg, 14.27 μmol), DMF (1 mL), and water(0.05 mL) were added to a microwave tube. The microwave tube was sealed,and kept at 130° C. for microwave reaction for 30 min. The reactionmixture was filtered, and washed with ethyl acetate (10 mL). Thefiltrate was concentrated under reduced pressure. 1N hydrochloric acidwas added to the residue obtained from the concentration (pH 6-7), whichwas extracted with ethyl acetate (20 mL). The organic phase was washedwith saturated brine (20 mL), dried over anhydrous sodium sulfate, andconcentrated under reduced pressure to obtain Compound 14-4. LCMS (ESI)m/z: 392 (M+1).

4) Synthesis of Compound 14-5

A solution of TMSCHN₂ in n-hexane (2M, 0.1 mL) was added to a solutionof Compound 14-4 (25 mg, 63.87 μmol) in dichloromethane (1 mL) andmethanol (0.1 mL). The resulting reaction mixture was stirred at 10° C.for 1 h. The reaction mixture was concentrated under reduced pressure.The residue obtained from the concentration was purified by apreparative TLC plate to obtain Compound 14-5. LCMS (ESI) m/z: 428(M+23).

5) Synthesis of Compound 14-6

A mixed solution of Compound 14-5 (10 mg, 24.66 μmol), Compound 1-7 (28mg, 122.81 μmol), methylbenzene (1 mL), and DMF (0.2 mL) was heated to110° C., and stirred for 16 h. Compound 1-7 (28 mg, 122.81 μmol) wassupplemented to the reaction mixture, and the resulting reaction mixturewas further stirred at 110° C. for 8 h. Methanol (1 mL) was added to thereaction mixture, which was stirred for 30 min, and then concentratedunder reduced pressure. The residue obtained from the concentration waspurified by a preparative TLC plate to obtain Compound 14-6. LCMS (ESI)m/z: 624 (M+23).

6) Synthesis of Compound 14

Trifluoroacetic acid (0.1 mL) was added to a solution of Compound 14-6(10 mg, 16.62 μmol) in dichloromethane (1 mL). The resulting reactionmixture was stirred at 15° C. for 1 h. A saturated aqueous solution ofsodium bicarbonate was added to the reaction mixture (pH about 8), andthe resulting mixture was extracted with dichloromethane (10 mL). Theorganic phase was washed with saturated brine (10 mL), dried overanhydrous sodium sulfate, and concentrated under reduced pressure. Theresidue obtained from the concentration was purified by a preparativeTLC plate to obtain Compound 14. ¹H NMR (400 MHz, CDCl₃) δ ppm 9.33 (s,1H), 8.04-7.96 (m, 3H), 7.90-7.83 (m, 2H), 7.76 (dd, J=2.3, 8.8 Hz, 1H),4.76-4.65 (m, 2H), 4.14-4.02 (m, 2H), 2.67 (br s, 1H), 1.67 (s, 6H);LCMS (ESI) m/z: 502 (M+1).

Example 14 Synthesis of Compound 15

1) Synthesis of Compound 15-1

At room temperature (10° C.),0-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (7.82 g, 20.55 mmol) was added to a solution ofCompound 11-1 (3.40 g, 15.81 mmol), 2,2-difluoroacetic acid (3.04 g,31.62 mmol), and triethylamine (4.80 g, 47.43 mmol) in dichloromethane(50 mL). The reaction mixture reacted at 10° C. for 12 h. The reactionmixture was directly concentrated to obtain a crude product. The crudeproduct was purified by flash column chromatography to obtain Compound15-1. ¹H NMR (400 MHz, CDCl₃) δ ppm 12.72 (br s, 1H), 8.34 (br d, J=8.78Hz, 1H), 8.05 (br s, 1H), 7.87 (br s, 1H), 7.41 (br d, J=9.03 Hz, 1H),6.57 (br s, 1H), 6.01-5.65 (m, 1H).

2) Synthesis of Compound 15-2

Sodium methoxide (1.77 g, 32.76 mmol) was added to a solution ofCompound 15-1 (3.20 g, 10.92 mmol) in methanol (10 mL) at roomtemperature (10° C.). The reaction mixture reacted at 30° C. for 12 h.The reaction mixture was cooled to room temperature, and concentrated toobtain a crude product. The crude product was purified by flash columnchromatography to obtain Compound 15-2. ¹H NMR (400 MHz, CDCl₃) δ ppm12.69 (br s, 1H), 8.28 (s, 1H), 7.75 (br d, J=8.78 Hz, 1H), 7.52 (d,J=8.53 Hz, 1H), 6.51-6.18 (m, 1H); LCMS (ESI) m/z: 277 (M+3).

3) Synthesis of Compound 15-3

With reference to the synthesis of Compound 11-4, Compound 15-3 wasprepared with Compound 15-2 as the starting material. LCMS (ESI) m/z:321 (M+3).

4) Synthesis of Compound 15-4

With reference to the synthesis of Compound 11-5, Compound 15-4 wasprepared with Compound 15-3 as the starting material. LCMS (ESI) m/z:419 (M+1).

5) Synthesis of Compound 15-5

With reference to the synthesis of Compound 11-6, Compound 15-5 wasprepared with Compound 15-4 as the starting material. LCMS (ESI) m/z:442 (M+1).

6) Synthesis of Compound 15-6

With reference to the synthesis of Compound 11-7, Compound 15-6 wasprepared with Compound 15-5 as the starting material. LCMS (ESI) m/z:456 (M+1).

7) Synthesis of Compound 15-7

With reference to the synthesis of Compound 11-8, Compound 15-7 wasprepared with Compound 15-6 as the starting material. LCMS (ESI) m/z:652 (M+1).

8) Synthesis of Compound 15

With reference to the synthesis of Compound 11, Compound 15 was preparedwith Compound 15-7 as the starting material. ¹H NMR (400 MHz, CDCl₃) δppm 8.26-8.20 (m, 2H), 8.06-8.00 (m, 2H), 7.91-7.83 (m, 2H), 6.85-6.52(m, 1H), 4.92-4.87 (m, 2H), 4.15 (br d, J=3.8 Hz, 2H), 2.40 (br s, 1H),1.70 (s, 6H); LCMS (ESI) m/z: 552 (M+1).

Example 15 Synthesis of Compound 16

1) Synthesis of Compound 16-1

CDI (11.31 g, 69.75 mmol) was added to a turbid liquid of Compound 11-1(10 g, 46.50 mmol) in tetrahydrofuran (100 mL). The resulting mixturewas stirred at 75° C. for 18 h. The reaction mixture was cooled to roomtemperature, and a solid precipitated, and was filtered. The filter cakewas washed with tetrahydrofuran (10 mL×3). The filter cake wasconcentrated to dryness under reduced pressure to obtain Compound 16-1.¹H NMR (400 MHz, DMSO-d6) δ ppm 11.47-11.16 (m, 2H), 7.92 (d, J=2.3 Hz,1H), 7.77 (dd, J=2.3, 8.8 Hz, 1H), 7.10 (d, J=8.5 Hz, 1H).

2) Synthesis of Compound 16-2

N,N-diisopropylethylamine (5.87 g, 45.43 mmol) was added dropwise to asolution of Compound 16-1 (7.3 g, 30.29 mmol) in phosphorus oxychloride(100 mL). The resulting mixture was stirred at 110° C. for 2 h. Thereaction mixture was cooled to room temperature, diluted withdichloromethane (400 mL), slowly added to water (500 mL) under stirring,extracted with dichloromethane (50 mL×3), and washed with saturatedbrine (50 mL×3). The organic phases were combined, dried over anhydroussodium sulfate, and filtered. The filtrate was concentrated underreduced pressure to obtain Compound 16-2. LCMS (ESI) m/z: 279 (M+3).

3) Synthesis of Compound 16-3

Sodium hydride (173 mg, 4.32 mmol, 60% purity) was added to a solutionof Compound 16-2 (1 g, 3.60 mmol) and ethanediol (268 mg, 4.32 mmol) intetrahydrofuran (50 mL). The mixture was stirred at 10° C. for 1 h. Thereaction mixture was quenched with water (20 mL), and the resultingmixture was extracted with dichloromethane (20 mL×3). The combinedorganic phase was washed with saturated brine (20 mL), dried overanhydrous sodium sulfate, filtered, and concentrated to obtain Compound16-3. LCMS (ESI) m/z: 305 (M+3).

4) Synthesis of Compound 16-4

At 10° C., triethylamine (1.10 g, 10.87 mmol) was added to a mixture ofCompound 16-3 (1.1 g, 3.62 mmol), diBoc (1.19 g, 5.44 mmol), and4-dimethylaminopyridine (88.55 mg, 724.78 μmol) in dichloromethane (20mL). The reaction mixture reacted at 10° C. for 1 h. The reactionmixture was washed with 1M dilute hydrochloric acid (20 mL) and water(20 mL×2) respectively, dried over anhydrous sodium sulfate, filtered,and concentrated to obtain Compound 16-4. ¹HNMR (400 MHz, CDCl₃) δ ppm8.23 (d, J=2.26 Hz, 1H), 7.66 (d, J=9.03 Hz, 1H), 7.85 (dd, J=8.78, 2.26Hz, 1H), 4.75 (dt, J=4.27, 2.38 Hz, 2H), 4.48 (dt, J=4.20, 2.29 Hz, 2H),1.44 (s, 9H).

5) Synthesis of Compound 16-5

A solution of methylamine in tetrahydrofuran (2.0 M, 2.5 mL) was addedto a solution of Compound 16-4 (1 g, 2.48 mmol) in tetrahydrofuran (3mL) at 10° C. The reaction mixture was kept at 80° C. for microwavereaction for 0.5 h. The reaction mixture was directly concentrated toobtain a crude product. The crude product was purified by flash columnchromatography to obtain Compound 16-5. LCMS (ESI) m/z: 400 (M+3).

6) Synthesis of Compound 16-6

With reference to the synthesis of Compound 11-6, Compound 16-6 wasprepared with Compound 16-5 as the starting material. LCMS (ESI) m/z:421 (M+1).

7) Synthesis of Compound 16-7

With reference to the synthesis of Compound 11-7, Compound 16-7 wasprepared with Compound 16-6 as the starting material. LCMS (ESI) m/z:435 (M+1).

8) Synthesis of Compound 16-8

With reference to the synthesis of Compound 11-8, Compound 16-8 wasprepared with Compound 16-7 as the starting material. LCMS (ESI) m/z:631 (M+1).

9) Synthesis of Compound 16

With reference to the synthesis of Compound 11, Compound 16 was preparedwith Compound 16-8 as the starting material. ¹H NMR (400 MHz, CDCl₃) δppm 7.99-7.87 (m, 2H), 7.85-7.74 (m, 2H), 7.58 (br d, J=8.03 Hz, 1H),7.42 (dd, J=8.78, 2.26 Hz, 1H), 4.59 (br s, 2H), 4.09-3.85 (m, 2H),3.08-2.98 (m, 3H), 1.56 (s, 6H); LCMS (ESI) m/z: 531 (M+1).

Example 16 Synthesis of Compound 17

1) Synthesis of Compound 17-1

Propionyl chloride (12.91 g, 139.50 mmol) was added to a solution ofCompound 11-1 (10.00 g, 46.50 mmol) in trichloromethane (200 mL) at 20°C. The reaction mixture was heated to 70° C., and reacted for 12 h. Thereaction mixture was cooled to room temperature, and concentrated toobtain a crude product. Ethyl acetate (100 mL) was added to the crudeproduct and the resulting mixture was stirred at 25° C. for 0.5 h, andfiltered. The collected filter cake was dried in a drying oven to obtainCompound 17-1. LCMS (ESI) m/z: 253 (M+1).

2) Synthesis of Compound 17-2

2-Bromoethanol (1.24 g, 9.88 mmol, 0.7 mL) was added to a mixed solutionof Compound 17-1 (1.00 g, 3.95 mmol), potassium carbonate (1.36 g, 9.88mmol), benzyltriethylammonium chloride (90 mg, 395.00 μmol), anddimethoxyethane (20 mL). The resulting reaction mixture was heated to90° C., and stirred for 16 h. 2-Bromoethanol (1.24 g, 9.88 mmol, 0.7 mL)and benzyltriethylammonium chloride (135 mg, 592.70 μmol) weresupplemented to the reaction mixture. The resulting reaction mixture washeated to 90° C., and stirred for 16 h. The reaction mixture wasfiltered, and the filtrate was concentrated under reduced pressure. Theresidue obtained from the concentration was purified by a silica gelcolumn to obtain Compound 17-2. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.30 (d,J=2.0 Hz, 1H), 7.87 (dd, J=2.3, 8.8 Hz, 1H), 7.75 (d, J=8.8 Hz, 1H),4.80-4.72 (m, 2H), 4.08 (br d, J=3.5 Hz, 2H), 3.31 (br s, 1H), 2.96 (q,J=7.5 Hz, 2H), 1.40 (t, J=7.7 Hz, 3H).

3) Synthesis of Compound 17-3

diBoc (171 mg, 783.51 μmol), triethylamine (139 mg, 1.37 mmol, 0.19 mL),and 4-dimethylaminopyridine (10 mg, 81.85 μmol) were added to a mixedsolution of Compound 17-2 (200 mg, 673.06 μmol) in dichloromethane (4mL). The resulting reaction mixture was stirred at 10° C. for 1 h. Thereaction mixture was concentrated under reduced pressure. The residueobtained from the concentration was purified by a silica gel column toobtain Compound 17-3. LCMS (ESI) m/z: 397 (M+1).

4) Synthesis of Compound 17-4

A mixture of Compound 17-3 (130 mg, 327.24 μmol), Boc-NH₂ (50 mg, 426.80μmol), cesium carbonate (266 mg, 816.40 μmol),bis(dibenzylideneacetone)palladium (20 mg, 34.78 μmol),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (20 mg, 34.56 μmol), andmethylbenzene (2 mL) was added to a microwave tube, and kept at 120° C.for microwave reaction for 0.5 h. The reaction mixture was filteredthrough Celite. The filtrate was diluted with ethyl acetate (30 mL),washed with water (20 mL) and saturated brine (20 mL), dried overanhydrous sodium sulfate, and concentrated under reduced pressure. Theresidue obtained from the concentration was purified by a preparativeTLC plate to obtain Compound 17-4. LCMS (ESI) m/z: 434 (M+1).

5) Synthesis of Compound 17-5

Trifluoroacetic acid (0.2 mL) was added to a solution of Compound 17-4(85 mg, 196.08 μmol) in dichloromethane (2 mL). The resulting reactionmixture was stirred at 15° C. for 12 h. A saturated aqueous solution ofsodium bicarbonate was added to the reaction mixture (pH about 8), whichwas extracted with dichloromethane (20 mL). The organic phase was washedwith saturated brine (20 mL), dried over anhydrous sodium sulfate, andconcentrated under reduced pressure. Lithium hydroxide (82 mg, 1.95mmol) was added to a solution of the resulting yellow oil (64 mg, 194.37μmol) in tetrahydrofuran (2 mL) and water (0.5 mL). The resultingreaction mixture was stirred at 15° C. for 16 h. The reaction mixturewas dried over anhydrous sodium sulfate, and concentrated under reducedpressure to obtain Compound 17-5. LCMS (ESI) m/z: 234 (M+1).

6) Synthesis of Compound 17-6

Trimethylsilyl cyanide (25 mg, 252.00 μmol) and zinc chloride (4 mg,29.32 μmol) were added to a mixed solution of Compound 17-5 (20 mg,85.74 μmol), cyclobutanone (36 mg, 513.63 μmol), sodium sulfate (50 mg,352.01 μmol) and tetrahydrofuran (2 mL). The resulting reaction mixturewas stirred at 10° C. for 19 h. An aqueous solution of sodium sulfite (5mL) was added to the reaction mixture, which was extracted with ethylacetate (5 mL×3). The organic phase was washed with saturated brine (10mL), dried over anhydrous sodium sulfate, and concentrated under reducedpressure to obtain Compound 17-6. LCMS (ESI) m/z: 313 (M+1).

7) Synthesis of Compound 17-7

diBoc (23 mg, 105.39 μmol), triethylamine (20 mg, 197.65 μmol), and4-dimethylaminopyridine (2 mg, 16.37 μmol) were added to a mixedsolution of Compound 17-6 (30 mg, 96.04 μmol) in dichloromethane (1 mL).The resulting reaction mixture was stirred at 10° C. for 1 h. Thereaction mixture was concentrated under reduced pressure. The residueobtained from the concentration was purified by a preparative TLC plateto obtain Compound 17-7. LCMS (ESI) m/z: 413 (M+1).

8) Synthesis of Compound 17-8

A mixed solution of Compound 17-7 (20 mg, 48.49 μmol), Compound 1-7 (28mg, 122.70 μmol), methylbenzene (1 mL), and DMF (0.2 mL) was heated to110° C., and stirred for 16 h. Compound 1-7 (54 mg, 236.64 μmol) wassupplemented to the reaction mixture, and the resulting mixture wasfurther stirred at 110° C. for 4 h. Methanol (1 mL) was added to thereaction mixture, which was stirred for 30 min, and then concentratedunder reduced pressure. The residue obtained from the concentration waspurified by a preparative TLC plate (petroleum ether/ethyl acetate=1/1)to obtain Compound 17-8. LCMS (ESI) m/z: 642 (M+1).

9) Synthesis of Compound 17

Trifluoroacetic acid (0.2 mL) was added to a solution of Compound 17-8(30 mg, 46.75 μmol) in dichloromethane (1 mL). The resulting reactionmixture was stirred at 10° C. for 2 h. A saturated aqueous solution ofsodium bicarbonate was added to the reaction mixture (pH about 8), whichwas extracted with dichloromethane (10 mL×3). The organic phase waswashed with saturated brine (15 mL), dried over anhydrous sodiumsulfate, and concentrated under reduced pressure. The residue obtainedfrom the concentration was purified by a preparative TLC plate to obtainCompound 17. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.09 (d, J=2.3 Hz, 1H), 8.01(d, J=8.8 Hz, 1H), 7.92 (dd, J=3.1, 5.1 Hz, 2H), 7.80 (dd, J=1.8, 8.3Hz, 1H), 7.64 (dd, J=2.5, 8.8 Hz, 1H), 4.77-4.69 (m, 2H), 4.07-3.98 (m,2H), 3.12-2.81 (m, 3H), 2.73-2.62 (m, 2H), 2.59-2.46 (m, 2H), 2.26-2.13(m, 1H), 1.65-1.55 (m, 1H), 1.38-1.33 (m, 3H); LCMS (ESI) m/z: 542(M+1).

Example 17 Synthesis of Compound 18

1) Synthesis of Compound 18-1

With reference to the synthesis of Compound 11-2, Compound 18-1 wasprepared with Compound 10-3 as the starting material. LCMS (ESI) m/z:301 (M+1).

2) Synthesis of Compound 18-2

A solution of potassium tert-butoxide in tetrahydrofuran (1M, 81 mL) wasadded to a solution of Compound 18-1 (8.1 g, 26.90 mmol) intetrahydrofuran (150 mL). The resulting mixture was stirred at 30° C.for 16 h. The reaction mixture was cooled to room temperature, andconcentrated to dryness under reduced pressure. The residue obtainedfrom the concentration was dissolved in water (40 mL), and adjusted to apH of about 7 with dilute hydrochloric acid (2 mol/L), and a white solidprecipitated. The turbid liquid was filtered, and the filter cake waswashed with water (10 mL×2). The resulting filter cake was dried in aninfrared oven to obtain Compound 18-2. LCMS (ESI) m/z: 285 (M+3).

3) Synthesis of Compound 18-3

With reference to the synthesis of Compound 11-4, Compound 18-3 wasprepared with Compound 18-2 as the starting material. LCMS (ESI) m/z:329 (M+3).

4) Synthesis of Compound 18-4

With reference to the synthesis of Compound 11-5, Compound 18-4 wasprepared with Compound 18-3 as the starting material. LCMS (ESI) m/z:429 (M+3).

5) Synthesis of Compound 18-5

With reference to the synthesis of Compound 11-6, Compound 18-5 wasprepared with Compound 18-4 as the starting material. LCMS (ESI) m/z:450(M+1).

6) Synthesis of Compound 18-6

With reference to the synthesis of Compound 11-7, Compound 18-6 wasprepared with Compound 18-5 as the starting material. LCMS (ESI) m/z:464(M+1).

7) Synthesis of Compound 18-7

With reference to the synthesis of Compound 11-8, Compound 18-7 wasprepared with Compound 18-6 as the starting material. LCMS (ESI) m/z:660(M+1).

8) Synthesis of Compound 18

With reference to the synthesis of Compound 11, Compound 18 was preparedwith Compound 18-7 as the starting material. ¹H NMR (400 MHz, CDCl₃) δppm 8.05-7.96 (m, 2H), 7.90-7.84 (m, 2H), 7.44 (dd, J=2.3, 10.0 Hz, 1H),4.77-4.70 (m, 2H), 4.10 (br s, 2H), 2.44-2.36 (m, 1H), 2.32 (br s, 1H),1.68 (s, 6H), 1.31-1.24 (m, 2H), 1.21-1.13 (m, 2H); LCMS (ESI) m/z:560(M+1).

Example 18 Synthesis of Compound 19

1) Synthesis of Compound 19-1

P-methylbenzenesulfonic acid (1 g, 5.26 mmol) was added to a turbidliquid of Compound 10-3 (10 g, 42.44 mmol) and trimethyl orthoformate(60 mL). The resulting turbid liquid was heated to 120° C., and stirredfor 32 h. The reaction mixture was concentrated under reduced pressure.The residue obtained from the concentration was purified by a silica gelcolumn to obtain Compound 19-1. LCMS (ESI) m/z: 271 (M+1).

2) Synthesis of Compound 19-2

DMF (742 mg, 5.74 mmol, 1 mL) was added to a mixed solution of Compound19-1 (1 g, 3.69 mmol) and phosphorus oxychloride (19.3 g, 125.87 mmol,11.7 mL). The resulting reaction mixture was heated to 110° C., andstirred for 4 h. The reaction mixture was concentrated under reducedpressure, diluted with dichloromethane (100 mL), and then slowly pouredinto water (80 mL). The resulting mixture was extracted withdichloromethane (50 mL×2), and the organic phase was successively washedwith a saturated aqueous solution of sodium bicarbonate (pH about 7) andsaturated brine (150 mL), dried over anhydrous sodium sulfate, andconcentrated under reduced pressure to obtain Compound 19-2. LCMS (ESI)m/z: 289 (M+1).

3) Synthesis of Compound 19-3

Sodium hydride (166 mg, 4.14 mmol, 60% purity) was added to a solutionof Compound 19-2 (1 g, 3.45 mmol) and tetrahydropyran-4-ol (423 mg, 4.14mmol) in tetrahydrofuran (30 mL). The mixture was stirred at 13° C. for1 h, and further stirred at 10° C. for 12 h. Tetrahydropyran-4-ol (176mg, 1.73 mmol) and sodium hydride (69 mg, 1.73 mmol, 60% purity) weresupplemented, and the resulting mixture was further stirred at 14° C.for 12 h. The reaction mixture was quenched with water (20 mL), andextracted with dichloromethane (20 mL×3). The combined organic phase waswashed with saturated brine (20 mL), dried over anhydrous sodiumsulfate, filtered, and concentrated to obtain a crude product. The crudeproduct was purified by flash column chromatography to obtain Compound19-3. LCMS (ESI) m/z: 355 (M+1).

4) Synthesis of Compound 19-4

With reference to the synthesis of Compound 11-6, Compound 19-4 wasprepared with Compound 19-3 as the starting material. LCMS (ESI) m/z:378 (M+1).

5) Synthesis of Compound 19-5

With reference to the synthesis of Compound 11-7, Compound 19-5 wasprepared with Compound 19-4 as the starting material. LCMS (ESI) m/z:392 (M+1).

6) Synthesis of Compound 19

With reference to the synthesis of Compound 11-8, Compound 19 wasprepared with Compound 19-5 as the starting material. ¹H NMR (400 MHz,CDCl₃) δ ppm 8.06-7.98 (m, 2H), 7.92-7.83 (m, 2H), 7.47 (dd, J=10.04,2.26 Hz, 1H), 5.66 (tt, J=8.63, 4.30 Hz, 1H), 4.06 (dt, J=11.80, 4.52Hz, 2H), 3.70 (ddd, J=11.86, 9.10, 2.89 Hz, 2H), 3.06 (q, J=7.70 Hz,2H), 2.26-2.16 (m, 2H), 2.02-1.89 (m, 2H), 1.69 (s, 6H), 1.43 (t, J=7.53Hz, 3H); LCMS (ESI) m/z: 588 (M+1).

Example 19 Synthesis of Compound 20

1) Synthesis of Compound 20-1

Sodium hydride (170 mg, 4.25 mmol, 60%) was added to a solution ofCompound 19-2 (1 g, 3.45 mmol) and ethanediol (266 mg, 4.29 mmol) intetrahydrofuran (10 mL). The resulting reaction mixture was stirred at10° C. for 6 h. The reaction mixture was quenched with a saturatedaqueous solution of ammonium chloride (100 mL), and then extracted withdichloromethane (100 mL×2). The organic phase was washed with saturatedbrine (100 mL), dried over anhydrous sodium sulfate, and concentratedunder reduced pressure to obtain Compound 20-1. LCMS (ESI) m/z: 315(M+1).

2) Synthesis of Compound 20-2

diBoc (835 mg, 3.83 mmol), triethylamine (654 mg, 6.47 mmol, 0.9 mL),and 4-dimethylaminopyridine (46 mg, 376.53 μmol) were added to a mixedsolution of Compound 20-1 (1 g, 3.17 mmol) in dichloromethane (10 mL).The resulting reaction mixture was stirred at 10° C. for 1 h. Thereaction mixture was concentrated under reduced pressure. The residueobtained from the concentration was purified by a silica gel column toobtain Compound 20-2. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.12-8.06 (m, 1H),7.62 (dd, J=2.0, 9.5 Hz, 1H), 4.84-4.76 (m, 2H), 4.58-4.51 (m, 2H), 2.99(q, J=7.5 Hz, 2H), 1.51 (s, 9H), 1.39 (t, J=7.7 Hz, 3H).

3) Synthesis of Compound 20-3

A mixture of Compound 20-2 (800 mg, 1.93 mmol), Boc-NH₂ (339 mg, 2.89mmol), cesium carbonate (1.57 g, 4.82 mmol),bis(dibenzylideneacetone)palladium (111 mg, 193.04 μmol),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (112 mg, 193.56 μmol),and methylbenzene (10 mL) was added to a microwave tube, and kept at120° C. for microwave reaction for 0.5 h. The reaction mixture wasfiltered through Celite, and the filtrate was concentrated under reducedpressure. The residue obtained from the concentration was purified by asilica gel column to obtain Compound 20-3. LCMS (ESI) m/z: 452 (M+1).

4) Synthesis of Compound 20-4

Trifluoroacetic acid (2 mL) was added to a solution of Compound 20-3(750 mg, 1.66 mmol) in anhydrous dichloromethane (8 mL). The resultingreaction mixture was stirred at 10° C. for 3 h. A saturated aqueoussolution of sodium bicarbonate was added to the reaction mixture (pHabout 7), which was extracted with dichloromethane (30 mL). The organicphase was washed with saturated brine (20 mL), dried over anhydroussodium sulfate, and concentrated under reduced pressure. Lithiumhydroxide (520 mg, 12.39 mmol) was added to a solution of the resultingyellow oil (430 mg, 1.24 mmol) in tetrahydrofuran (6 mL) and water (1.5mL). The resulting reaction mixture was stirred at 10° C. for 3 h. Thereaction mixture was dried over anhydrous sodium sulfate, andconcentrated under reduced pressure to obtain Compound 20-4. LCMS (ESI)m/z: 252 (M+1).

5) Synthesis of Compound 20-5

Trimethylsilyl cyanide (232 mg, 2.34 mmol) and zinc chloride (33 mg,241.98 μmol) were added to a mixed solution of Compound 20-4 (200 mg,796.00 μmol), cyclobutanone (334 mg, 4.77 mmol), sodium sulfate (453 mg,3.19 mmol) and tetrahydrofuran (5 mL). The resulting reaction mixturewas stirred at 10° C. for 16 h. An aqueous solution of sodium sulfite(20 mL) was added to the reaction mixture, and the resulting mixture wasextracted with ethyl acetate (15 mL×3). The organic phase was washedwith saturated brine (20 mL), dried over anhydrous sodium sulfate, andconcentrated under reduced pressure to obtain Compound 20-5. LCMS (ESI)m/z: 331 (M+1).

6) Synthesis of Compound 20-6

diBoc (237 mg, 1.09 mmol), triethylamine (189 mg, 1.87 mmol), and4-dimethylaminopyridine (12 mg, 98.23 μmol) were added to a mixedsolution of Compound 20-5 (300 mg, 908.11 μmol) in dichloromethane (4mL). The resulting reaction mixture was stirred at 10° C. for 16 h. Thereaction mixture was concentrated under reduced pressure. The residueobtained from the concentration was purified by a silica gel column toobtain Compound 20-6. LCMS (ESI) m/z: 431 (M+1).

7) Synthesis of Compound 20-7

A mixed solution of Compound 20-6 (80 mg, 185.84 μmol), Compound 1-7(170 mg, 744.98 μmol), methylbenzene (2 mL), and DMF (0.5 mL) was heatedto 110° C., and stirred for 16 h. Methanol (1 mL) was added to thereaction mixture, which was stirred for 30 min, and then concentratedunder reduced pressure. The residue obtained from the concentration waspurified by a preparative TLC plate to obtain Compound 20-7. LCMS (ESI)m/z: 660 (M+1).

8) Synthesis of Compound 20

Trifluoroacetic acid (0.4 mL) was added to a solution of Compound 20-7(70 mg, 106.12 μmol) in anhydrous dichloromethane (2 mL). The resultingreaction mixture was stirred at 10° C. for 1 h. A saturated aqueoussolution of sodium bicarbonate was added to the reaction mixture (pHabout 8), which was extracted with dichloromethane (10 mL×3). Theorganic phase was washed with saturated brine (15 mL), dried overanhydrous sodium sulfate, and concentrated under reduced pressure. Theresidue obtained from the concentration was purified by preparative HPLCto obtain Compound 20. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.98-7.86 (m, 3H),7.79 (br d, J=8.0 Hz, 1H), 7.40 (br d, J=9.8 Hz, 1H), 4.79-4.68 (m, 2H),4.03 (br s, 2H), 2.99 (q, J=7.5 Hz, 2H), 2.76-2.60 (m, 3H), 2.59-2.46(m, 2H), 2.30-2.14 (m, 1H), 1.52 (br s, 1H), 1.36 (t, J=7.5 Hz, 3H);LCMS (ESI) m/z: 560 (M+1).

Example 20 Synthesis of Compound 21

1) Synthesis of Compound 21-1

At room temperature (10° C.),0-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (10.61 g, 27.89 mmol) was added to a solution ofCompound 10-3 (5 g, 21.46 mmol), 2,2-difluoroacetic acid (6.18 g, 64.37mmol), and triethylamine (8.68 g, 85.82 mmol) in dichloromethane (10mL). The reaction mixture was kept at 10° C. for 13 h. The reactionmixture was concentrated to obtain a crude product. The crude productwas purified by flash column chromatography to obtain Compound 21-1. ¹HNMR (400 MHz, CDCl₃) δ ppm 12.90 (br s, 1H), 7.79 (s, 1H), 7.38-7.29 (m,1H), 6.50-5.96 (m, 1H).

2) Synthesis of Compound 21-2

With reference to the synthesis of Compound 11-4, Compound 21-2 wasprepared with Compound 21-1 as the starting material. LCMS (ESI) m/z:337 (M+1).

3) Synthesis of Compound 21-3

With reference to the synthesis of Compound 11-5, Compound 21-3 wasprepared with Compound 21-2 as the starting material. LCMS (ESI) m/z:439 (M+3).

4) Synthesis of Compound 21-4

Compound 21-3 (1.5 g, 3.43 mmol), Compound 1-4 (531 mg, 5.15 mmol),cuprous chloride (34 mg, 343.09 μmol), 2-acetylcyclohexanone (48 mg,343.09 μmol), and potassium carbonate (948 mg, 6.86 mmol) were added toa microwave tube filled with DMF (15 mL) and water (1.5 mL). Afternitrogen purge for 1 min, the resulting mixture was kept at 130° C. formicrowave reaction for 20 min. The reaction mixture was cooled to roomtemperature, and filtered. The filter cake was washed with DMF (5 mL×2).The filtrates were combined, acidified to pH=6-7 with an aqueoussolution of dilute hydrochloric acid (2M), and concentrated. Theresulting oil was added to dichloromethane/methanol (30 mL/3 mL),stirred at room temperature (20° C.) for 10 min, and filtered to removeinsolubles. The filtrate was concentrated to obtain a mixture ofCompound 21-4 and Compound 21-4A. LCMS (ESI) m/z: 360 (M+1); 460 (M+1).

5) Synthesis of Compound 21-5

At 0° C., a solution of TMSCHN₂ in n-hexane (2M, 5 mL) was addeddropwise to a solution of Compound 21-4 (2.3 g, 5.01 mmol) (a mixturecontaining Compound 21-4A) in dichloromethane (20 mL) and methanol (4mL), and then the resulting mixture was further stirred at 10° C. for 2h. The reaction mixture was concentrated to obtain a crude product. Thecrude product was purified by flash column chromatography to obtainCompound 21-5. LCMS (ESI) m/z: 374 (M+1).

6) Synthesis of Compound 21-6

With reference to the synthesis of Compound 11-5, Compound 21-6 wasprepared with Compound 21-5 as the starting material. LCMS (ESI) m/z:474 (M+1).

7) Synthesis of Compound 21-7

With reference to the synthesis of Compound 11-8, Compound 21-7 wasprepared with Compound 21-6 as the starting material. LCMS (ESI) m/z:670 (M+1).

8) Synthesis of Compound 21

With reference to the synthesis of Compound 11, Compound 21 was preparedwith Compound 21-7 as the starting material. ¹H NMR (400 MHz, CDCl₃) δppm 7.95 (s, 3H), 7.78 (dd, J=8.28, 2.01 Hz, 1H), 7.52 (dd, J=9.79, 2.01Hz, 1H), 6.84-6.36 (m, 1H), 4.89-4.75 (m, 2H), 4.17-4.00 (m, 2H),2.25-2.12 (m, 1H), 1.61 (s, 6H); LCMS (ESI) m/z: 570 (M+1).

Example 21 Synthesis of Compound 22

1) Synthesis of Compound 22-1

Sodium hydride (166 mg, 4.14 mmol, 60% purity) was added to a solutionof Compound 19-2 (1 g, 3.45 mmol) and 3-(methylsulfonyl)-1-propanol (573mg, 4.14 mmol) in tetrahydrofuran (20 mL). The mixture was stirred at16° C. for 1 h. Water (20 mL) was added to the reaction mixture, whichwas extracted with dichloromethane (20 mL×2). The combined organic phasewas washed with saturated brine (20 mL), dried over anhydrous sodiumsulfate, filtered, and concentrated to obtain Compound 22-1. LCMS (ESI)m/z: 393 (M+3).

2) Synthesis of Compound 22-2

With reference to the synthesis of Compound 11-6, Compound 22-2 wasprepared with Compound 22-1 as the starting material. LCMS (ESI) m/z:414 (M+1).

3) Synthesis of Compound 22-3

With reference to the synthesis of Compound 11-7, Compound 22-3 wasprepared with Compound 22-2 as the starting material. LCMS (ESI) m/z:428 (M+1).

4) Synthesis of Compound 22

With reference to the synthesis of Compound 11-8, Compound 22 wasprepared with Compound 22-3 as the starting material. ¹H NMR (400 MHz,CDCl₃) δ ppm 8.07-7.99 (m, 2H), 7.94-7.83 (m, 2H), 7.48 (dd, J=10.04,2.26 Hz, 1H), 4.81 (t, J=6.27 Hz, 2H), 3.37-3.23 (m, 2H), 3.07 (q,J=7.53 Hz, 2H), 3.00 (s, 3H), 2.57-2.47 (m, 2H), 1.69 (s, 6H), 1.44 (t,J=7.53 Hz, 3H); LCMS (ESI) m/z: 624 (M+1).

Example 22 Synthesis of Compound 23

1) Synthesis of Compound 23-2

Compound 23-1 (10 g, 61.31 mmol) was dissolved in a mixed solution ofacetonitrile (50 mL) and DMF (50 mL), and NBS (13.79 g, 61.31 mmol) wasadded. The resulting mixture was heated to 80° C., and stirred for 2 h.The reaction mixture was cooled to room temperature. 1 mol/L sodiumbicarbonate solution (62 mL) was added to the reaction mixture, andstirred for 5 min. The resulting mixture was concentrated to drynessunder reduced pressure. Water (80 mL) was added to the residue obtainedfrom the concentration, and the resulting mixture was extracted withdichloromethane (100 mL×4). The organic phases were combined, dried overanhydrous sodium sulfate, and filtered. The filtrate was concentrated todryness under reduced pressure. At room temperature, dichloromethane (15mL) was added to the residue obtained from the concentration. Theresulting mixture was stirred for 5 min, and filtered. The filter cakewas washed with dichloromethane (5 mL), and the filter cake was driedunder reduced pressure to obtain Compound 23-2. ¹H NMR (400 MHz,DMSO-d6) δ ppm 12.57 (br s, 1H), 8.00 (s, 1H), 7.99-7.97 (m, 1H); LCMS(ESI) m/z: 290 (M+1).

2) Synthesis of Compound 23-3

DMF (8 mL) was added to a solution of Compound 23-2 (8.1 g, 28.03 mmol)in phosphorus oxychloride (21.38 g, 139.58 mmol). The resulting mixturewas stirred at 110° C. for 80 min. The reaction mixture was cooled toroom temperature, and slowly added dropwise to water (150 mL) which wasstirred at room temperature. The resulting mixture was adjusted to a pHof about 8 with a saturated sodium bicarbonate solution, and extractedwith dichloromethane (40 mL×4). The organic phases were combined, driedover anhydrous sodium sulfate, and filtered. The filtrate wasconcentrated under reduced pressure to obtain Compound 23-3. ¹H NMR (400MHz, CDCl₃) δ ppm 8.71 (d, J=1.8 Hz, 1H), 8.21 (d, J=2.0 Hz, 1H).

3) Synthesis of Compound 23-4

P-methoxybenzylamine (3.25 g, 23.68 mmol),bis(dibenzylideneacetone)palladium (2.72 g, 4.74 mmol),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (2.74 g, 4.74 mmol), andsodium tert-butoxide (3.41 g, 35.52 mmol) were added to a solution ofCompound 23-3 (7.28 g, 23.68 mmol) in methylbenzene (100 mL). Theresulting mixture was subjected to nitrogen displacement four times,heated to 110° C. and stirred for 1 h under nitrogen protection. Thereaction mixture was cooled to room temperature, water (100 mL) wasadded to the reaction mixture, and the resulting mixture was extractedwith ethyl acetate (80 mL×3). The organic phases were combined, driedover anhydrous sodium sulfate, and filtered. The filtrate wasconcentrated to dryness under reduced pressure. The residue obtainedfrom the concentration was purified by a silica gel column to obtainCompound 23-4. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.84 (d, J=2.8 Hz, 1H),7.18 (d, J=8.0 Hz, 2H), 7.13-7.09 (m, 1H), 6.84-6.80 (m, 2H), 4.20 (d,J=5.5 Hz, 2H), 3.73 (s, 3H); LCMS (ESI) m/z:317 (M+1).

4) Synthesis of Compound 23-5

Zinc cyanide (4.16 g, 35.42 mmol) was added to a solution of Compound23-4 (7.1 g, 22.42 mmol) in DMF (100 mL).1,1′-Bis(diphenylphosphino)ferrocene (4.53 g, 4.48 mmol) was added afternitrogen displacement three times, and thenbis(dibenzylideneacetone)palladium (2.58 g, 4.48 mmol) was added afternitrogen displacement three times. After nitrogen displacement threetimes, the resulting mixture was heated to 150° C. and stirred for 50min under nitrogen protection. The reaction mixture was cooled to roomtemperature, and concentrated to dryness under reduced pressure. Theresidue obtained from the concentration was purified by a silica gelcolumn to obtain Compound 23-5. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.18 (d,J=2.5 Hz, 1H), 7.27 (d, J=8.5 Hz, 2H), 7.09 (d, J=2.8 Hz, 1H), 6.93 (d,J=8.5 Hz, 2H), 5.07 (br s, 1H), 4.38 (d, J=5.3 Hz, 2H), 3.83 (s, 3H);LCMS (ESI) m/z: 308 (M+1).

5) Synthesis of Compound 23-6

Compound 23-5 (3.4 g, 11.07 mmol) was dissolved in a mixed solution ofdichloromethane (4 mL) and trifluoroacetic acid (16 mL). The resultingmixture was stirred at 10° C. for 2 h. The reaction mixture wasconcentrated to dryness under reduced pressure. The residue obtainedfrom the concentration was diluted with ethyl acetate (50 mL), andwashed with a saturated sodium bicarbonate solution (50 mL×3). Theresulting organic phase was dried over anhydrous sodium sulfate, andfiltered. The filtrate was concentrated to dryness under reducedpressure. The residue obtained from the concentration was slurried withethyl acetate (20 mL) at room temperature for 20 min, and filtered. Thefilter cake was concentrated under reduced pressure to obtain Compound23-6. ¹H NMR (400 MHz, DMSO-d6) δ ppm 8.19 (d, J=2.3 Hz, 1H), 7.29 (d,J=2.5 Hz, 1H), 7.00 (s, 2H).

6) Synthesis of Compound 23-7

Thiophosgene (1.76 g, 15.28 mmol) was added dropwise to water (50 mL),and the resulting mixture was stirred at 10° C. for 30 min. Then,Compound 23-6 (1.43 g, 7.64 mmol) was added in batches, and theresulting mixture was stirred at 10° C. for 5 h. The reaction mixturewas extracted with dichloromethane (40 mL×2). The organic phases werecombined, dried over anhydrous sodium sulfate, and filtered. Thefiltrate was concentrated under reduced pressure to obtain Compound23-7.

7) Synthesis of Compound 23-8

With reference to the synthesis of Compound 11-8, Compound 23-8 wasprepared with Compound 18-6 and Compound 23-7 as the starting materials.LCMS (ESI) m/z: 661(M+1).

8) Synthesis of Compound 23

With reference to the synthesis of Compound 11, Compound 23 was preparedwith Compound 23-8 as the starting material. ¹H NMR (400 MHz, CDCl₃) δppm 9.12 (d, J=2.01 Hz, 1H), 8.39 (d, J=2.26 Hz, 1H), 7.88 (s, 1H), 7.43(dd, J=9.91, 2.13 Hz, 1H), 4.79-4.68 (m, 2H), 4.15-4.05 (m, 2H),2.45-2.35 (m, 1H), 2.30 (t, J=5.65 Hz, 1H), 1.75-1.73 (m, 1H), 1.70 (s,5H), 1.31-1.25 (m, 2H), 1.20-1.15 (m, 2H); LCMS (ESI) m/z: 561 (M+1).

Example 23 Synthesis of Compound 24

1) Synthesis of Compound 24-1

Sodium hydride (166 mg, 4.15 mmol, 60%) was added to a solution ofCompound 19-2 (1 g, 3.45 mmol) and N,N-dimethylethanolamine (370 mg,4.15 mmol) in tetrahydrofuran (20 mL). The resulting reaction mixturewas stirred at 10° C. for 1 h. The reaction mixture was quenched with asaturated aqueous solution of ammonium chloride (50 mL), and thenextracted with dichloromethane (40 mL×2). The organic phase was washedwith saturated brine (50 mL), dried over anhydrous sodium sulfate, andconcentrated under reduced pressure. The residue obtained from theconcentration was purified by a silica gel column to obtain Compound24-1. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.10-8.04 (m, 1H), 7.60 (dd, J=2.1,9.7 Hz, 1H), 4.70 (t, J=5.8 Hz, 2H), 2.99 (q, J=7.5 Hz, 2H), 2.84 (t,J=5.8 Hz, 2H), 2.38 (s, 6H), 1.40 (t, J=7.7 Hz, 3H).

2) Synthesis of Compound 24-2

Compound 24-1 (400 mg, 1.17 mmol), Compound 1-4 (180 mg, 1.75 mmol),potassium carbonate (404 mg, 2.92 mmol), cuprous chloride (23 mg, 232.32μmol), 2-acetylcyclohexanone (33 mg, 235.41 μmol), DMF (4 mL), and water(0.2 mL) were added to a microwave tube. The microwave tube was sealed,and kept at 130° C. for microwave reaction for 40 min. The reactionmixture was filtered, and washed with ethyl acetate (20 mL). Thefiltrate was concentrated under reduced pressure. 1N hydrochloric acidwas added to the residue obtained from the concentration (pH 6-7). Theresulting mixture was freeze-dried. Dichloromethane/methanol (20 mL,10/1) were added to the resulting solid, and the resulting mixture wasdried over anhydrous sodium sulfate, filtered, and concentrated underreduced pressure to obtain Compound 24-2. LCMS (ESI) m/z: 365 (M+1).

3) Synthesis of Compound 24-3

A solution of TMSCHN₂ in n-hexane (2M, 0.4 mL) was added to a solutionof Compound 24-2 (0.25 g, 686.03 μmol) in dichloromethane (2 mL) andmethanol (0.2 mL). The resulting reaction mixture was stirred at 10° C.for 1 h. Water was poured into the reaction mixture, which was extractedwith dichloromethane (20 mL). The organic phase was washed withsaturated brine (15 mL), dried over anhydrous sodium sulfate, andconcentrated under reduced pressure. The residue obtained from theconcentration was purified by a preparative TLC plate to obtain Compound24-3. LCMS (ESI) m/z: 379 (M+1).

4) Synthesis of Compound 24

A mixed solution of Compound 24-3 (60 mg, 158.55 μmol), Compound 1-7(120 mg, 525.87 μmol), methylbenzene (2 mL), and DMF (0.5 mL) was heatedto 110° C., and stirred for 16 h. Methanol (1 mL) was added to thereaction mixture, and the resulting mixture was stirred for 30 min, andthen concentrated under reduced pressure. The residue obtained from theconcentration was purified by a preparative TLC plate, and then purifiedby preparative HPLC to obtain Compound 24. ¹H NMR (400 MHz, CDCl₃) δ ppm7.97-7.84 (m, 3H), 7.79 (br d, J=10.0 Hz, 1H), 7.37 (dd, J=2.1, 10.2 Hz,1H), 4.70 (t, J=5.9 Hz, 2H), 2.98 (q, J=7.5 Hz, 2H), 2.83 (br s, 2H),2.36 (br s, 6H), 1.59 (s, 6H), 1.35 (t, J=7.5 Hz, 3H); LCMS (ESI) m/z:575.0 (M+1).

Example 24 Synthesis of Compound 25

1) Synthesis of Compound 25-1

A mixed solution of Compound 20-6 (80 mg, 185.84 μmol), Compound 23-7(130 mg, 567.24 μmol), methylbenzene (2 mL), and DMF (0.5 mL) was heatedto 110° C., and stirred for 16 h. Methanol (1 mL) was added to thereaction mixture, and the resulting mixture was stirred for 30 min, andthen concentrated under reduced pressure. The residue obtained from theconcentration was purified by a preparative TLC plate to obtain Compound25-1. LCMS (ESI) m/z: 661 (M+1).

2) Synthesis of Compound 25

Trifluoroacetic acid (0.4 mL) was added to a solution of Compound 25-1(90 mg, 136.23 μmol) in dichloromethane (2 mL). The resulting reactionmixture was stirred at 10° C. for 1 h. A saturated aqueous solution ofsodium bicarbonate was added to the reaction mixture (pH about 8), whichwas extracted with dichloromethane (10 mL×3). The organic phase waswashed with saturated brine (15 mL), dried over anhydrous sodiumsulfate, and concentrated under reduced pressure. The residue obtainedfrom the concentration was purified by preparative HPLC to obtainCompound 25. ¹H NMR (400 MHz, CDCl₃) δ ppm 9.03 (d, J=1.8 Hz, 1H), 8.30(d, J=1.8 Hz, 1H), 7.91 (s, 1H), 7.39 (dd, J=2.0, 9.8 Hz, 1H), 4.78-4.69(m, 2H), 4.08-3.97 (m, 2H), 2.99 (q, J=7.5 Hz, 2H), 2.70 (br t, J=9.4Hz, 2H), 2.61-2.48 (m, 2H), 2.30-2.13 (m, 1H), 1.73-1.55 (m, 2H), 1.36(t, J=7.7 Hz, 3H); LCMS (ESI) m/z: 561 (M+1).

Example 25 Synthesis of Compound 26

1) Synthesis of Compound 26-1

With reference to the synthesis of Compound 11-8, Compound 26-1 wasprepared with Compound 21-6 as the starting material. LCMS (ESI) m/z:671 (M+1).

2) Synthesis of Compound 26

With reference to the synthesis of Compound 11, Compound 26 was preparedwith Compound 26-1 as the starting material. ¹H NMR (400 MHz, CDCl₃) δppm 9.03 (d, J=1.76 Hz, 1H), 8.29 (d, J=2.01 Hz, 1H), 7.96 (s, 1H),7.58-7.45 (m, 1H), 6.85-6.44 (m, 1H), 4.89-4.76 (m, 2H), 4.07 (br d,J=3.76 Hz, 2H), 2.16 (br s, 1H), 1.64 (s, 6H); LCMS (ESI) m/z: 571(M+1).

Example 26 Synthesis of Compound 27

1) Synthesis of Compound 27-1

Compound 17-1 (1.50 g, 5.93 mmol), Compound 1-4 (917 mg, 8.89 mmol),cuprous chloride (117 mg, 1.19 mmol), 2-acetylcyclohexanone (166 mg,1.19 mmol), potassium carbonate (2.05 g, 14.82 mmol),N,N-dimethylformamide (10 mL), and water (2.5 mL) were added to a 30 mLmicrowave tube. The resulting mixture was kept at 130° C. for microwavereaction for 1 h. The reaction mixture was filtered, and the filter cakewas washed with DMF (10 mL×3). Dilute hydrochloric acid (2 mol/L) wasadded dropwise to the filtrate, such that the filtrate was weakly acidic(pH about 6). The filtrate was concentrated to dryness under reducedpressure. The residue obtained from the concentration was slurried withdichloromethane/methanol (10/1, 30 mL) at 15° C. for 2 min, andfiltered. The filtrate was concentrated to dryness under reducedpressure to obtain Compound 27-1. LCMS (ESI) m/z: 276 (M+1).

2) Synthesis of Compound 27-2

Compound 27-1 (4.40 g, 15.98 mmol) was dissolved in methanol (40 mL),and dichlorosulfoxide (19.01 g, 159.80 mmol, 11.59 mL) was addeddropwise at 0° C. The resulting mixture was heated to 50° C., andstirred for 18 h. The reaction mixture was cooled to 15° C., andconcentrated to dryness under reduced pressure. The residue obtainedfrom the concentration was dissolved in a saturated sodium bicarbonatesolution (50 mL), and extracted with dichloromethane/methanol (10:1, 80mL×4). The organic phases were combined, washed with saturated brine (50mL), dried over anhydrous sodium sulfate, and filtered. The filtrate wasconcentrated to dryness under reduced pressure. The residue obtainedfrom the concentration was purified by a silica gel column to obtainCompound 27-2. LCMS (ESI) m/z: 290 (M+1).

3) Synthesis of Compound 27-3

Under nitrogen protection, Compound 27-2 (560 mg, 1.94 mmol) andCompound 1-7 (1.77 g, 7.74 mmol) were dissolved in N,N-dimethylformamide(2 mL) and methylbenzene (20 mL), and the resulting mixture was heatedto 120° C., and stirred for 18 h. The reaction mixture was cooled toroom temperature, and concentrated to dryness under reduced pressure.The residue obtained from the concentration was purified by a silica gelcolumn to obtain Compound 27-3. LCMS (ESI) m/z: 486 (M+1).

4) Synthesis of Compound 27

Under nitrogen protection, a turbid liquid of Compound 27-3 (789 mg,1.63 mmol), 2-bromoethanol (609 mg, 4.88 mmol), potassium carbonate (674mg, 4.88 mmol), and N,N-dimethylformamide (10 mL) was stirred at 30° C.for 17 h, supplemented with 2-bromoethanol (609 mg, 4.88 mmol) andfurther stirred at 30° C. for 5 h, and supplemented with 2-bromoethanol(609 mg, 4.88 mmol) and further stirred at 30° C. for 18 h. The reactionmixture was cooled to room temperature, and then directly filtered. Thefiltrate was separated and purified by preparative HPLC to obtainCompound 27. ¹HNMR (400 MHz, CDCl₃) δ ppm 8.13 (d, J=2.5 Hz, 1H),8.08-7.99 (m, 3H), 7.88 (dd, J=2.0, 8.3 Hz, 1H), 7.73 (dd, J=2.4, 8.9Hz, 1H), 4.85-4.78 (m, 2H), 4.14-4.07 (m, 2H), 3.16 (t, J=5.6 Hz, 1H),3.03 (q, J=7.5 Hz, 2H), 1.68 (s, 6H), 1.44 (t, J=7.5 Hz, 3H); LCMS (ESI)m/z: 530 (M+1).

Example 27 Synthesis of Compound 28

1) Synthesis of Compound 28-1

Sodium hydride (166 mg, 60% purity) was added to a solution of Compound19-2 (1.00 g) and methyl 2-hydroxyacetate (373 mg) in tetrahydrofuran(20 mL). The mixture was stirred at 16° C. for 1 h. The reaction mixturewas quenched with water (20 mL), and extracted with dichloromethane (20mL×3). The combined organic phase was washed with saturated brine (20mL), dried over anhydrous sodium sulfate, filtered, and concentrated toobtain Compound 28-1. LCMS (ESI) m/z: 345 (M+3).

2) Synthesis of Compound 28-2

Compound 28-1 (600 mg), Compound 1-4 (270 mg), cuprous chloride (17 mg),2-acetylcyclohexanone (25 mg), and potassium carbonate (604 mg) wereadded to a microwave tube filled with DMF (10 mL) and water (2 mL).After nitrogen purge for 1 min, the resulting mixture was kept at 130°C. for microwave reaction for 1 h, and filtered, and the filter cake waswashed with DMF (2 mL). The filtrate was adjusted to pH=7 with 2Mhydrochloric acid, and then concentrated. Dichloromethane/methanol(10/1, 20 mL) was added to the resulting oil to precipitate a solid.After filtration, the resulting filtrate was concentrated to obtainCompound 28-2. LCMS (ESI) m/z: 352 (M+1).

3) Synthesis of Compound 28-3

TMSCHN₂ (2M, 4.70 mL) was added dropwise to a solution of Compound 28-2(1.10 g) in dichloromethane (20 mL) and methanol (2 mL). After thecompletion of the dropwise addition, the mixture reacted at 18° C. for 2h. The reaction mixture was concentrated, and the concentrate waspurified by thin layer chromatography to obtain Compound 28-3. LCMS(ESI) m/z: 380 (M+1).

4) Synthesis of Compound 28-4

Compound 1-7 (230 mg) was added to Compound 28-3 (130 mg) in a mixedsolvent of methylbenzene (4 mL) and DMF (1 mL), and then the resultingmixture was heated to 120° C., and stirred for 28 h. The reactionmixture was cooled to room temperature, and concentrated. Theconcentrate was purified by thin layer chromatography to obtain Compound28-4. LCMS (ESI) m/z: 576 (M+1).

5) Synthesis of Compound 28-5

Lithium hydroxide (1M, 0.5 mL) was added to a solution of Compound 28-4(90 mg) in tetrahydrofuran (3 mL), and the resulting mixture was stirredat 15° C. for 1 h. Then, the reaction mixture was adjusted to a pH ofabout 6 with 1M dilute hydrochloric acid, and extracted withdichloromethane (20 mL×2). The combined organic phase was washed withsaturated brine (20 mL), dried over anhydrous sodium sulfate, filtered,and concentrated to obtain Compound 28-5. LCMS (ESI) m/z: 562 (M+1).

6) Synthesis of Compound 28

HATU (75 mg) was added to a solution of Compound 28-5 (80 mg),methylamine hydrochloride (16 mg), and triethylamine (50 mg) indichloromethane (5 mL). Then, the resulting mixture was stirred at 15°C. for 1 h. The reaction mixture was concentrated, and the concentratewas purified by thin layer chromatography. The resulting sample wasfurther purified by HPLC (alkaline) to obtain Compound 28. ¹H NMR (400MHz, CDCl₃) δ ppm 7.97-8.08 (m, 2H), 7.94 (s, 1H), 7.87 (dd, J=8.28,1.76 Hz, 1H), 7.52 (dd, J=10.04, 2.01 Hz, 1H), 6.12 (br s, 1H), 5.17 (s,2H), 3.08 (q, J=7.53 Hz, 2H), 2.94 (d, J=4.77 Hz, 3H), 1.70 (s, 6H),1.42 (t, J=7.53 Hz, 3H); LCMS (ESI) m/z: 575 (M+1).

Example 28 Synthesis of Compound 29

1) Synthesis of Compound 29-2

With reference to the synthesis of Compound 28-1, Compound 29-2 wasprepared with Compound 19-2 as the starting material. LCMS (ESI) m/z:343 (M+3).

2) Synthesis of Compound 29-3

With reference to the synthesis of Compound 28-2, Compound 29-3 wasprepared with Compound 29-2 as the starting material. LCMS (ESI) m/z:364 (M+1).

3) Synthesis of Compound 29-4

With reference to the synthesis of Compound 28-3, Compound 29-4 wasprepared with Compound 29-3 as the starting material. ¹H NMR (400 MHz,CDCl³) δ ppm 6.71 (dd, J=12.17, 2.64 Hz, 1H), 6.64 (d, J=2.01 Hz, 1H),4.76 (dd, J=7.78, 6.27 Hz, 2H), 4.62 (d, J=6.27 Hz, 2H), 4.53 (t, J=6.15Hz, 2H), 4.29 (s, 1H), 3.58 (s, 3H), 3.35-3.45 (m, 1H), 2.79 (q, J=7.53Hz, 2H), 1.47 (s, 6H), 1.22 (t, J=7.65 Hz, 3H); LCMS (ESI) m/z: 378(M+1).

4) Synthesis of Compound 29

With reference to the synthesis of Compound 28-4, Compound 29 wasprepared with Compound 29-4 as the starting material. ¹H NMR (400 MHz,CDCl₃) δ ppm 7.88-7.98 (m, 2H), 7.74-7.84 (m, 2H), 7.39 (dd, J=10.04,2.01 Hz, 1H), 4.85 (dd, J=7.78, 6.27 Hz, 2H), 4.79 (d, J=6.27 Hz, 2H),4.59 (t, J=6.15 Hz, 2H), 3.44-3.55 (m, 1H), 2.98 (q, J=7.53 Hz, 2H),1.58 (s, 6H), 1.32-1.40 (m, 3H); LCMS (ESI) m/z: 574 (M+1).

Example 29 Synthesis of Compound 30

1) Synthesis of Compound 30-3

Compound 30-1 (20.00 g) and Compound 30-2 (16.67 g) were added to aceticacid (250 mL). Then, the resulting mixture was heated to 120° C., andstirred at this temperature for 16 h. The reaction mixture wasconcentrated under reduced pressure, diluted with 200 mL of water, andextracted with ethyl acetate (200 mL×3). After liquid separation, theorganic phases were collected, and combined. The combined organic phasewas dried over anhydrous sodium sulfate, filtered, and concentratedunder reduced pressure. The concentrate was slurried with petroleumether to obtain Compound 30-3. ¹H NMR (400 MHz, CDCl₃) δ ppm 9.16 (d,J=1.98 Hz, 1H), 7.73 (dd, J=9.48, 2.21 Hz, 1H), 7.48 (d, J=9.48 Hz, 1H),6.39 (s, 1H), 2.72 (q, J=7.64 Hz, 2H), 1.32 (t, J=7.61 Hz, 3H).

2) Synthesis of Compound 30-4

Compound 30-3 (1.50 g), Compound 1-4 (916 mg), cuprous chloride (58 mg),2-acetylcyclohexanone (83 mg), and potassium carbonate (2.05 g) wereadded to a microwave reaction tube. Then, the solvent of DMF (15 mL) andwater (3 mL) was added, and the resulting mixture was kept at 130° C.for microwave reaction for 1 h. The reaction mixture was filtered, andthe filter cake was washed with DMF (10 mL×3). The combined filtrate wasconcentrated to obtain Compound 30-4. LCMS (ESI) m/z: 276 (M+1).

3) Synthesis of Compound 30-5

A solution of methanol/hydrochloric acid (100 mL) was added to Compound30-4 (3.76 g). The resulting mixture was heated to 70° C., and stirredat this temperature for 16 h. The reaction mixture was concentrated,adjusted to pH=7 with a saturated sodium bicarbonate solution, andextracted with ethyl acetate (25 mL×3). The organic phases werecombined, and were successively washed with saturated brine (25 mL×3),dried over anhydrous sodium sulfate, filtered, and concentrated. Theconcentrate was purified by column chromatography to obtain Compound30-5. LCMS (ESI) m/z: 290 (M+1).

4) Synthesis of Compound 30

Compound 30-5 (200 mg) and Compound 1-7 (315 mg) were dissolved in amixed solution of methylbenzene (4 mL) and DMF (1 mL), and the resultingmixture was heated to 120° C., and stirred at this temperature in anitrogen atmosphere for 16 h. The reaction mixture was concentratedunder reduced pressure, dissolved in acetonitrile, and purified bypreparative HPLC to obtain Compound 30. ¹H NMR (400 MHz, CDCl₃) δ ppm9.02 (d, J=1.98 Hz, 1H), 8.02 (d, J=8.38 Hz, 1H), 7.96 (s, 1H),7.82-7.88 (m, 1H), 7.67-7.73 (m, 1H), 7.60-7.66 (m, 1H), 6.44 (s, 1H),2.77 (q, J=7.57 Hz, 2H), 1.35 (t, J=7.61 Hz, 3H). LCMS (ESI) m/z: 486(M+1).

Example 30 Synthesis of Compound 31

1) Synthesis of Compound 31-1

In a dry single-necked flask, iodobenzene diacetate (16.09 g) andmethanol (250 mL) were added, then a solution of boron trifluoridediethyl etherate (7.09 g) was added dropwise, and then Compound 30-2(6.86 g) was added. The resulting mixture was stirred at 25° C. for 28h. After the completion of the reaction, the reaction mixture wasconcentrated. 50 mL of a saturated aqueous solution of sodiumbicarbonate was added, and the resulting mixture was extracted withethyl acetate (75 mL×3). After liquid separation, the organic phase waswashed with 50 ml of saturated brine, dried over anhydrous sodiumsulfate, filtered, and concentrated. The concentrate was purified by achromatographic column to obtain Compound 31-1. ¹H NMR (400 MHz, CDCl₃)δ ppm 4.27-4.18 (m, 3H), 3.43 (s, 3H), 2.67-2.51 (m, 2H), 1.26 (t, J=7.2Hz, 3H), 1.02 (t, J=7.3 Hz, 3H), LCMS (ESI) m/z: 175 (M+1).

2) Synthesis of Compound 31-4

In a dry reaction flask, Compound 31-1 (2.15 g) and Compound 31-2 (2.14g) were added, and then ethanol (22 mL) and acetic acid (2.2 mL) wereadded. The resulting mixture was heated to 90° C., stirred for 72 h, andconcentrated to dryness to remove the solvent. 50 mL of water was addedto the residue, and the resulting mixture was fully stirred, andextracted with ethyl acetate (30 mL×3). The organic phase was dried overanhydrous sodium sulfate, and filtered. The filtrate was concentrated,and the concentrate was purified by a chromatographic column to obtainCompound 31-4. ¹H NMR (400 MHz, CDCl₃) δ ppm 9.08-9.07 (m, 1H), 7.59(dd, J=2.2, 9.5 Hz, 1H), 7.44 (dd, J=0.7, 9.5 Hz, 1H), 3.97 (s, 3H),2.81 (q, J=7.7 Hz, 2H), 1.27 (t, J=7.6 Hz, 3H).

3) Synthesis of Compound 31-5

In a microwave tube, Compound 31-4 (250 mg), Compound 2-aminoisobutyricacid (149 mg), potassium carbonate (332 mg), cuprous chloride (19 mg),and 2-acetylcyclohexanone (27 mg, 192 μmol) were dissolved in a mixedsolvent of DMF (5 mL) and water (0.5 mL), and the resulting mixture waskept at 130° C. for microwave reaction for 1.5 h. The reaction mixturewas cooled, and then filtered. 12 mL of water was added to the filtrate,which was then extracted with ethyl acetate (20 mL×3), and the aqueousphase was concentrated under reduced pressure to obtain Compound 31-5.LCMS (ESI) m/z: 306 (M+1).

4) Synthesis of Compound 31-6

In a pre-dried single-necked flask, Compound 31-5 (5.50 g) and asolution of hydrochloric acid in methanol (4N, 50 mL) were added, andthe resulting mixture was heated to 90° C. and stirred for 12 h undernitrogen protection. A solid residue was obtained by concentration underreduced pressure. The solid residue was dissolved in 100 mL of ethylacetate, and then washed with a saturated aqueous solution of sodiumbicarbonate (50 mL×1). After liquid separation, the organic phase wascollected, washed with saturated brine (50 mL×1), dried over anhydroussodium sulfate, and filtered. The filtrate was concentrated, and theresulting concentrate was purified by a chromatographic column to obtainCompound 31-6. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.15 (d, J=2.2 Hz, 1H),7.44 (d, J=9.5 Hz, 1H), 7.15 (dd, J=2.8, 9.6 Hz, 1H), 4.28 (s, 1H), 3.95(s, 3H), 3.77 (s, 3H), 2.78 (q, J=7.6 Hz, 2H), 1.62 (s, 6H), 1.26 (t,J=7.6 Hz, 3H). LCMS (ESI) m/z: 320 (M+1).

5) Synthesis of Compound 31

In a dry single-necked flask, Compound 31-6 (200 mg), DMF (1.5 mL) andmethylbenzene (6 mL) were added, and then Compound 1-7 (429 mg) wasadded. Under nitrogen protection, the resulting mixture was heated to80° C., and stirred at this temperature for 3 h. After concentrationunder reduced pressure, the concentrate was purified by preparative HPLCmethod to obtain Compound 31. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.97 (d,J=2.2 Hz, 1H), 8.02 (d, J=8.2 Hz, 1H), 7.97 (s, 1H), 7.85 (br d, J=8.4Hz, 1H), 7.68 (d, J=9.5 Hz, 1H), 7.51 (dd, J=2.2, 9.5 Hz, 1H), 4.02 (s,3H), 2.88 (q, J=7.6 Hz, 2H), 1.69 (s, 6H), 1.32 (t, J=7.6 Hz, 3H). LCMS(ESI) m/z: 516 (M+1).

Example 31 Synthesis of Compound 32

1) Synthesis of Compound 32-1

In a dry reaction flask, Compound 19-2 (1.00 g), methyl 2-hydroxyacetate(466 mg) and tetrahydrofuran (10 mL) were added, and then NaH (207 mg,60% purity) was added in batches. The reaction mixture reacted at 20° C.for 1 h, then was diluted with a saturated aqueous solution of ammoniumchloride (50 mL), and extracted with ethyl acetate (30 mL×3). Theorganic phases were combined, and concentrated. The resultingconcentrate was purified by a chromatographic column to obtain Compound32-1. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.16-8.20 (m, 1H), 7.67 (dd, J=9.54,2.13 Hz, 1H), 5.15 (s, 2H), 3.82 (s, 3H), 2.99 (q, J=7.57 Hz, 2H), 1.37(t, J=7.53 Hz, 3H).

2) Synthesis of Compound 32-2

In a microwave tube, Compound 32-1 (500 mg), Compound 1-4 (225 mg),cuprous chloride (14 mg), 2-acetylcyclohexanone (20 mg), and potassiumcarbonate (402 mg) were added, and then DMF (4 mL) and water (0.5 mL)were added. After nitrogen purge for 1 min, the resulting mixture waskept at 130° C. for microwave reaction for 1 h. The reaction mixture wasfiltered in the presence of Celite, and the filter cake was washed withDMF (5 mL×2). The filtrate was collected, and concentrated to drynessunder reduced pressure, to obtain Compound 32-2. LCMS (ESI) m/z: 352(M+1).

3) Synthesis of Compound 32-3

A solution of TMSCHN₂ in n-hexane (2M, 4.70 mL) was added dropwise to asolution of Compound 32-2 (1.10 g) in dichloromethane (20 mL) andmethanol (2 mL). The resulting mixture reacted at 20° C. for 2 h.TMSCHN₂ (2M, 4.70 mL) was supplemented, and then the mixture was stirredfor 16 h. The reaction mixture was concentrated to dryness. The residuewas purified by a chromatographic column to obtain Compound 32-3. ¹H NMR(400 MHz, CDCl₃) δ ppm 6.84-6.91 (m, 2H) 5.04-5.12 (m, 2H) 4.48 (s, 1H)3.79 (s, 3H) 3.75 (s, 3H) 2.91 (q, J=7.53 Hz, 2H) 1.64 (s, 6H) 1.32 (t,J=7.59 Hz, 3H).

4) Synthesis of Compound 32-4

In a dry single-necked flask, Compound 32-3 (630 mg) and Compound 1-7(378 mg) were added, and then methylbenzene (4 mL) and DMF (1 mL) wereadded. The resulting mixture reacted at 120° C. for 24 h. The reactionmixture was concentrated under reduced pressure. The resulting residuewas purified by preparative HPLC to obtain Compound 32-4. LCMS (ESI)m/z: 576 (M+1).

5) Synthesis of Compound 32-5

In a pre-dried single-necked flask, Compound 32-4 (55 mg) andtetrahydrofuran (4 mL) were added, and then a solution of lithiumhydroxide monohydrate (6 mg) in water (1 mL) was added. The resultingmixture was stirred at 25° C. for 2 h. A saturated ammonium chloridesolution (5 mL) and ethyl acetate (10 mL) were added to the reactionmixture for liquid separation. The aqueous phase was extracted withethyl acetate (5 mL×3). The organic phases were combined, dried oversodium sulfate, and concentrated. The resulting residue was purified bypreparative TLC to obtain Compound 32-5. LCMS (ESI) m/z: 562 (M+1). 6)Synthesis of Compound 32

In a 10 mL dry reaction flask, Compound 32-5 (37 mg) and dichloromethane(2 mL) were added, and then HATU (30 mg), ammonium chloride (5 mg), andtriethylamine (20 mg) were added at 0° C. The resulting mixture wasstirred at 25° C. for 16 h, then diluted with 4 mL of water, extractedwith dichloromethane (5 mL×3), dried, and concentrated. The resultingresidue was separated by preparative HPLC to obtain Compound 32. ¹H NMR(400 MHz, CDCl₃) δ ppm 7.99 (d, J=8.16 Hz, 1H), 7.95 (s, 1H), 7.90 (s,1H), 7.83 (dd, J=8.27, 1.87 Hz, 1H), 7.48 (dd, J=9.81, 2.09 Hz, 1H),6.03 (br s, 1H), 5.59 (br s, 1H), 5.13 (s, 2H), 3.05 (q, J=7.57 Hz, 2H),1.66 (s, 6H), 1.40 (t, J=7.61 Hz, 3H); LCMS (ESI) m/z: 561 (M+1).

Example 32 Synthesis of Compound 33

1) Synthesis of Compound 33

In a dry single-necked flask, Compound 31 (50 mg) and dichloromethane (2mL) were added, and then boron tribromide (97 mg) was added in an icebath. The resulting mixture was controlled at a temperature of 0° C.,and stirred for 2 h. At 0° C., 0.5 mL of ice water was added to thereaction mixture to quench the reaction, and then a small amount ofsodium bicarbonate solids were added to adjust the pH to 7-8. Afterdichloromethane was removed under reduced pressure at 0° C., 3 mL ofDMSO was added to the residue to dissolve the mixture. After filtration,the resulting solution was purified by preparative HPLC method to obtainCompound 33. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.83 (d, J=1.5 Hz, 1H), 8.02(d, J=8.4 Hz, 1H), 7.97 (d, J=2.0 Hz, 1H), 7.85 (dd, J=2.0, 8.2 Hz, 1H),7.70-7.67 (m, 1H), 7.40 (dd, J=2.3, 9.6 Hz, 1H), 2.92 (q, J=7.6 Hz, 2H),1.69 (s, 6H), 1.35 (t, J=7.6 Hz, 3H); LCMS (ESI) m/z: 502 (M+1).

Example 33 Synthesis of Compound 34

1) Synthesis of Compound 34-2

Compound 31-1 (5.03 g) was added to a solution of Compound 34-1 (2.00 g)in acetic acid (20 mL), and the resulting mixture was heated to 110° C.,and stirred for 16 h. The reaction mixture was concentrated. Theconcentrate was diluted with dichloromethane (30 mL), washed with asaturated sodium bicarbonate solution (30 mL×2) and saturated brine (30mL) respectively, dried over anhydrous sodium sulfate, filtered, andconcentrated. The concentrate was purified by flash columnchromatography (model: ISCO-RF150) to obtain Compound 34-2. LCMS (ESI)m/z: 301 (M+1).

2) Synthesis of Compound 34-3

With reference to the synthesis of Compound 31-5, Compound 34-3 wasprepared with Compound 34-2 as the starting material. LCMS (ESI) m/z:324 (M+1).

3) Synthesis of Compound 34-4

With reference to the synthesis of Compound 31-6, Compound 34-4 wasprepared with Compound 34-3 as the starting material. ¹H NMR (400 MHz,CDCl₃) δ ppm 7.92 (dd, J=2.38, 0.88 Hz, 1H), 6.90 (dd, J=10.42, 2.38 Hz,1H), 3.89-3.94 (m, 1H), 3.91 (s, 2H), 3.73 (s, 3H), 2.77 (q, J=7.70 Hz,2H), 1.57 (s, 6H), 1.21 (t, J=7.53 Hz, 3H); LCMS (ESI) m/z: 337.9 (M+1).

4) Synthesis of Compound 34

With reference to the synthesis of Compound 31, Compound 34 was preparedwith Compound 34-4 as the starting material. ¹H NMR (400 MHz, CDCl₃) δppm 8.74-8.85 (m, 1H), 8.02 (d, J=8.28 Hz, 1H), 7.95 (d, J=2.01 Hz, 1H),7.83 (dd, J=8.28, 2.01 Hz, 1H), 7.27-7.31 (m, 1H), 4.03 (s, 3H), 2.91(q, J=7.53 Hz, 2H), 1.69 (s, 6H), 1.33 (t, J=7.53 Hz, 3H); LCMS (ESI)m/z: 534 (M+1).

Example 34 Synthesis of Compound 35

1) Synthesis of Compound 35-1

Methyl propionylacetate (4.00 g) was added to a solution of Compound34-1 (4.00 g) in acetic acid (40 mL). The resulting mixture was heatedto 110° C., and stirred for 94 h. Methyl propionylacetate (8.26 g) wassupplemented to the reaction mixture, and the reaction mixture wasfurther stirred for 16 h. The reaction mixture was concentrated. Theconcentrate was diluted with ethyl acetate (80 mL), and a saturatedaqueous solution of sodium bicarbonate (80 mL) was added. After liquidseparation, the organic phase was washed with saturated brine (80 mL),dried over anhydrous sodium sulfate, filtered, and concentrated. Theresidue obtained from the concentration was purified by a silica gelcolumn to obtain Compound 35-1. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.89 (s,1H), 7.45 (dd, J=2.0, 8.0 Hz, 1H), 6.36 (s, 1H), 2.70 (q, J=7.5 Hz, 2H),1.25 (t, J=7.5 Hz, 3H).

2) Synthesis of Compound 35-2

Compound 35-1 (400 mg), Compound 1-4 (228 mg), potassium carbonate (510mg), cuprous chloride (30 mg), 2-acetylcyclohexanone (42 mg),N,N-dimethylformamide (4 mL), and water (0.2 mL) were added to amicrowave tube. The microwave tube was sealed, and kept at 130° C. formicrowave reaction for 30 min. The reaction mixture was filtered, andwashed with ethyl acetate (20 mL). The filtrate was concentrated. 1Nhydrochloric acid was added to the residue obtained from theconcentration (to adjust the pH to 6-7), and the resulting mixture wasconcentrated. Dichloromethane/methanol (40 mL, 10/1) were added to theresidue obtained from the concentration, and the resulting mixture wasdried over anhydrous sodium sulfate, and filtered. The filtrate wasconcentrated under reduced pressure to obtain Compound 35-2. LCMS (ESI)m/z: 294 (M+1).

3) Synthesis of Compound 35-3

A solution of trimethylsilyldiazomethane in n-hexane (2M, 1.2 mL) wasadded to a solution of Compound 35-2 (500 mg) in dichloromethane (10 mL)and methanol (1 mL). The resulting mixture was stirred at 15° C. for 2h. The reaction mixture was concentrated. The residue obtained from theconcentration was purified by a silica gel column to obtain Compound35-3. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.01 (d, J=1.3 Hz, 1H), 7.04 (dd,J=2.4, 10.4 Hz, 1H), 6.26 (s, 1H), 4.43 (br s, 1H), 3.72 (s, 3H), 2.66(q, J=7.5 Hz, 2H), 1.56 (s, 6H), 1.23 (t, J=7.5 Hz, 3H).

4) Synthesis of Compound 35

A mixed solution of Compound 35-3 (100 mg) and Compound 1-7 (297 mg) inN,N-dimethylformamide (0.5 mL) and methylbenzene (2 mL) was heated to120° C., and stirred for 16 h. Methanol (0.5 mL) was added to thereaction mixture, which was stirred for 30 min, and then concentratedunder reduced pressure. The residue obtained from the concentration waspurified by a preparative chromatoplate to obtain Compound 35. ¹H NMR(400 MHz, CDCl₃) δ ppm 8.76 (d, J=1.8 Hz, 1H), 7.94 (d, J=8.3 Hz, 1H),7.88 (d, J=2.0 Hz, 1H), 7.76 (dd, J=2.0, 8.3 Hz, 1H), 7.33 (dd, J=2.3,8.8 Hz, 1H), 6.42 (s, 1H), 2.74 (q, J=7.7 Hz, 2H), 1.62 (s, 6H), 1.28(t, J=7.5 Hz, 3H); LCMS (ESI) m/z: 504 (M+1).

Example 35 Synthesis of Compound 36

1) Synthesis of Compound 36-1

In a 50 mL dry single-necked flask, Compound 19-1 (1.00 g), Compound 1-4(571 mg), water (2.5 mL) and DMF (10 mL) were added, and then cuprouschloride (36 mg), 2-acetylcyclohexanone (52 mg), and potassium carbonate(1.02 g) were added. The resulting mixture was stirred at 130° C. for 90min. Water (10 mL) was added, the mixture was adjusted to pH=2-3 with 1Mdilute hydrochloric acid, and ethyl acetate (40 mL) was added. Theaqueous phase was extracted with ethyl acetate (40 mL×3). The organicphases were combined, and concentrated to remove the solvent.Dichloromethane (5 mL) was added to the concentrate, and stirred for 5min. Petroleum ether (10 mL) was slowly added dropwise, and theresulting mixture was stirred for 10 min. The mixture was filtered, andthe filter cake was dried to obtain Compound 36-1. LCMS (ESI) m/z: 294(M+1).

2) Synthesis of Compound 36-2

In a 50 mL dry single-necked flask, Compound 36-1 (3.00 g) and ahydrochloric acid/methanol solution (30 mL) were added, and theresulting mixture was stirred at 60° C. for 16 h, and then concentrated.Ethyl acetate (20 mL) and a saturated potassium carbonate solution (20mL) were added to the residue obtained from the concentration. Afterliquid separation, the resulting organic phase was dried over anhydroussodium sulfate, and filtered. The filtrate was concentrated to obtainCompound 36-2. LCMS (ESI) m/z: 308 (M+1).

3) Synthesis of Compound 36-3

In a single-necked flask, Compound 36-2 (2.10 g), Compound 1-7 (4.68 g),methylbenzene (20 mL), and DMF (5 mL) were added, and the resultingmixture reacted at 120° C. for 16 h under nitrogen protection, and thenwas concentrated to remove methylbenzene and DMF. The residue obtainedfrom the concentration was purified by column chromatography to obtainCompound 36-3. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.97-8.06 (m, 4H), 7.86(dd, J=8.22, 1.82 Hz, 1H), 7.48 (dd, J=9.79, 2.26 Hz, 1H), 2.85-2.91 (m,2H), 1.67 (s, 6H), 1.47 (t, J=7.59 Hz, 3H).

4) Synthesis of Compound 36-4

In a single-necked flask, Compound 36-3 (200 mg) and phosphorusoxychloride (3.30 g) were added. Under nitrogen protection,N,N-diisopropylethylamine (80 mg) was added, and the resulting mixturereacted at 110° C. for 0.5 h. Phosphorus oxychloride was removed fromthe reaction mixture under reduced pressure. The resulting residue wasdissolved in 10 mL of dichloromethane in an ice water bath, and then 30mL of a saturated sodium bicarbonate solution was added. After liquidseparation, the aqueous phase was extracted with dichloromethane (10mL×3). The organic phases were combined, washed with 10 mL of saturatedbrine, dried over anhydrous sodium sulfate, and filtered. The filtratewas concentrated under reduced pressure at 45° C. to obtain Compound36-4. LCMS (ESI) m/z: 522 (M+1).

5) Synthesis of Compound 36

In a reaction flask, Compound 36-4 (100 mg), Compound 36-5 (25 mg), andtetrahydrofuran (1 mL) were added. Under nitrogen protection, sodiumhydride (11 mg, 60% purity) was added at 0° C., and the resultingmixture reacted at 20° C. for 0.5 h. The reaction was quenched with asaturated ammonium chloride solution (3 mL). After extraction with ethylacetate (3 mL×3), the organic phase was washed with saturated brine (1mL), dried over anhydrous sodium sulfate, and filtered. The filtrate wasconcentrated at 45° C. The residue obtained from the concentration waspurified by preparative HPLC method to obtain Compound 36. ¹H NMR (400MHz, CDCl₃) δ ppm 8.02 (d, J=8.16 Hz, 1H), 7.99 (s, 1H), 7.94 (s, 1H),7.86 (br d, J=8.41 Hz, 1H), 7.48 (dd, J=10.04, 2.26 Hz, 1H), 4.76 (s,2H), 4.05 (s, 1H), 3.06 (q, J=7.49 Hz, 2H), 1.68 (s, 6H), 1.43 (t,J=7.59 Hz, 3H), 0.98-1.02 (m, 2H), 0.82-0.86 (m, 2H). LCMS (ESI) m/z:574 (M+1).

Example 36 Synthesis of Compound 37

1) Synthesis of Compound 37-1

Boron tribromide (2.40 g) was added dropwise to a solution of Compound31-6 (300 mg) in dichloromethane (8 mL) at 0° C. The resulting mixturewas stirred at 0° C. for 2 h. The reaction was quenched with 3 g of icewater, and the reaction mixture was concentrated under reduced pressureto obtain Compound 37-1. LCMS (ESI) m/z: 292 (M+1).

2) Synthesis of Compound 37-2

Methanol/hydrochloric acid (4M, 100 mL) as a solvent was added toCompound 37-1 (2.02 g), and the resulting mixture was stirred at 70° C.for 16 h. The reaction mixture was concentrated, the residue obtainedfrom the concentration was neutralized to a neutral pH with a saturatedsodium bicarbonate solution, and filtered. The filtrate was freeze-driedto obtain Compound 37-2. LCMS (ESI) m/z: 306 (M+1).

3) Synthesis of Compound 37-3

Compound 37-2 (200 mg) and Compound 1-7 (448 mg) were dissolved in amixed solution of DMF (4 mL) and methylbenzene (1 mL). The resultingmixture was heated to 120° C., and stirred for 16 h. The reactionmixture was concentrated, dissolved in acetonitrile, and purified bypreparative HPLC method to obtain Compound 37-3. LCMS (ESI) m/z: 502(M+1).

4) Synthesis of Compound 37

Compound 37-3 (75 mg), Compound 37-4 (25 mg), and potassium carbonate(62 mg) were dissolved in DMF (1 mL). The resulting mixture was heatedto 110° C., and stirred at this temperature for 3 h. Compound 37 wasobtained by preparative HPLC. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.95 (d,J=2.21 Hz, 1H), 8.02 (d, J=8.16 Hz, 1H), 7.97 (s, 1H), 7.82-7.88 (m,1H), 7.68 (d, J=9.26 Hz, 1H), 7.51 (dd, J=9.48, 2.43 Hz, 1H), 4.37-4.42(m, 2H), 3.72-3.77 (m, 2H), 3.46 (s, 3H), 2.93 (q, J=7.50 Hz, 2H), 1.68(s, 6H), 1.33 (t, J=7.61 Hz, 3H). LCMS (ESI) m/z: 560 (M+1).

Example 37 Synthesis of Compound 38

1) Synthesis of Compound 38

Compound 37-3 (100 mg), Compound 38-1 (41 mg), and potassium carbonate(82 mg) were added to DMF (1 mL), and the resulting mixture was heatedto 110° C., and stirred at this temperature for 3 h. Compound 38 wasobtained through purification by preparative HPLC method. ¹H NMR (400MHz, CDCl₃) δ ppm 8.94 (d, J=1.98 Hz, 1H), 8.00 (d, J=8.38 Hz, 1H), 7.94(s, 1H), 7.83 (br d, J=8.38 Hz, 1H), 7.69 (d, J=9.70 Hz, 1H), 7.54 (dd,J=9.59, 2.32 Hz, 1H), 4.19-4.25 (m, 2H), 4.05-4.12 (m, 1H), 3.87-3.94(m, 2H), 2.89 (q, J=7.50 Hz, 2H), 1.67 (s, 6H), 1.33 (t, J=7.61 Hz, 3H);LCMS (ESI) m/z: 546 (M+1).

Example 38 Synthesis of Compound 39

-   -   1) Synthesis of Compound 39-1

Boron tribromide (0.4 mL) was added to a solution of Compound 34-4 (320mg) in anhydrous dichloromethane (8 mL) at 0° C. The resulting mixturewas stirred at 0° C. for 2 h, diluted with dichloromethane (40 mL),slowly poured into water (20 mL), and extracted withdichloromethane/methanol (10/1, 40 mL). The organic phase was dried overanhydrous sodium sulfate, filtered, and concentrated to obtain Compound39-1. LCMS (ESI) m/z: 310 (M+1).

2) Synthesis of Compound 39-2

A solution of trimethylsilyldiazomethane in n-hexane (2M, 0.3 mL) wasadded to a solution of Compound 39-1 (120 mg) in dichloromethane (3 mL)and methanol (0.3 mL). The resulting mixture was stirred at 20° C. for 1h. The reaction mixture was concentrated under reduced pressure. Theresidue obtained from the concentration was purified by a preparativechromatoplate to obtain Compound 39-2. ¹H NMR (400 MHz, CDCl₃) δ ppm7.73 (s, 1H), 6.80 (br d, J=9.5 Hz, 1H), 6.22 (br s, 1H), 4.21 (br s,1H), 3.73 (s, 3H), 2.81 (q, J=7.5 Hz, 2H), 1.57 (s, 6H), 1.24 (t, J=7.7Hz, 3H).

3) Synthesis of Compound 39

A mixture of Compound 39-2 (30 mg), Compound 1-7 (100 mg), methylbenzene(1 mL), and N,N-dimethylformamide (0.2 mL) was heated to 110° C., andstirred for 16 h. Methanol (1 mL) was added to the reaction mixture,which was stirred for 30 min, and then concentrated under reducedpressure. The residue obtained from the concentration was separated andpurified successively by a preparative chromatoplate and preparativeHPLC to obtain Compound 39. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.58 (s, 1H),7.94 (d, J=8.3 Hz, 1H), 7.88 (s, 1H), 7.76 (br d, J=8.0 Hz, 1H), 7.11(dd, J=2.0, 9.0 Hz, 1H), 2.88 (q, J=7.4 Hz, 2H), 1.62 (s, 6H), 1.28 (t,J=7.7 Hz, 3H); LCMS (ESI) m/z: 520 (M+1).

Example 39 Synthesis of Compound 40

1) Synthesis of Compound 40

1-Bromo-2-methoxy-ethane (41 mg) and potassium carbonate (54 mg) wereadded to a solution of Compound 39 (100 mg) in N,N-dimethylformamide (2mL). The resulting mixture was stirred at 80° C. for 1 h, and filtered.The filtrate was separated and purified by preparative HPLC to obtainCompound 40. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.69 (br s, 1H), 8.03-7.69(m, 3H), 7.20 (br s, 1H), 4.33 (br s, 2H), 3.66 (br s, 2H), 3.37 (br s,3H), 2.88 (br d, J=7.3 Hz, 2H), 1.61 (br s, 6H), 1.26 (br t, J=7.0 Hz,3H); LCMS (ESI) m/z: 578 (M+1).

Example 40 Synthesis of Compound 41

1) Synthesis of Compound 41

Potassium carbonate (60 mg) was added to a solution of Compound 39 (100mg) and 2-bromoethanol (40 mg) in DMF (2 mL), and the resulting mixturewas heated to 100° C. and stirred for 1 h under nitrogen protection. Thereaction mixture was cooled to room temperature, and concentrated. Theconcentrate was purified successively by preparative TLC and preparativeHPLC to obtain Compound 41. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.80 (d, J=1.5Hz, 1H), 8.04 (d, J=8.3 Hz, 1H), 7.97 (s, 1H), 7.85 (dd, J=8.3, 2.0 Hz,1H), 7.35 (dd, J=8.8, 2.0 Hz, 1H), 4.23-4.35 (m, 2H), 3.95 (br s, 2H),3.77 (br s, 1H), 2.97 (q, J=7.7 Hz, 2H), 1.71 (s, 6H), 1.38 ppm (t,J=7.5 Hz, 3H); LCMS (ESI) m/z: 564 (M+1).

Example 41 Synthesis of Compound 42

1) Synthesis of Compound 42-1

Potassium carbonate (110 mg) was added to a solution of Compound 39 (200mg) and ethyl 2-bromoacetate (100 mg) in DMF (5 mL), and the resultingmixture heated to 80° C. and stirred for 1 h under nitrogen protection.The reaction mixture was cooled to room temperature, and filtered. Thefilter cake was washed with ethyl acetate (2 mL). The filtrate wasconcentrated to obtain Compound 42-1. LCMS (ESI) m/z: 606 (M+1).

2) Synthesis of Compound 42-2

An aqueous solution of lithium hydroxide monohydrate (1M, 0.7 mL) wasadded to a solution of Compound 42-1 (200 mg) in tetrahydrofuran (5 mL),and the resulting mixture was stirred at 26° C. for 1 h under nitrogenprotection. The reaction mixture was acidified to pH=5-6 with an aqueoussolution of dilute hydrochloric acid (1M), and extracted with ethylacetate (20 mL×3). The combined organic phase was washed with saturatedbrine (20 mL), dried over anhydrous sodium sulfate, filtered, andconcentrated to obtain Compound 42-2. LCMS (ESI) m/z: 578 (M+1).

3) Synthesis of Compound 42

Methylamine hydrochloride (18 mg) was added to a solution of Compound42-2 (100 mg), HATU (80 mg), and triethylamine (50 mg, 494.12 μmol) indichloromethane (5 mL), and the resulting mixture was stirred at 26° C.for 1 h. The reaction mixture was acidified to pH=5-6 with an aqueoussolution of dilute hydrochloric acid (1M), and extracted with ethylacetate (20 mL×3). The combined organic phase was washed with saturatedbrine (20 mL), dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue obtained from the concentration was purifiedby preparative TLC and preparative HPLC to obtain Compound 42. ¹H NMR(400 MHz, CDCl₃) δ ppm 8.68 (s, 1H), 7.95 (d, J=8.3 Hz, 1H), 7.88 (d,J=1.5 Hz, 1H), 7.76 (dd, J=8.3, 1.8 Hz, 1H), 7.31-7.36 (m, 1H), 7.29(dd, J=8.8, 2.0 Hz, 1H), 4.51 (s, 2H), 2.90 (d, J=5.0 Hz, 3H), 2.84 (q,J=7.7 Hz, 2H), 1.62 (s, 6H), 1.29 ppm (t, J=7.5 Hz, 3H); LCMS (ESI) m/z:591 (M+1).

Example 42 Synthesis of Compound 43

1) Synthesis of Compound 43

Ammonia water (30 mg) was added to a solution of Compound 42-2 (100 mg),HATU (79 mg), and triethylamine (53 mg) in DMF (5 mL), and the resultingmixture was stirred at 26° C. for 1 h. The reaction mixture wasacidified to pH=5-6 with an aqueous solution of dilute hydrochloric acid(1M), and extracted with ethyl acetate (20 mL×3). The combined organicphase was washed with saturated brine (20 mL), dried over anhydroussodium sulfate, filtered, and concentrated. The concentrate was purifiedby preparative TLC and preparative HPLC to obtain Compound 43. ¹H NMR(400 MHz, CDCl₃) δ ppm 8.69 (s, 1H), 7.91-7.99 (m, 1H), 7.88 (s, 1H),7.76 (dd, J=8.3, 1.8 Hz, 1H), 7.29 (dd, J=8.8, 2.0 Hz, 2H), 5.62 (br s,1H), 4.53 (s, 2H), 2.77-2.95 (m, 1H), 1.62 (s, 6H), 1.26-1.34 ppm (m,3H); LCMS (ESI) m/z: 577.0 (M+1).

Example 43 Synthesis of Compound 44

1) Synthesis of Compound 44-2 and Compound 44-3

In a dry single-necked flask, Compound 7-5 (5.00 g), benzoic acid (21.28g), and methylbenzene (5 mL) were added. Under nitrogen protection,diphenyl phosphate (1.45 g) was added, and the resulting mixture reactedat 25° C. for 16 h. The reaction mixture was separated successively by achromatographic column and a preparative SFC method (instrument model:Thar SFC80 preparative SFC) to obtain Compound 44-2 and Compound 44-3.LCMS (ESI) m/z: 209(M+1).

2) Synthesis of Compound 44-4

In a dry reaction flask, Compound 36-4 (200 mg), Compound 44-2 (120 mg),and tetrahydrofuran (2 mL) were added. Under nitrogen protection, sodiumhydride (23 mg, 60% purity) was added, and the resulting mixture reactedat 25° C. for 0.5 h. The reaction was quenched with a saturated ammoniumchloride solution (2 mL). After extraction with dichloromethane (3mL×3), the organic phase was washed with saturated brine (10 mL), driedover anhydrous sodium sulfate, and filtered. The filtrate wasconcentrated under reduced pressure at 45° C. The residue obtained fromthe concentration was purified by a preparative TLC plate, to obtainCompound 44-4. LCMS (ESI) m/z: 694 (M+1).

3) Synthesis of Compound 44

In a dry reaction flask, Compound 44-4 (140 mg), LiOH·H₂O (13 mg), water(0.8 mL), and tetrahydrofuran (1.5 mL) were added, and the resultingmixture reacted at 25° C. for 3 h under nitrogen protection. Thereaction mixture was directly spin-dried, and purified by preparativeHPLC method to obtain Compound 44. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.02(d, J=8.38 Hz, 1H), 7.98 (s, 1H), 7.83-7.88 (m, 2H), 7.49 (dd, J=9.92,2.21 Hz, 1H), 5.46-5.50 (m, 1H), 4.52 (br s, 1H), 4.36 (dd, J=11.03,5.73 Hz, 1H), 4.23 (dd, J=10.03, 5.84 Hz, 1H), 4.16 (dd, J=10.58, 2.87Hz, 1H), 3.82 (dd, J=9.81, 4.74 Hz, 1H), 3.40 (d, J=2.65 Hz, 1H), 3.09(q, J=7.50 Hz, 2H), 1.67 (s, 6H), 1.45 (t, J=7.50 Hz, 3H).

Example 44 Synthesis of Compound 45

1) Synthesis of Compound 45-1

In a dry single-necked flask, methanol (2 mL) and sodium (24 mg) wereadded, and the resulting mixture was stirred at 25° C. until sodiumdisappeared. Then, a readily prepared solution of sodium methoxide inmethanol was added to a dry single-necked flask filled with Compound19-2 (300 mg), and the resulting mixture was stirred at 25° C. for 2 h.After filtration, the filter cake was washed with ethyl acetate (10 mL).The filtrate was collected, and concentrated under reduced pressure toobtain Compound 45-1. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.00 (dd, J=1.3, 2.0Hz, 1H), 7.54 (dd, J=2.1, 9.6 Hz, 1H), 4.12-4.09 (m, 3H), 2.93 (q, J=7.5Hz, 2H), 1.34 (t, J=7.6 Hz, 3H). LCMS (ESI) m/z: 285 (M+1).

2) Synthesis of Compound 45-2

In a dry microwave tube, Compound 45-1 (888 mg), Compound 3-2 (489 mg),cesium carbonate (2.54 g),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (180 mg),bis(dibenzylideneacetone)palladium (179 mg), and methylbenzene (18 mL)were added. After nitrogen purge for five min, the resulting mixture wasmicrowaved and stirred at 130° C. for 4 h, and then was concentrated todryness under reduced pressure to remove the solvent. The residueobtained from the concentration was purified by a chromatographic columnto obtain Compound 45-2. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.19 (d, J=4.9Hz, 1H), 7.20 (d, J=4.9 Hz, 1H), 6.96 (dd, J=2.5, 11.6 Hz, 1H),6.81-6.77 (m, 1H), 5.79 (s, 1H), 4.09 (s, 3H), 3.00-2.91 (m, 2H), 2.24(s, 3H), 1.38 (t, J=7.5 Hz, 3H). LCMS (ESI) m/z: 347 (M+1).

3) Synthesis of Compound 45-3

In a dry microwave tube, Compound 45-2 (190 mg), Compound 2-5 (112 mg),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (31 mg),bis(dibenzylideneacetone)palladium (31 mg), and cesium carbonate (357mg) were added, and then methylbenzene (5 mL) was added. After nitrogenpurge for 5 min, the microwave tube was sealed. The resulting mixturewas microwaved and stirred at 130° C. for 4 h, and then was concentratedto dryness under reduced pressure to remove the solvent. The residueobtained from the concentration was purified by a chromatographic columnto obtain a crude product of Compound 45-3. The resulting crude productwas slurried with 5 mL of methyl tert-butyl ether to obtain Compound45-3. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.27 (d, J=2.2 Hz, 1H), 8.15 (d,J=5.1 Hz, 1H), 8.00 (dd, J=2.1, 8.7 Hz, 1H), 7.72 (d, J=8.8 Hz, 1H),7.14 (dd, J=2.5, 12.5 Hz, 1H), 7.00 (d, J=5.7 Hz, 1H), 6.56-6.53 (m,1H), 4.02 (s, 3H), 3.19 (s, 3H), 2.85 (q, J=7.5 Hz, 2H), 1.33 (t, J=7.6Hz, 3H). LCMS (ESI) m/z: 497 (M+1).

4) Synthesis of Compound 45-4

In a dry single-necked flask, Compound 45-3 (65 mg), tetrahydrofuran(0.5 mL), and methylbenzene (0.5 mL) were added, and then sodiumtert-butoxide (50 mg) was added. The resulting mixture was stirred at30° C. for 1 h, and then thiophosgene (45 mg) was added at 30° C. Theresulting mixture was stirred at 30° C. for 1 h under nitrogenprotection, and then was concentrated to dryness under reduced pressureto remove the solvent. The residue obtained from the concentration waspurified by a chromatographic column to obtain Compound 45-4. LCMS (ESI)m/z: 539 (M+1).

5) Synthesis of Compound 45

In a dry single-necked flask, Compound 45-4 (45 mg), hydrochloric acid(2M, 2 mL), and tetrahydrofuran (2 mL) were added. The resulting mixturewas stirred at 30° C. for 1 h under nitrogen protection, and wasconcentrated to dryness under reduced pressure to remove the solvent.The residue obtained from the concentration was purified by preparativeHPLC method to obtain Compound 45. ¹H NMR (400 MHz, CDCl₃) δ ppm 10.55(br s, 1H), 8.30 (br s, 1H), 8.17 (br d, J=19.6 Hz, 3H), 8.09 (br s,1H), 7.67 (br s, 1H), 7.03 (br s, 1H), 2.87 (br s, 2H), 1.99 (br s, 3H),1.47 (br s, 3H). LCMS (ESI) m/z: 525 (M+1).

Example 45 Synthesis of Compound 46

1) Synthesis of Compound 46-1

In a dry reaction flask, Compound 36-4 (200 mg), Compound 44-3 (120 mg),and tetrahydrofuran (2 mL) were added. Under nitrogen protection, sodiumhydride (23 mg, 60% purity) was added, and the resulting mixture reactedat 25° C. for 0.5 h. The reaction was quenched with a saturated ammoniumchloride solution (5 mL). After extraction with dichloromethane (5mL×3), the organic phase was washed with saturated brine (10 mL), driedover anhydrous sodium sulfate, and filtered. The filtrate wasconcentrated under reduced pressure at 45° C. The residue was purifiedby a preparative TLC plate to obtain Compound 46-1. LCMS (ESI) m/z: 694(M+1).

2) Synthesis of Compound 46

In a dry reaction flask, Compound 46-1 (130 mg), lithium hydroxidemonohydrate (12 mg), water (0.5 mL), and tetrahydrofuran (1 mL) wereadded, and the resulting mixture reacted at 25° C. for 4 h undernitrogen protection. The reaction mixture was directly concentrated todryness, and the residue obtained from the concentration was purified bypreparative HPLC method to obtain Compound 46. ¹H NMR (400 MHz, CDCl₃) δppm 8.02 (d, J=8.38 Hz, 1H), 7.98 (s, 1H), 7.83-7.89 (m, 2H), 7.49 (dd,J=9.81, 2.09 Hz, 1H), 5.45-5.51 (m, 1H), 4.52 (br s, 1H), 4.36 (dd,J=10.80, 5.95 Hz, 1H), 4.23 (dd, J=9.92, 5.73 Hz, 1H), 4.16 (dd,J=10.80, 3.09 Hz, 1H), 3.82 (dd, J=9.70, 4.85 Hz, 1H), 3.40 (d, J=2.65Hz, 1H), 3.09 (q, J=7.57 Hz, 2H), 1.67 (s, 6H), 1.45 (t, J=7.61 Hz, 3H).LCMS (ESI) m/z: 590 (M+1).

Example 46 Synthesis of Compound 47

1) Synthesis of Compound 47-2

Compound 47-1 (23.00 g) and propionyl chloride (50.14 g) weresuccessively added to a solution of sodium ethoxide (22.13 g) andtriethylamine (1.10 g) in tetrahydrofuran (220 mL) at 5° C. After thecompletion of the addition, the resulting mixture was stirred at 25° C.for 16 h. The reaction mixture was concentrated under reduced pressure,and then distilled under reduced pressure, to obtain Compound 47-2 bycollecting fractions at the temperatures of 36° C., 40° C., and 60° C.,respectively.

2) Synthesis of Compound 47-3

Compound 34-1 (5.00 g) and Compound 47-2 (5.52 g) were added topolyphosphoric acid (15.00 g), and the resulting mixture was heated to110° C., and stirred for 16 h. The reaction mixture was diluted with 50mL of water, adjusted to a neutral pH with a saturated sodium hydroxidesolution, and extracted with ethyl acetate (30 mL×3). The organic phasewas collected, dried, filtered and concentrated. The residue waspurified by column chromatography to obtain Compound 47-3. ¹H NMR (400MHz, CDCl₃) δ ppm 8.93 (t, J=1.65 Hz, 1H), 7.49 (dd, J=8.16, 1.76 Hz,1H), 2.90 (qd, J=7.61, 2.98 Hz, 2H), 1.35 (t, J=7.61 Hz, 3H).

3) Synthesis of Compound 47-4

Compound 47-3 (800 mg), tert-butyl carbamate (972 mg), cesium carbonate(2.25 g), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (160.13 mg),and bis(dibenzylideneacetone)palladium (159 mg) were added to amicrowave tube filled with methylbenzene (8 mL). The resulting mixturereacted at 120° C. for microwave reaction for 50 min. The reactionmixture was concentrated under reduced pressure, and the residueobtained from the concentration was purified by column chromatography toobtain Compound 47-4. ¹H NMR (400 MHz, CDCl₃) δ ppm 9.00 (s, 1H)7.31-7.37 (m, 1H) 2.92 (qd, J=7.57, 2.87 Hz, 2H) 1.57 (s, 9H) 1.36 (t,J=7.61 Hz, 3H).

4) Synthesis of Compound 47-5

Compound 47-4 (400 mg) was added to a solution of hydrochloricacid-methanol (4M, 20 mL), and the resulting mixture was stirred at 25°C. for 1 h. The reaction mixture was concentrated under reducedpressure. Water (25 mL) was added to the residue obtained from theconcentration, and the resulting mixture was extracted with ethylacetate (30 mL×3). The organic phase was collected, dried, filtered, andconcentrated under reduced pressure to obtain Compound 47-5. LCMS (ESI)m/z: 226 (M+1).

5) Synthesis of Compound 47-6

In a reaction flask, Compound 47-5 (200 mg), zinc chloride (36 mg),sodium sulfate (504 mg), acetone (331 mg), TMSCN (264 mg), andtetrahydrofuran (2 mL) were added, and the resulting mixture reacted at25° C. for 16 h. The reaction mixture was concentrated under reducedpressure, and the residue obtained from the concentration was purifiedby a preparative chromatoplate to obtain Compound 47-6. ¹H NMR (400 MHz,CDCl₃) δ ppm 8.48 (s, 1H), 7.30 (dd, J=10.03, 2.32 Hz, 1H), 4.28 (s,1H), 3.50 (s, 1H), 2.90 (qd, J=7.61, 2.98 Hz, 2H), 1.80 (s, 5H),1.31-1.39 (m, 3H).

6) Synthesis of Compound 47-7

In a reaction flask, Compound 47-6 (100 mg), Compound 1-7 (312 mg),methylbenzene (2 mL), and DMF (0.5 mL) were added, and the resultingmixture was stirred at 25° C. Then, sodium hydride (21 mg, 60% purity)was added, and the resulting mixture reacted for 4 h under stirring. Thereaction mixture was concentrated under reduced pressure, and theresidue obtained from the concentration was purified by preparative HPLCto obtain Compound 47-7. LCMS (ESI) m/z: 521 (M+1).

7) Synthesis of Compound 47

In a reaction flask, Compound 47-7 (20 mg), methylbenzene (2 mL), andacetic acid (0.5 mL) were added, and the resulting mixture was refluxedat 120° C. for 16 h. The reaction mixture was concentrated under reducedpressure, and the residue obtained from the concentration was purifiedby preparative HPLC to obtain Compound 47. ¹H NMR (400 MHz, CDCl₃) δ ppm8.80 (s, 1H), 8.02 (d, J=8.38 Hz, 1H), 7.95 (s, 1H), 7.83 (d, J=9.04 Hz,1H), 7.37 (d, J=7.28 Hz, 1H), 2.95 (dd, J=7.72, 3.09 Hz, 2H), 1.70 (s,6H), 1.38 (t, J=7.61 Hz, 3H). LCMS (ESI) m/z: 522 (M+1).

Example 47 Synthesis of Compound 48

1) Synthesis of Compound 48-2

Potassium nitrate (4.10 g) was added to a solution of Compound 48-1(5.00 g) in concentrated sulfuric acid (40 mL) at 0° C. The resultingmixture was stirred at 0° C. for 1 h. The reaction mixture was slowlypoured into ice water (150 mL) which was stirred for dilution, and asolid precipitated. After filtration, the filter cake was washed withwater (50 mL), dissolved in ethyl acetate (150 mL), dried over anhydroussodium sulfate, filtered, and concentrated to obtain Compound 48-2. ¹HNMR (400 MHz, CDCl₃) δ ppm 10.27-10.35 (m, 1H), 8.65 (d, J=2.8 Hz, 1H),8.23 (dd, J=8.8, 2.8 Hz, 1H), 7.82 ppm (d, J=8.5 Hz, 1H).

2) Synthesis of Compound 48-3

DAST (8.54 g) was added to a solution of Compound 48-2 (6 g) indichloromethane (100 mL) at 0° C. The resulting mixture was stirred at0° C. for 1 h, and then cooled to 0° C. A saturated sodium bicarbonatesolution (50 mL) was added to quench the reaction. After extraction withdichloromethane (50 mL), the organic phase was washed with saturatedbrine (50 mL), dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue obtained from the concentration was purifiedby flash column chromatography (model: ISCO-RF150) to obtain Compound48-3. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.45 (d, J=2.5 Hz, 1H), 8.14 (dd,J=8.8, 2.8 Hz, 1H), 7.77 (d, J=8.8 Hz, 1H), 6.71-7.01 ppm (m, 1H).

3) Synthesis of Compound 48-4

Zinc cyanide (4.00 g), zinc powder (1.60 g, 24.47 mmol), DPPF (1.76 g)and bis(dibenzylideneacetone)palladium (1.83 g) were successively addedto a solution of Compound 48-3 (4.00 g) in DMF (15 mL). After nitrogenpurge for 30 sec, the resulting mixture was heated to 130° C. formicrowave reaction for 1 h, then cooled to room temperature, andfiltered. The filtrate was concentrated, and the residue obtained fromthe concentration was purified by flash column chromatography(ISCO-RF150) to obtain Compound 48-4. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.41(d, J=8.3 Hz, 1H), 6.58-6.90 (m, 3H), 4.32 ppm (br s, 2H).

4) Synthesis of Compound 48-5

At 29° C., thiophosgene (900 mg) was added to H₂O (10 mL) to form asolution, and the resulting mixture was stirred for half an hour. Then,Compound 48-4 (500 mg) was added to the above mixture, and the mixturewas further stirred at 29° C. for 2 h. The reaction mixture wasextracted with dichloromethane (30 mL×2). The combined organic phase waswashed with saturated brine (20 mL), dried over anhydrous sodiumsulfate, filtered, and concentrated to obtain Compound 48-5. ¹H NMR (400MHz, CDCl₃) δ ppm 7.69 (d, J=8.3 Hz, 1H), 7.50 (s, 1H), 7.28-7.39 (m,1H), 6.64-6.99 ppm (m, 1H).

5) Synthesis of Compound 48-6

Compound 17-3 (200 mg), Compound 1-4 (100 mg), cuprous chloride (10 mg),2-acetylcyclohexanone (10 mg), and potassium carbonate (180 mg) wereadded to a microwave tube filled with DMF (5 mL) and water (1 mL). Afternitrogen purge for 1 min, the resulting mixture was kept at 130° C. formicrowave reaction for 1.5 h. The reaction mixture was filtered, and thefilter cake was washed with DMF (2 mL). The filtrate was neutralizedwith 1M dilute hydrochloric acid to pH=7, and concentrated. The residueobtained from the concentration was added to DCM/MeOH (20 mL, v/v=10/1)to precipitate a solid, and filtered. The filtrate was concentrated toobtain Compound 48-6. LCMS (ESI) m/z: 320 (M+1).

6) Synthesis of Compound 48-7

A solution of TMSCHN₂ in n-hexane (2M, 0.75 mL) was added dropwise to asolution of Compound 48-6 (320 mg) in dichloromethane (10 mL) andmethanol (1 mL) at 29° C. After the completion of the dropwise addition,the resulting mixture reacted at 29° C. for 1 h. The reaction mixturewas concentrated, and the residue obtained from the concentration waspurified by preparative TLC to obtain Compound 48-7. LCMS (ESI) m/z: 334(M+1). 7) Synthesis of Compound 48-8

Boc₂O (160 mg) was added to a solution of Compound 48-7 (220 mg),triethylamine (170 mg), and DMAP (20 mg) in dichloromethane (10 mL) at29° C. After the completion of the dropwise addition, the resultingmixture reacted at 29° C. for 0.5 h. The reaction mixture wasconcentrated, and the residue obtained from the concentration waspurified by preparative TLC to obtain Compound 48-8. LCMS (ESI) m/z: 434(M+1).

8) Synthesis of Compound 48-9

Compound 48-5 (75 mg) was added to Compound 48-8 (50 mg) in a mixedsolvent of methylbenzene (15 mL) and DMF (3 mL), and then the resultingmixture was heated to 120° C. and stirred for 12 h under nitrogenprotection. The reaction mixture was cooled to room temperature, andconcentrated to obtain a crude product. The crude product was purifiedby preparative TLC to obtain Compound 48-9. LCMS (ESI) m/z: 612 (M+1).

9) Synthesis of Compound 48

Trifluoroacetic acid (581 mg) was added dropwise to a solution ofCompound 48-9 (35 mg) in dichloromethane (5 mL). Then, the resultingmixture was stirred at 28° C. for 0.5 h. The reaction mixture wasneutralized with a saturated sodium bicarbonate solution to pH=−7, andextracted with dichloromethane (20 mL×2). The combined organic phase waswashed with saturated brine (20 mL), dried over anhydrous sodiumsulfate, filtered, and concentrated to obtain a crude product. The crudeproduct was purified by preparative TLC to obtain Compound 48. ¹H NMR(400 MHz, CDCl₃) δ ppm 8.05 (d, J=2.0 Hz, 1H), 7.97 (d, J=9.0 Hz, 1H),7.86 (br d, J=4.5 Hz, 2H), 7.58-7.73 (m, 2H), 6.75-7.10 (m, 1H),4.62-4.84 (m, 2H), 4.02 (br s, 2H), 3.10 (br s, 1H), 2.94 (q, J=7.7 Hz,2H), 1.58 (s, 6H), 1.35 ppm (t, J=7.7 Hz, 3H); LCMS (ESI) m/z: 512(M+1).

Example 48 Synthesis of Compound 49

1) Synthesis of Compound 49-2

In a dry reaction flask, Compound 10-3 (10.00 g) and Compound 49-1 (5.67g) were added, and then trimethylsilyl polyphosphate (42.91 mmol) wasadded. The resulting mixture was heated to 130° C. and stirred for 12 hunder nitrogen protection. 100 mL of water and 100 mL of ethyl acetatewere added to the reaction mixture. After liquid separation, the organicphase was collected, dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue obtained from the concentration was purifiedby a chromatographic column to obtain a crude product. The resultingcrude product was slurried with 20 mL of ethyl acetate and 40 mL ofmethyl tert-butyl ether to obtain Compound 49-2. ¹H NMR (400 MHz, CDCl₃)δ ppm 8.09-8.00 (m, 2H), 2.00 (t, J=19.3 Hz, 3H). LCMS (ESI) m/z: 307(M+1).

2) Synthesis of Compound 49-3

In a dry microwave tube, Compound 49-2 (1.00 g), Compound 1-4 (1.01 g),DMF (20 mL), water (4 mL), potassium carbonate (2.25 g), and2-acetylcyclohexanone (91 mg) were added, and then cuprous chloride (645mg) was added. After nitrogen purge for five min, the microwave tube wassealed, and then the resulting mixture was microwaved and stirred at 90°C. for 1 h. The mixture was concentrated under reduced pressure toobtain Compound 49-3. LCMS (ESI) m/z: 330 (M+1).

3) Synthesis of Compound 49-4

In a dry single-necked flask, Compound 49-3 (8.58 g) and a solution ofhydrochloric acid-methanol (4M, 250 mL) were added, and the resultingmixture was stirred at 80° C. for 12 h, and then concentrated to drynessunder reduced pressure to remove the solvent and obtain a solid. Thesolid was purified by a chromatographic column to obtain Compound 49-4.¹H NMR (400 MHz, CDCl₃) δ ppm 9.33 (br s, 1H), 7.08 (d, J=1.8 Hz, 1H),6.77 (dd, J=2.8, 12.0 Hz, 1H), 4.68 (s, 1H), 3.75 (s, 3H), 2.09 (t,J=19.0 Hz, 3H), 1.63 (s, 6H). LCMS (ESI) m/z: 344 (M+1).

4) Synthesis of Compound 49-5

In a dry single-necked flask, Compound 49-4 (2.85 g, 8.30 mmol) andphosphorus oxychloride (43.29 g) were added, and thendiisopropylethylamine (1.67 g) was added. The resulting mixture wasstirred at 110° C. for 4 h, and then was concentrated under reducedpressure to remove the solvent. The solid obtained from theconcentration was dissolved in 26 mL of ethyl acetate, and the resultingsolution was slowly added dropwise to a mixed solution of 31 mL ofmethanol and 110 mL of triethylamine at a controlled temperature of0-10° C. After the completion of the dropwise addition, the resultingmixture was filtered. The filtrate was collected, and was concentratedto dryness under reduced pressure at 40° C. to remove the solvent. Theresidue obtained from the concentration was purified by achromatographic column to obtain Compound 49-5. LCMS (ESI) m/z: 362(M+1).

5) Synthesis of Compound 49-6

In a dry single-necked flask, Compound 49-5 (4.00 g) was added, thenmethanol (100 mL) was added, and then sodium methoxide (2.99 g) wasadded. The resulting mixture was stirred at 30° C. for 0.5 h undernitrogen protection. 200 mL of ethyl acetate was added to the reactionmixture, and the resulting mixture was filtered. A solution ofhydrochloric acid-methanol (4M, 3 mL) was added to the filtrate. Theresulting mixture was concentrated under reduced pressure at 30° C. to100 mL, and filtered. The filtrate was concentrated to dryness underreduced pressure at 30° C., and the residue obtained from theconcentration was purified by a chromatographic column to obtainCompound 49-6. ¹H NMR (400 MHz, CDCl₃) δ ppm 6.89 (dd, J=2.5, 11.8 Hz,1H), 6.78 (d, J=1.8 Hz, 1H), 4.60 (br s, 1H), 4.18 (s, 3H), 3.73 (s,3H), 2.09 (t, J=18.5 Hz, 3H), 1.67-1.63 (m, 6H). LCMS (ESI) m/z: 358(M+1).

6) Synthesis of Compound 49-7

In a dry single-necked flask, Compound 49-6 (2.66 g), Compound 1-7 (3.40g), DMF (3.6 mL), and methylbenzene (18 mL) were added. Under nitrogenprotection, the resulting mixture was stirred at 90° C. for 48 h, andthen was concentrated under reduced pressure to remove the solvent. Theresidue obtained from the concentration was purified by columnchromatography to obtain Compound 49-7. ¹H NMR (400 MHz, CDCl₃) δ ppm8.00 (d, J=8.4 Hz, 1H), 7.98-7.95 (m, 2H), 7.84 (dd, J=1.9, 8.3 Hz, 1H),7.54 (dd, J=2.2, 9.7 Hz, 1H), 4.28 (s, 3H), 2.14 (t, J=18.5 Hz, 3H),1.67 (s, 6H). LCMS (ESI) m/z: 554 (M+1).

7) Synthesis of Compound 49-8

In a dry single-necked flask, Compound 49-7 (200 mg) was added, and thentetrahydrofuran (1 mL) and concentrated hydrochloric acid (12M, 1 mL)were added, and the resulting mixture was stirred at 25° C. for 5 min.Dichloromethane (5 mL) was added to the reaction mixture. After liquidseparation, the organic phase was dried over anhydrous sodium sulfate,filtered, and concentrated to dryness under reduced pressure to removethe solvent and obtain Compound 49-8. ¹H NMR (400 MHz, CDCl₃) δ ppm 9.73(br s, 1H), 8.05 (s, 1H), 8.00 (d, J=8.4 Hz, 1H), 7.95 (s, 1H), 7.83 (d,J=8.2 Hz, 1H), 7.53 (dd, J=2.2, 9.5 Hz, 1H), 2.15 (t, J=19.2 Hz, 3H),1.65 (s, 6H). LCMS (ESI) m/z: 540 (M+1).

8) Synthesis of Compound 49-9

In a dry single-necked flask, Compound 49-8 (300 mg) and phosphorusoxychloride (2.90 g) were added, and then diisopropylethylamine (112 mg)was added. The resulting mixture was heated to 110° C., and stirred for12 h, and then concentrated to dryness under reduced pressure to removethe solvent. Dichloromethane (5 mL) was added to the residue obtainedfrom the concentration, and the resulting mixture was washed with 10 mLof an iced saturated sodium bicarbonate solution. After liquidseparation, the organic phase was washed with saturated brine, driedover anhydrous sodium sulfate, filtered, and concentrated to drynessunder reduced pressure to remove the solvent, and the residue obtainedfrom the concentration was purified by preparative TLC to obtainCompound 49-9. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.11-8.08 (m, 1H), 8.02 (d,J=8.2 Hz, 1H), 7.97 (d, J=2.0 Hz, 1H), 7.84 (dd, J=2.1, 8.3 Hz, 1H),7.72 (dd, J=2.1, 9.2 Hz, 1H), 2.18 (t, J=18.5 Hz, 3H), 1.70 (s, 6H).LCMS (ESI) m/z: 558 (M+1).

9) Synthesis of Compound 49

In a dry single-necked flask, Compound 49-9 (44 mg), ethanediol (45 mg),and tetrahydrofuran (0.5 mL) were added, and then sodium hydride (9 mg,60% purity) was added. The resulting mixture was stirred at 25° C. for 1h. The reaction mixture was purified successively by a preparative TLCplate and preparative HPLC method to obtain Compound 49. ¹H NMR (400MHz, CDCl₃) δ ppm 8.05-7.99 (m, 2H), 7.98 (s, 1H), 7.85 (br d, J=7.5 Hz,1H), 7.58 (br d, J=9.5 Hz, 1H), 4.91-4.85 (m, 2H), 4.13 (br d, J=3.5 Hz,2H), 2.47 (t, J=5.7 Hz, 1H), 2.15 (t, J=18.5 Hz, 3H), 1.69 (s, 6H); LCMS(ESI) m/z: 584.

Example 49 Synthesis of Compound 50

1) Synthesis of Compound 50-1

With reference to the synthesis of Compound 48-6, Compound 50-1 wasprepared with Compound 20-1 as the starting material. LCMS (ESI) m/z:338 (M+1).

2) Synthesis of Compound 50-2

With reference to the synthesis of Compound 48-7, Compound 50-2 wasprepared with Compound 50-1 as the starting material. LCMS (ESI) m/z:352 (M+1).

3) Synthesis of Compound 50-3

With reference to the synthesis of Compound 48-8, Compound 50-3 wasprepared with Compound 50-2 as the starting material. LCMS (ESI) m/z:452 (M+1).

4) Synthesis of Compound 50-4

With reference to the synthesis of Compound 48-9, Compound 50-4 wasprepared with Compound 50-3 and Compound 48-5 as the starting materials.LCMS (ESI) m/z: 630 (M+1).

5) Synthesis of Compound 50

With reference to the synthesis of Compound 48, Compound 50 was preparedwith Compound 50-4 as the starting material. ¹H NMR (400 MHz, CDCl₃) δppm 7.80-7.91 (m, 3H), 7.69 (d, J=8.3 Hz, 1H), 7.40 (dd, J=10.0, 2.0 Hz,1H), 6.75-7.08 (m, 1H), 4.68-4.78 (m, 2H), 4.02 (br s, 2H), 2.98 (q,J=7.6 Hz, 2H), 2.74 (br s, 1H), 1.59 (s, 6H), 1.35 ppm (t, J=7.5 Hz,3H); LCMS (ESI) m/z: 530 (M+1).

Example 50 Synthesis of Compound 51

1) Synthesis of Compound 51

In a dry microwave tube, Compound 36-4 (500 mg), Compound 55-1 (564 mg),sodium carbonate (2M, 800 μL, an aqueous solution), 1,2-dichloroethane(7 mL), and water (3 mL) were added. After nitrogen purge,dichlorobis(triphenylphosphine)palladium (67 mg) was added, and theresulting mixture reacted at 140° C. for 10 min. The reaction mixturewas concentrated, and the residue obtained from the concentration waspurified successively by a preparative TLC plate and preparative HPLCmethod to obtain Compound 51. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.28 (s,2H), 8.08 (s, 1H), 8.03 (d, J=8.16 Hz, 1H), 7.99 (s, 1H), 7.86 (d,J=8.16 Hz, 1H), 7.51-7.55 (m, 1H), 3.23 (q, J=7.50 Hz, 2H), 1.69 (s,6H), 1.51 (t, J=7.72 Hz, 3H). LCMS (ESI) m/z: 554 (M+1).

Example 51 Synthesis of Compound 52

1) Synthesis of Compound 52

In a dry single-necked flask, Compound 36-4 (300 mg), Compound 52-1 (129mg), sodium carbonate (102 mg), 1,2-dichloroethane (2.1 mL), and water(0.9 mL) were added. After nitrogen purge,dichlorobis(triphenylphosphine)palladium (40 mg) was added, and theresulting mixture was refluxed at 100° C. and reacted for 16 h. Thereaction mixture was concentrated, and the residue obtained from theconcentration was purified successively by a preparative TLC plate andpreparative HPLC method to obtain Compound 52. ¹H NMR (400 MHz, CDCl₃) δppm 9.52-9.55 (m, 1H), 8.93 (d, J=2.89 Hz, 1H), 7.98-8.04 (m, 2H), 7.92(d, J=0.88 Hz, 1H), 7.86-7.91 (m, 1H), 7.59 (dd, J=9.91, 2.13 Hz, 1H),6.60 (dd, J=2.89, 1.63 Hz, 1H), 3.20 (q, J=7.53 Hz, 2H), 1.73 (s, 5H),1.67-1.77 (m, 1H), 1.50 (t, J=7.59 Hz, 3H). LCMS (ESI) m/z: 554 (M+1).

Example 52 Synthesis of Compound 53

1) Synthesis of Compound 53

A mixed solution of Compound 35-4 (100 mg), Compound 23-7 (299 mg),N,N-dimethylformamide (0.5 mL), and methylbenzene (2 mL) was heated to120° C., and stirred for 16 h. Methanol (5 mL) was added to the reactionmixture, and the resulting mixture was stirred for 30 min, and thenconcentrated under reduced pressure. The residue obtained from theconcentration was purified successively by a silica gel column andpreparative HPLC to obtain Compound 53. ¹H NMR (400 MHz, CDCl₃) δ ppm9.01 (d, J=1.5 Hz, 1H), 8.76 (s, 1H), 8.28 (d, J=1.8 Hz, 1H), 7.32 (dd,J=1.8, 8.8 Hz, 1H), 6.42 (s, 1H), 2.75 (q, J=7.5 Hz, 2H), 1.64 (s, 6H),1.29 (t, J=7.5 Hz, 3H); LCMS (ESI) m/z: 505 (M+1).

Example 53 Synthesis of Compound 54

1) Synthesis of Compound 54-1

In a microwave tube, Compound 35-2 (500 mg), tert-butyl carbamate (324mg), cesium carbonate (1.50 g),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (107 mg),bis(dibenzylideneacetone)palladium (170 mg), and methylbenzene (6 mL)were added. The microwave tube was sealed, and the resulting mixture waskept at 120° C. for microwave reaction for 30 min. The reaction mixturewas filtered, and washed with ethyl acetate (20 mL). The filtrate wasconcentrated under reduced pressure. The residue obtained from theconcentration was purified by a silica gel column to obtain Compound54-1. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.90 (s, 1H), 8.15 (br s, 1H), 7.57(br s, 1H), 6.32 (s, 1H), 2.71 (q, J=7.5 Hz, 2H), 1.49 (s, 9H), 1.26 (t,J=7.5 Hz, 3H).

2) Synthesis of Compound 54-2

Trifluoroacetic acid (0.4 mL) was added to a solution of Compound 54-1(200 mg) in dichloromethane (2 mL). The resulting reaction mixture wasstirred at 26° C. for 4 h. A saturated aqueous solution of sodiumbicarbonate (pH about 7) was added to the reaction mixture, which wasextracted with dichloromethane (20 mL). The organic phase was washedwith saturated brine (15 mL), dried over anhydrous sodium sulfate, andconcentrated under reduced pressure to obtain Compound 54-2. LCMS (ESI)m/z: 208 (M+1).

3) Synthesis of Compound 54-3

Cyclobutanone (115 mg) and zinc chloride (12 mg) were added to a mixedsolution of Compound 54-2 (60 mg), trimethylsilyl cyanide (81 mg),sodium sulfate (154 mg), and tetrahydrofuran (2 mL). The resultingreaction mixture was stirred at 25° C. for 16 h. An aqueous solution ofsodium sulfite (10 mL) was added to the reaction mixture, and theresulting mixture was extracted with ethyl acetate (10 mL×3). Theorganic phase was washed with saturated brine (10 mL), dried overanhydrous sodium sulfate, and concentrated under reduced pressure. Theresidue obtained from the concentration was purified by a silica gelcolumn to obtain Compound 54-3. LCMS (ESI) m/z: 287 (M+1).

4) Synthesis of Compound 54

Compound 1-7 (224 mg) was added to a solution of Compound 54-3 (70 mg),N,N-dimethylformamide (0.5 mL), and methylbenzene (2 mL). The resultingmixture was heated to 120° C., and stirred for 16 h. Compound 1-7 (224mg) was supplemented to the reaction mixture, which was further stirredfor 16 h. Methanol (5 mL) was added to the reaction mixture, which wasstirred for 30 min, and then concentrated under reduced pressure. Theresidue obtained from the concentration was purified successively by asilica gel column and preparative HPLC to obtain Compound 54. ¹H NMR(400 MHz, CDCl₃) δ ppm 8.82 (s, 1H), 7.94 (d, J=8.3 Hz, 1H), 7.89 (s,1H), 7.76 (br d, J=8.3 Hz, 1H), 7.33 (dd, J=1.8, 8.8 Hz, 1H), 6.43 (s,1H), 2.82-2.63 (m, 4H), 2.58-2.43 (m, 2H), 2.34-2.18 (m, 1H), 1.73 (q,J=10.5 Hz, 1H), 1.29 (t, J=7.5 Hz, 3H); LCMS (ESI) m/z: 516 (M+1).

Example 54 Synthesis of Compound 55

1) Synthesis of Compound 55-1

In a dry single-necked flask, Compound 34-1 (15.00 g) anddichloromethane (150 mL) were added, and cooled to −40° C. Then, malonyldichloride (14.72 g) was added. The resulting mixture was slowly warmedto 25° C., and stirred for 24 h. After filtration, a solid wascollected. The resulting solid was slurried with a mixed solvent of 100mL of methanol and 100 mL of dichloromethane, and filtered to obtainCompound 55-1. ¹H NMR (400 MHz, DMSO-d6) δ ppm 8.73 (t, J=1.7 Hz, 1H),8.20 (dd, J=2.0, 9.3 Hz, 1H), 5.54 (s, 1H). LCMS (ESI) m/z: 259 (M+1).

2) Synthesis of Compound 55-2

In a dry single-necked flask, Compound 55-1 (1.00 g), potassiumcarbonate (1.07 g), iodoethane (682 mg), and NMP (10 mL) were added.Under nitrogen protection, the resulting mixture was heated to 60° C.,and stirred for 48 h. Iodoethane (682 mg) was supplemented, and theresulting mixture was heated to 60° C., and refluxed for 12 h. 100 mL ofsaturated brine and 100 mL of ethyl acetate were successively added tothe reaction mixture, which was filtered to remove the solid. Afterliquid separation of the filtrate, the organic phase was collected,dried over anhydrous sodium sulfate, filtered, and concentrated todryness under reduced pressure. The residue obtained from theconcentration was successively purified by a chromatographic column, andslurried with 20 mL of methyl tert-butyl ether to obtain Compound 55-2.¹H NMR (400 MHz, CDCl₃) δ ppm 8.98 (t, J=1.7 Hz, 1H), 7.56 (dd, J=2.1,7.8 Hz, 1H), 5.82 (s, 1H), 4.42 (q, J=7.1 Hz, 2H), 1.42 (t, J=7.1 Hz,3H). LCMS (ESI) m/z: 287 (M+1).

3) Synthesis of Compound 55-3

In a dry microwave tube, Compound 55-2 (600 mg), 2-aminoisobutyric acid(646 mg), 2-acetylcyclohexanone (59 mg), potassium carbonate (578 mg),DMF (12 mL), and water (2.4 mL) were added, and then cuprous chloride(41 mg) was added. After nitrogen purge for 5 min, the microwave tubewas sealed. The resulting mixture was microwaved and stirred at 90° C.for 2 h. 2-Acetylcyclohexanone (59 mg) and cuprous chloride (41 mg) weresupplemented, and the resulting mixture was microwaved and stirred for1.5 h, and then concentrated under reduced pressure to obtain Compound55-3. LCMS (ESI) m/z: 310 (M+1).

4) Synthesis of Compound 55-4

In a dry single-necked flask, Compound 55-3 (1.20 g), a solution ofTMSCHN₂ in n-hexane (2M, 3.88 mL), dichloromethane (20 mL), and methanol(3 mL) were added. Under nitrogen protection, the resulting mixture wasstirred at 25° C. for 12 h. A solution of TMSCHN₂ in n-hexane (2M, 3.88mL) was supplemented, and the resulting mixture was stirred at 25° C.for 6 h; a solution of TMSCHN₂ in n-hexane (2M, 3.88 mL) wassupplemented, and the resulting mixture was stirred at 25° C. for 12 h;a solution of TMSCHN₂ in n-hexane (2M, 3.88 mL) was supplemented, andthe resulting mixture was stirred at 25° C. for 6 h; and a solution ofTMSCHN₂ in n-hexane (2M, 7.76 mL) was supplemented, and the resultingmixture was stirred at 25° C. for 12 h. The resulting mixture wasconcentrated to dryness under reduced pressure to remove the solvent.The resulting crude product was purified by a chromatographic column toobtain Compound 55-4. LCMS (ESI) m/z: 324 (M+1).

5) Synthesis of Compound 55

In a dry single-necked flask, Compound 55-4 (80 mg), DMF (0.4 mL), andmethylbenzene (2 mL) were added, and then Compound 1-7 (624 mg) wasadded. Under nitrogen protection, the resulting mixture was heated to90° C., and stirred for 10 h, and then concentrated to dryness underreduced pressure to remove the solvent. The crude product was purifiedsuccessively by a preparative TLC plate and preparative HPLC method toobtain Compound 55. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.80 (s, 1H), 7.94 (d,J=8.4 Hz, 1H), 7.87 (s, 1H), 7.75 (br d, J=7.7 Hz, 1H), 7.39 (br d,J=8.6 Hz, 1H), 5.82 (s, 1H), 4.41 (q, J=7.2 Hz, 2H), 1.61 (s, 6H), 1.39(t, J=7.1 Hz, 3H). LCMS (ESI) m/z: 520 (M+1).

Example 55 Synthesis of Compound 56

1) Synthesis of Compound 56-1

In a reaction flask, phosphorous oxychloride (50 mL) was added, Compound17-1 (5.00 g) was slowly added, and then N,N-diisopropylethylamine (3.98g) was added. The resulting mixture reacted at 110° C. for 2 h. Thereaction mixture was concentrated under reduced pressure to obtain acrude product. The crude product was dissolved in 80 mL of ethylacetate, and 20 mL of ice water was added for liquid separation. 40 mLof an iced saturated sodium bicarbonate solution was added to theorganic phase. After liquid separation, the organic phase was dried overanhydrous sodium sulfate, filtered, and concentrated under reducedpressure, to obtain Compound 56-1.

2) Synthesis of Compound 56-2

In a round-bottomed flask, Compound 56-1 (4.65 g), sodium methoxide(4.63 g), and methanol (47 mL) were added, and reacted at 25° C. for 60min. After the completion of the reaction, the resulting mixture wasconcentrated, and the residue obtained from the concentration waspurified by flash column chromatography to obtain Compound 56-2. ¹H NMR(400 MHz, CDCl₃) δ ppm 8.25 (d, J=2.21 Hz, 1H), 7.83 (dd, J=8.93, 2.32Hz, 1H), 7.70-7.74 (m, 1H), 4.13-4.20 (m, 3H), 2.96 (q, J=7.50 Hz, 2H),1.41 (t, J=7.50 Hz, 3H).

3) Synthesis of Compound 56-3

In a reaction flask, Compound 56-2 (500 mg), Compound 3-2 (801 mg),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (108 mg), cesiumcarbonate (1.52 g), and DMF (5 mL) were added. After nitrogen purge for1 min, bis(dibenzylideneacetone)palladium (107 mg) was added, and theresulting mixture reacted at 80° C. for 16 h. The reaction mixture wasconcentrated under reduced pressure to obtain a crude product. The crudeproduct was separated and purified by flash column chromatography toobtain Compound 56-3. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.18 (d, J=4.85 Hz,1H), 7.79 (d, J=9.04 Hz, 1H), 7.29 (d, J=2.87 Hz, 1H), 7.20 (d, J=4.85Hz, 1H), 6.99 (d, J=2.65 Hz, 1H), 5.84 (s, 1H), 4.10 (s, 3H), 2.90-2.98(m, 2H), 2.23 (s, 3H), 1.40 (t, J=7.61 Hz, 3H).

4) Synthesis of Compound 56-4

In a microwave tube, Compound 56-3 (500 mg), Compound 2-5 (311 mg),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (88 mg), cesiumcarbonate (991 mg), and methylbenzene (5 mL) were added. Under nitrogenpurge, Pd(dba)₂ (87 mg) was added, and after nitrogen purge for 1 min,the resulting mixture was kept at 130° C. for microwave reaction for 2h. The reaction mixture was concentrated under reduced pressure toobtain a crude product. The crude product was purified by columnchromatography to obtain Compound 56-4. ¹H NMR (400 MHz, CDCl₃) δ ppm8.23 (d, J=5.02 Hz, 1H), 8.16 (d, J=2.13 Hz, 1H), 7.98 (dd, J=8.66, 2.26Hz, 1H), 7.79 (d, J=8.91 Hz, 1H), 7.76 (s, 1H), 7.68 (d, J=8.66 Hz, 1H),7.00 (d, J=2.64 Hz, 1H), 6.91 (d, J=5.14 Hz, 1H), 5.31 (s, 1H), 5.27 (s,1H), 4.07 (s, 3H), 2.93 (q, J=7.57 Hz, 2H), 2.21 (s, 3H), 1.39 (t,J=7.59 Hz, 3H).

5) Synthesis of Compound 56-5

At 0° C., in a reaction flask, Compound 56-4 (79 mg) and tetrahydrofuran(0.8 mL) were added, and fully stirred, and then sodium hydride (22 mg,60% purity) was added. After the resulting mixture reacted for 0.5 h,thiophosgene (30 mg) was added, and the reaction mixture was stirred at25° C. for 15.5 h. The reaction mixture was concentrated under reducedpressure to obtain a crude product. The crude product was purified by asilica gel plate of thin layer chromatography to obtain Compound 56-5.¹H NMR (400 MHz, CDCl₃) δ ppm 8.29 (s, 1H), 8.27 (d, J=2.43 Hz, 1H),8.24-8.28 (m, 1H), 8.08-8.12 (d, J=5.07 Hz, 1H), 8.07 (s, 1H), 8.05 (s,1H), 7.84 (dd, J=8.82, 2.43 Hz, 1H), 6.97-7.01 (m, 1H), 4.17 (s, 3H),2.98-3.07 (m, 2H), 1.88 (s, 3H), 1.44 (t, J=7.50 Hz, 3H).

8) Synthesis of Compound 56

In a reaction flask, Compound 56-5 (70 mg), an aqueous solution ofhydrochloric acid (2M, 1 mL), and tetrahydrofuran (1 mL) were added, andstirred at 30° C. for 16 h. The reaction mixture was concentrated underreduced pressure to obtain a crude product. The crude product waspurified by preparative HPLC method to obtain Compound 56. ¹H NMR (400MHz, CDCl₃) δ ppm 9.28 (br s, 1H), 8.36 (d, J=1.98 Hz, 1H), 8.31 (s,1H), 8.19 (d, J=8.16 z, 1H), 8.13 (d, J=5.07 Hz, 1H), 8.08 (d, J=8.38Hz, 1H), 7.91-7.95 (m, 1H), 7.85-7.90 (m, 1H), 6.99-7.02 (m, 1H), 2.81(q, J=7.64 Hz, 2H), 1.93 (s, 3H), 1.45 (t, J=7.61 Hz, 3H). LCMS (ESI)m/z: 507 (M+1).

Example 56 Synthesis of Compound 57

1) Synthesis of Compound 57-2

Methyl propionylacetate (2.56 g) was added to a solution of Compound57-1 (1.00 g) in acetic acid (10 mL). The resulting mixture was heatedto 110° C., and stirred for 16 h. The reaction mixture was concentratedunder reduced pressure. The residue obtained from the concentration wasdiluted with ethyl acetate (30 mL), and a saturated aqueous solution ofsodium bicarbonate (30 mL) was added. After liquid separation, theorganic phase was washed with saturated brine (30 mL), dried overanhydrous sodium sulfate, filtered, and concentrated. The residueobtained from the concentration was purified by a silica gel column toobtain Compound 57-2. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.83 (s, 1H), 7.05(s, 1H), 6.44 (s, 1H), 4.08 (s, 3H), 2.82 (q, J=7.5 Hz, 2H), 1.34 (t,J=7.7 Hz, 3H).

2) Synthesis of Compound 57-3

Compound 57-2 (300 mg), Compound 1-4 (165 mg), potassium carbonate (366mg), 2-acetylcyclohexanone (30 mg), cuprous chloride (21 mg),N,N-dimethylformamide (2 mL), and water (0.1 mL) were added to amicrowave tube. The microwave tube was sealed, and the resulting mixturewas kept at 130° C. for microwave reaction for 30 min. The reactionmixture was filtered, the filter cake was washed with ethyl acetate (20mL), and the filtrate was concentrated under reduced pressure. 1Nhydrochloric acid was added to the residue obtained from theconcentration (pH 6-7). The resulting mixture was extracted with ethylacetate (20 mL×3), and the organic phase was washed with saturated brine(30 mL), dried over anhydrous sodium sulfate, and filtered. The filtratewas concentrated. Dichloromethane/methanol (10/1, 20 mL) were added tothe residue obtained from the concentration. The resulting mixture wasfiltered, and the filtrate was concentrated under reduced pressure toobtain Compound 57-3. LCMS (ESI) m/z: 306(M+1).

3) Synthesis of Compound 57-4

A solution of trimethylsilyldiazomethane in n-hexane (2M, 0.8 mL) wasadded to a solution of Compound 57-3 (300 mg), dichloromethane (5 mL)and methanol (0.5 mL). The resulting reaction mixture was stirred at 20°C. for 16 h. The reaction mixture was concentrated under reducedpressure. The residue obtained from the concentration was purified by asilica gel column to obtain Compound 57-4. ¹H NMR (400 MHz, CDCl₃) δ ppm7.88 (d, J=2.3 Hz, 1H), 6.55 (d, J=1.8 Hz, 1H), 6.26 (s, 1H), 3.94 (s,3H), 3.72 (s, 3H), 2.72 (q, J=7.4 Hz, 2H), 1.57 (s, 6H), 1.24 (t, J=7.5Hz, 3H).

4) Synthesis of Compound 57

A mixed solution of Compound 57-4 (150 mg), Compound 1-7 (430 mg),N,N-dimethylformamide (0.5 mL), and methylbenzene (2 mL) was heated to120° C., and stirred for 16 h. Methanol (5 mL) was added to the reactionmixture, which was stirred for 30 min, and then concentrated underreduced pressure. The residue obtained from the concentration waspurified successively by a silica gel column and preparative HPLC toobtain Compound 57. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.71 (d, J=2.0 Hz,1H), 8.03 (d, J=8.3 Hz, 1H), 7.98 (d, J=1.5 Hz, 1H), 7.86 (dd, J=2.0,8.3 Hz, 1H), 6.90 (d, J=2.0 Hz, 1H), 6.49 (s, 1H), 4.09 (s, 3H), 2.86(q, J=7.5 Hz, 2H), 1.72 (s, 6H), 1.37 (t, J=7.5 Hz, 3H); LCMS (ESI) m/z:516 (M+1).

Example 57 Synthesis of Compound 58

1) Synthesis of Compound 58-1

In a dry reaction flask, Compound 54-2 (300 mg), zinc chloride (59 mg),sodium sulfate (823 mg), acetone (505 mg), trimethylsilyl cyanide (431mg), and tetrahydrofuran (3 mL) were added, and reacted at 25° C. for 4h under nitrogen protection. The reaction mixture was directlyconcentrated, and the residue obtained from the concentration waspurified by preparative TLC method to obtain Compound 58-1. ¹H NMR (400MHz, CDCl₃) δ ppm 8.52 (s, 1H), 7.33 (dd, J=9.98, 2.32 Hz, 1H), 6.46 (s,1H), 2.78 (q, J=7.65 Hz, 2H), 1.78 (s, 6H), 1.33 (t, J=7.59 Hz, 3H).

2) Synthesis of Compound 58-3

Water (10 mL) was added to a single-necked flask, and then thiophosgene(1.13 g) was added dropwise. After stirring at 25° C. for 0.5 h undernitrogen protection, Compound 58-2 (1.00 g) was added in batches, andthe resulting mixture further reacted at 25° C. for 2 h. The reactionmixture was extracted with dichloromethane (10 mL×3). The organic phasewas washed with saturated brine (15 mL), dried over anhydrous sodiumsulfate, and filtered. The filtrate was concentrated. The residueobtained from the concentration was purified by column chromatography toobtain Compound 58-3. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.67 (d, J=8.38 Hz,1H), 7.37 (d, J=1.98 Hz, 1H) 7.21 (dd, J=8.38, 1.98 Hz, 1H).

3) Synthesis of Compound 58-4

In a dry reaction flask, Compound 58-1 (200 mg), Compound 58-3 (568 mg),methylbenzene (2 mL), and DMF (0.5 mL) were added. Under nitrogenprotection, sodium hydride (44 mg, 60% purity) was added, and theresulting mixture reacted at 25° C. for 0.5 h. The reaction mixture wasconcentrated, and the residue obtained from the concentration waspurified by column chromatography to obtain Compound 58-4. LCMS (ESI)m/z: 469 (M+1).

4) Synthesis of Compound 58

In a dry reaction flask, Compound 58-4 (110 mg), methylbenzene (1.1 mL),and glacial acetic acid (1.1 mL) were added, and kept at 110° C. for 16h under nitrogen protection. The reaction mixture was concentrated, andthe residue obtained from the concentration was purified by preparativeHPLC to obtain Compound 58. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.83 (s, 1H),7.84 (d, J=8.16 Hz, 1H), 7.68 (d, J=1.98 Hz, 1H), 7.51 (dd, J=8.27, 2.09Hz, 1H), 7.41 (dd, J=8.71, 2.09 Hz, 1H), 6.49 (s, 1H), 2.82 (q, J=7.57Hz, 2H), 1.68 (s, 6H), 1.36 (t, J=7.61 Hz, 3H). LCMS (ESI) m/z: 470(M+1).

Example 58 Synthesis of Compound 59

1) Synthesis of Compound 59-2

Water (10 mL) was added to a single-necked flask, and then thiophosgene(1.27 g) was added dropwise. After stirring at 25° C. for 0.5 h undernitrogen protection, Compound 59-1 (1.00 g) was added in batches, andthe resulting mixture further reacted at 25° C. for 2 h. The reactionmixture was extracted with dichloromethane (10 mL×3). The organic phasewas washed with saturated brine (15 mL), dried over anhydrous sodiumsulfate, and filtered. The filtrate was concentrated. The residueobtained from the concentration was purified by column chromatography toobtain Compound 59-2. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.63 (dd, J=8.38,7.06 Hz, 1H), 7.10-7.15 (m, 1H), 7.07 (dd, J=9.15, 1.87 Hz, 1H).

2) Synthesis of Compound 59-3

In a dry reaction flask, Compound 58-1 (200 mg), Compound 59-2 (520 mg),methylbenzene (2 mL), and DMF (0.5 mL) were added. Under nitrogenprotection, sodium hydride (44 mg, 60% purity) was added, and theresulting mixture reacted at 25° C. for 0.5 h. The reaction mixture wasconcentrated, and the residue obtained from the concentration waspurified by column chromatography to obtain Compound 59-3. LCMS (ESI)m/z: 453 (M+1).

3) Synthesis of Compound 59

In a dry reaction flask, Compound 59-3 (80 mg), methylbenzene (0.8 mL),and glacial acetic acid (0.8 mL) were added, and reacted at 110° C. for16 h under nitrogen protection. The reaction mixture was concentrated toobtain a crude product, and the crude product was purified bypreparative HPLC to obtain Compound 59. ¹H NMR (400 MHz, CDCl₃) δ ppm8.83 (s, 1H) 7.77-7.84 (m, 1H) 7.38-7.45 (m, 3H) 6.49 (s, 1H) 2.82 (q,J=7.35 Hz, 2H) 1.68 (s, 6H) 1.36 (t, J=7.61 Hz, 3H).

Example 59 Synthesis of Compound 60

1) Synthesis of Compound 60-2

In a dry single-necked flask, Compound 60-1 (10.00 g), Compound 30-2(10.02 g), and polyphosphoric acid (30 g) were added, heated to 110° C.and stirred for 16 h under nitrogen protection. The reaction mixture waspoured to 200 mL of ice water, and then adjusted to pH=7 with a sodiumbicarbonate solid. 200 mL of ethyl acetate was added. After liquidseparation, the organic phase was collected, dried over anhydrous sodiumsulfate, and filtered. The filtrate was concentrated under reducedpressure, and the residue obtained from the concentration was purifiedby a chromatographic column to obtain Compound 60-2. ¹H NMR (400 MHz,DMSO-d6) δ ppm 8.81 (d, J=1.8 Hz, 1H), 7.94 (d, J=0.9 Hz, 1H), 6.31 (s,1H), 2.62 (q, J=7.5 Hz, 2H), 2.44 (s, 3H), 1.21 (t, J=7.5 Hz, 3H). LCMS(ESI) m/z: 267 (M+1).

2) Synthesis of Compound 60-3

In a dry microwave tube, Compound 60-2 (500 mg), 2-aminoisobutyric acid(579 mg), 2-acetylcyclohexanone (52 mg), potassium carbonate (517 mg),DMF (4 mL), and water (1 mL) were added, and then cuprous chloride (37mg) was added. After nitrogen purge for 5 min, the microwave tube wassealed, and the resulting mixture was microwaved and stirred at 90° C.for 4 h. The reaction mixture was concentrated under reduced pressure toobtain Compound 60-3. LCMS (ESI) m/z: 290 (M+1).

3) Synthesis of Compound 60-4

In a dry single-necked flask, Compound 60-3 (800 mg) and a solution ofhydrochloric acid-methanol (4M, 25 mL) were added, heated to 90° C. andrefluxed for 2 h under nitrogen protection. The reaction mixture wasconcentrated, and 20 mL of a saturated sodium bicarbonate solution and20 mL of ethyl acetate were added to the residue obtained from theconcentration. After liquid separation, the organic phase was collected,dried over anhydrous sodium sulfate, filtered, and concentrated underreduced pressure to obtain a crude product, which was purified by achromatographic column to obtain Compound 60-4. ¹H NMR (400 MHz, CDCl₃)δ ppm 8.18 (d, J=2.6 Hz, 1H), 7.13 (d, J=1.5 Hz, 1H), 7.14-7.11 (m, 1H),6.49-5.91 (m, 1H), 3.77 (s, 3H), 2.68 (q, J=7.6 Hz, 2H), 2.53 (s, 3H),1.61 (s, 6H), 1.29 (t, J=7.5 Hz, 3H). LCMS (ESI) m/z: 304 (M+1).

4) Synthesis of Compound 60

In a dry single-necked flask, Compound 60-4 (110 mg), Compound 1-7 (165mg), DMF (0.2 mL), and methylbenzene (1 mL) were added, heated to 90° C.and stirred for 48 h under nitrogen protection. The reaction mixture wasconcentrated to dryness, and the resulting crude product was purified bypreparative HPLC to obtain Compound 60. ¹H NMR (400 MHz, CDCl₃) δ ppm8.95 (d, J=2.0 Hz, 1H), 8.03 (d, J=8.4 Hz, 1H), 7.98 (s, 1H), 7.86 (brd, J=8.2 Hz, 1H), 7.48 (s, 1H), 6.44 (s, 1H), 2.79 (q, J=7.6 Hz, 2H),2.64 (s, 3H), 1.69 (s, 6H), 1.37 (t, J=7.5 Hz, 3H). LCMS (ESI) m/z: 500(M+1).

Example 60 Synthesis of Compound 61

1) Synthesis of Compound 61-2

In a dry single-necked flask, Compound 61-1 (5.00 g) and acetonitrile(50 mL) were added, and the temperature was controlled at 0° C., and NBS(6.92 g) dissolved in acetonitrile (50 mL) was slowly added dropwise tothe reaction flask and the temperature was controlled to no more than10° C. After the completion of the dropwise addition, the resultingmixture was stirred at 20° C. for 20 h, and then was concentrated todryness under reduced pressure to remove the solvent. A solid crudeproduct was obtained, and 200 mL of a saturated sodium bicarbonatesolution was added thereto. After ultrasonic processing for 1 h and thenfiltration, the filter cake was washed with 100 mL of water, to obtainCompound 61-2. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.06 (br s, 1H), 7.63 (d,J=2.0 Hz, 1H), 4.93 (br s, 2H). LCMS (ESI) m/z: 207 (M+1).

2) Synthesis of Compound 61-3

In a dry single-necked flask, Compound 61-2 (5.00 g), Compound 30-2(4.52 g), and polyphosphoric acid (15 g) were added, and stirred at 110°C. for 16 h under nitrogen protection. 200 mL of water was added to thereaction mixture, and the resulting mixture was stirred untildissolution. 200 mL of ethyl acetate was added for extraction. Afterliquid separation, the organic phase was dried over anhydrous sodiumsulfate, filtered, and concentrated to dryness under reduced pressure toremove the solvent. The obtained crude product was purified by achromatographic column to obtain Compound 61-3. ¹H NMR (400 MHz, CDCl₃)δ ppm 9.06 (d, J=2.0 Hz, 1H), 7.89 (d, J=2.0 Hz, 1H), 6.40 (s, 1H), 2.76(q, J=7.6 Hz, 2H), 1.32 (t, J=7.5 Hz, 3H). LCMS (ESI) m/z: 288 (M+1).

3) Synthesis of Compound 61-4

In a dry microwave tube, Compound 61-3 (500 mg), 2-aminoisobutyric acid(538 mg), 2-acetylcyclohexanone (49 mg), potassium carbonate (481 mg),DMF (4 mL), and water (1 mL) were added, and then cuprous chloride (34mg) was added. After nitrogen purge for 5 min, the microwave tube wassealed, and the resulting mixture was microwaved and stirred at 110° C.for 1 h. The reaction mixture was concentrated under reduced pressure toobtain Compound 61-4. LCMS (ESI) m/z: 310 (M+1).

4) Synthesis of Compound 61-5

In a dry single-necked flask, Compound 61-4 (300 mg) and a solution ofhydrochloric acid-methanol (4M, 8.76 mL) were added, heated to 90° C.and refluxed for 2 h under nitrogen protection. The reaction mixture wasconcentrated to dryness under reduced pressure. 50 mL of a saturatedsodium bicarbonate solution and 50 mL of ethyl acetate were added to theresidual solid product. After liquid separation, the organic phase wasdried over anhydrous sodium sulfate, filtered, and concentrated todryness to remove the solvent. The obtained crude product was purifiedby a chromatographic column to obtain Compound 61-5. ¹H NMR (400 MHz,CDCl₃) δ ppm 8.21 (d, J=2.6 Hz, 1H), 7.48 (d, J=2.6 Hz, 1H), 6.30 (s,1H), 4.41 (s, 1H), 3.77 (s, 3H), 2.73 (q, J=7.6 Hz, 2H), 1.61 (s, 6H),1.29 (t, J=7.6 Hz, 3H). LCMS (ESI) m/z: 323.77 (M+1).

5) Synthesis of Compound 61

In a dry single-necked flask, Compound 61-5 (110 mg), Compound 1-7 (155mg), DMF (0.2 mL), and methylbenzene (1 mL) were added, and stirred at90° C. for 20 h under nitrogen protection. The resulting mixture wasconcentrated to dryness under reduced pressure, and the obtained crudeproduct was purified by preparative HPLC to obtain Compound 61. ¹H NMR(400 MHz, CDCl3) δ ppm 8.94 (d, J=2.4 Hz, 1H), 8.00 (d, J=8.4 Hz, 1H),7.94 (s, 1H), 7.82 (d, J=8.2 Hz, 1H), 7.78 (d, J=2.2 Hz, 1H), 6.46 (s,1H), 2.81 (q, J=7.4 Hz, 2H), 1.68 (s, 6H), 1.36 (t, J=7.5 Hz, 3H). LCMS(ESI) m/z: 520 (M+1).

Example 61 Synthesis of Compound 62

1) Synthesis of Compound 62-2

In a dry single-necked flask, Compound 34-1 (5.00 g) and Compound 62-1(5.65 g) were added, and then polyphosphoric acid (15.00 g) was added.The resulting mixture was heated to 110° C. and stirred at thistemperature for 16 h under nitrogen protection. The reaction mixture wasslowly added to an iced aqueous solution of sodium bicarbonate (about500 mL), adjusted to pH=7, and extracted with ethyl acetate (200 mL×4).The organic phases were combined, dried over anhydrous sodium sulfate,filtered, and concentrated. The resulting residue was purified by columnchromatography to obtain Compound 62-2. ¹H NMR (400 MHz, CDCl₃) δ ppm9.04 (t, J=1.57 Hz, 1H), 7.67 (dd, J=7.78, 2.01 Hz, 1H), 6.84 (s, 1H),6.37-6.70 (m, 1H).

2) Synthesis of Compound 62-3

In a dry single-necked flask, Compound 62-2 (1.00 g), tert-butylcarbamate (1.20 g), cesium carbonate (2.78 g),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (197 mg), andmethylbenzene (20 mL) were added. Under nitrogen protection,bis(dibenzylideneacetone)palladium (196 mg) was added, and the resultingmixture was refluxed at 120° C. for 2 h. The reaction mixture wasdiluted with water (30 mL), and extracted with ethyl acetate (30 mL×3).The organic phases were combined, dried over anhydrous sodium sulfate,filtered, and concentrated under reduced pressure. The residue obtainedfrom the concentration was purified by column chromatography to obtainCompound 62-3. ¹H NMR (400 MHz, CDCl₃) δ ppm 9.10 (s, 1H), 8.35 (br s,1H), 7.88 (br s, 1H), 6.77 (s, 1H), 6.40-6.70 (m, 1H), 1.57 (s, 9H).

3) Synthesis of Compound 62-4

In a dry single-necked flask, Compound 62-3 (1.50 g) and a solution ofhydrochloric acid/methanol (4M, 576.92 mL) were added, and stirred at25° C. for 16 h. The reaction mixture was concentrated to dryness underreduced pressure. The resulting residue was dissolved in 50 mL of water,adjusted to pH=8-9 by adding a saturated sodium bicarbonate solution,extracted with ethyl acetate (50 mL×3), washed with saturated brine (50mL), dried over anhydrous sodium sulfate, filtered, and concentratedunder reduced pressure. The concentrate was purified by columnchromatography to obtain Compound 62-4. LCMS (ESI) m/z: 230 (M+1).

4) Synthesis of Compound 62-5

In a dry reaction flask, Compound 62-4 (450 mg), zinc chloride (80 mg),sodium sulfate (1.12 g), acetone (684 mg), trimethylsilyl cyanide (584mg), and tetrahydrofuran (4.5 mL) were added, and reacted at 30° C. for4 h under nitrogen protection. The reaction mixture was directlyspin-dried, and purified by column chromatography to obtain Compound62-5. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.55 (s, 1H), 7.38 (dd, J=9.79, 2.51Hz, 1H), 6.78 (s, 1H), 6.40-6.69 (m, 1H), 2.02-2.21 (m, 1H), 1.82 (s,6H).

5) Synthesis of Compound 62

In a dry reaction flask, Compound 62-5 (200 mg), Compound 1-7 (616 mg),methylbenzene (2 mL), and DMF (0.5 mL) were added. Under nitrogenprotection, sodium hydride (40 mg, 60% purity) was added, and theresulting mixture reacted at 25° C. for 0.5 h. The reaction mixture wasdirectly spin-dried, and purified by preparative HPLC. After thecompletion of separation, the product was left to stand still in aseparation system (water (0.05% HCl)-acetonitrile) for 16 h, thenadjusted to pH=8 with a saturated aqueous solution of sodiumbicarbonate, and extracted with dichloromethane (10 mL×3). The combinedorganic phase was dried over anhydrous sodium sulfate, filtered, andconcentrated. The resulting solid was dissolved in water (40 mL) andacetonitrile (8 mL), and the resulting solution was freeze-dried toobtain Compound 62. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.89 (s, 1H), 8.03 (d,J=8.38 Hz, 1H), 7.95 (s, 1H), 7.81-7.85 (m, 1H), 7.56 (dd, J=8.49, 2.09Hz, 1H), 6.90 (s, 1H), 6.43-6.72 (m, 1H), 1.71 (s, 6H).

Example 62 Synthesis of Compound 63

1) Synthesis of Compound 63-3

In a dry single-necked flask, Compound 63-1 (1.00 g), DMF (10 mL), andtriethylamine (620 mg) were added. Under nitrogen protection, Compound63-2 (1.44 g) was added, and the resulting mixture reacted at 20° C. for16 h. The reaction mixture was diluted with 10 mL of ice water, and thenfiltered. The filter cake was collected, and slurried with 3 mL ofmethyl tert-butyl ether for purification. The solid was collected toobtain Compound 63-3. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.34-7.38 (m, 9H),7.33 (d, J=1.38 Hz, 1H), 7.10-7.15 (m, 6H), 6.92 (d, J=1.38 Hz, 1H).

2) Synthesis of Compound 63

In a dry reaction flask, Compound 63-3 (167 mg) and tetrahydrofuran (1.2mL) were added. Under nitrogen protection, a solution of ethyl magnesiumbromide in tetrahydrofuran (3M, 147 μL) was quickly added, and theresulting mixture reacted at room temperature (15° C.) for 0.17 h. Asolution of zinc chloride in diethyl ether (1M, 766 μL) was quicklyadded to the reaction system, and the resulting mixture further reactedat 15° C. for 2 h. Then, under nitrogen protection, the reaction systemwas transferred to a dry reaction flask filled with Compound 36-4 (0.10g) and tetrakis(triphenylphosphine) palladium (22 mg), heated to 95° C.,and refluxed for 12 h. The reaction mixture was concentrated, and theobtained crude product was purified successively by a preparative TLCplate and preparative HPLC method to obtain Compound 63. ¹H NMR (400MHz, CDCl₃) δ ppm 8.29 (s, 1H), 8.02 (d, J=8.16 Hz, 1H), 7.97 (s, 1H),7.94 (d, J=1.54 Hz, 1H), 7.85 (dd, J=8.27, 1.87 Hz, 1H), 7.69 (t, J=1.43Hz, 1H), 7.61 (dd, J=9.59, 2.09 Hz, 1H), 7.36 (s, 1H), 3.24 (q, J=7.57Hz, 2H), 1.68 (s, 6H), 1.51 (t, J=7.61 Hz, 3H).

Example 63 Synthesis of Compound 64

1) Synthesis of Compound 64

In a dry single-necked flask, Compound 55-4 (5 mg), Compound 23-7 (7mg), DMF (0.1 mL), and methylbenzene (0.5 mL) were added, heated to 90°C. and stirred for 48 h under nitrogen protection. The reaction mixturewas concentrated to dryness to remove the solvent, and the obtainedcrude product was purified by preparative HPLC method to obtain Compound64. ¹H NMR (400 MHz, CDCl₃) δ ppm 9.08 (s, 1H), 8.87 (s, 1H), 8.34 (s,1H), 7.44 (br d, J=8.4 Hz, 1H), 5.89 (s, 1H), 4.48 (q, J=6.9 Hz, 2H),1.71 (s, 6H), 1.46 (t, J=6.9 Hz, 3H); LCMS (ESI) m/z: 521 (M+1).

Example 64 Synthesis of Compound 65

1) Synthesis of Compound 65-1

In a dry single-necked flask, Compound 55-1 (500 mg), potassiumcarbonate (533 mg), 2-bromoethyl methyl ether (606 mg), and NMP (5 mL)were added, heated to 70° C. and stirred for 72 h under nitrogenprotection. 100 mL of saturated brine and 100 mL of ethyl acetate weresuccessively added to the reaction mixture. After liquid separation, theorganic phase was collected, dried over anhydrous sodium sulfate, andfiltered. The filtrate was concentrated under reduced pressure. Theobtained crude product was purified by a chromatographic column,slurried with 10 mL of methyl tert-butyl ether, and filtered to obtainCompound 65-1. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.99 (d, J=1.3 Hz, 1H),7.57 (dd, J=1.8, 7.7 Hz, 1H), 5.90 (s, 1H), 4.56 (dd, J=4.0, 5.3 Hz,2H), 3.74 (dd, J=4.0, 5.3 Hz, 2H), 3.43 (d, J=1.1 Hz, 3H). LCMS (ESI)m/z: 317 (M+1).

2) Synthesis of Compound 65-2

In a dry microwave tube, Compound 65-1 (230 mg), 2-aminoisobutyric acid(224 mg), 2-acetylcyclohexanone (20 mg), potassium carbonate (200 mg),DMF (2 mL), and water (0.4 mL) were added, and then cuprous chloride (14mg) was added. After nitrogen purge for 5 min, the microwave tube wassealed, and the resulting mixture was microwaved and stirred at 90° C.for 4 h. The reaction mixture was concentrated, and the obtained crudeproduct was purified by a chromatographic column to obtain Compound65-2. LCMS (ESI) m/z: 340 (M+1).

3) Synthesis of Compound 65-3

In a dry single-necked flask, Compound 65-2 (320 mg), dichloromethane (6mL), and methanol (1 mL) were added, and then TMSCHN₂ (2M, 1.89 mL) wasadded. Under nitrogen protection, the resulting mixture was stirred at18° C. for 1 h. TMSCHN₂ (2M, 1.89 mL) was supplemented, and the reactionwas continued for additional 2 h. The reaction mixture was concentratedto dryness under reduced pressure to remove the solvent, and theobtained crude product was purified by preparative HPLC to obtainCompound 65-3. LCMS (ESI) m/z: 354 (M+1).

4) Synthesis of Compound 65

In a dry single-necked flask, Compound 65-3 (30 mg), Compound 1-7 (39mg), DMF (0.1 mL), and methylbenzene (0.5 mL) were added, kept at 90° C.and stirred for 48 h under nitrogen protection. The reaction mixture wasconcentrated to dryness under reduced pressure. The resulting crudeproduct was purified by preparative HPLC method to obtain Compound 65.¹H NMR (400 MHz, CDCl₃) δ ppm 8.88 (s, 1H), 8.01 (d, J=8.4 Hz, 1H), 7.94(s, 1H), 7.82 (dd, J=2.0, 8.4 Hz, 1H), 7.47 (dd, J=2.1, 8.5 Hz, 1H),5.96 (s, 1H), 4.64-4.60 (m, 2H), 3.79-3.74 (m, 2H), 3.45 (s, 3H), 1.68(s, 6H). LCMS (ESI) m/z: 550 (M+1).

Example 65 Synthesis of Compound 66

1) Synthesis of Compound 66-1

In a reaction flask, Compound 35-2 (500 mg), Compound 3-2 (789 mg),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (107 mg), cesiumcarbonate (1.50 g), and methylbenzene (5 mL) were added. Under nitrogenprotection, bis(dibenzylideneacetone)palladium (106 mg) was added, andthe resulting mixture reacted at 90° C. for 16 h. The reaction mixturewas concentrated under reduced pressure, and the resulting crude productwas separated by column chromatography to obtain Compound 66-1. LCMS(ESI) m/z: 333 (M+1).

2) Synthesis of Compound 66-2

In a microwave tube, Compound 66-1 (200 mg), Compound 2-5 (123 mg),cesium carbonate (392 mg),4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (35 mg), andmethylbenzene (2 mL) were added. Under nitrogen protection,bis(dibenzylideneacetone)palladium (34.56 mg) was added, and theresulting mixture was kept at 130° C. for microwave reaction for 2 h.The reaction mixture was concentrated under reduced pressure to obtain acrude product, which was purified by preparative HPLC to obtain Compound66-2. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.21-8.26 (m, 2H), 8.07-8.12 (m,2H), 7.85 (s, 1H), 7.70 (d, J=8.38 Hz, 1H), 7.08 (br d, J=7.50 Hz, 1H),6.90 (d, J=5.29 Hz, 1H), 6.33 (s, 1H), 5.63 (br s, 1H), 2.74 (q, J=7.64Hz, 2H), 2.25 (s, 3H), 1.22-1.24 (t, J=7.61 Hz, 3H).

3) Synthesis of Compound 66

At 0° C., in a reaction flask, Compound 66-3 (40 mg) and tetrahydrofuran(0.4 mL) were added, and fully stirred, and then NaH (11 mg, 60% purity)was added. After reaction for 0.5 h, thiophosgene (19 mg) was added, andthe reaction mixture was stirred at 25° C. for 15.5 h. The reactionmixture was concentrated under reduced pressure to obtain a crudeproduct, which was purified successively by a preparative TLC plate andpreparative HPLC to obtain Compound 66. ¹H NMR (400 MHz, CDCl₃) δ ppm9.01 (s, 1H), 8.28 (s, 1H), 8.17 (d, J=5.07 Hz, 1H), 8.15 (d, J=1.98 Hz,1H), 8.07-8.12 (m, 1H), 7.63 (dd, J=8.49, 2.32 Hz, 1H), 7.07 (d, J=5.29Hz, 1H), 6.52 (s, 1H), 2.85 (q, J=7.50 Hz, 2H), 2.15 (s, 3H), 1.39 (t,J=7.50 Hz, 3H). LCMS (ESI) m/z: 525 (M+1).

Example 66 Synthesis of Compound 67

1) Synthesis of Compound 67

In a dry reaction flask, Compound 65 (40 mg) and dichloromethane (0.5mL) were added. Under nitrogen protection, boron tribromide (73 mg) wasadded at 0° C., and the resulting mixture was warmed to 15° C. andreacted for 2 h. The reaction was quenched with a saturated sodiumbicarbonate solution (15 mL). The resulting mixture was extracted withdichloromethane (10 mL×3), dried over anhydrous sodium sulfate, andfiltered. The filtrate was concentrated. The residue obtained from theconcentration was purified by preparative HPLC to obtain Compound 67. ¹HNMR (400 MHz, CDCl₃) δ ppm 8.89 (s, 1H), 7.99-8.05 (m, 1H), 7.95 (br s,1H), 7.83 (br d, J=8.16 Hz, 1H), 7.51 (br d, J=7.72 Hz, 1H), 5.96 (d,J=3.09 Hz, 1H), 4.59 (br d, J=4.41 Hz, 2H), 4.01 (br s, 2H), 2.53 (br s,1H), 1.69 (d, J=2.87 Hz, 6H). LCMS (ESI) m/z: 536 (M+1).

Example 67 Synthesis of Compound 68

1) Synthesis of Compound 68-1

In a dry single-necked flask, Compound 55-1 (1.00 g),N-methylpyrrolidone (10 mL), and potassium carbonate (1.07 g) wereadded. Under nitrogen protection, iodomethane (1.24 g) was added, andthe resulting mixture reacted at 40° C. for 16 h. The reaction mixturewas diluted with water (200 mL), and extracted with ethyl acetate (150mL×2). The organic phases were combined, dried over anhydrous sodiumsulfate, and filtered. The filtrate was concentrated to dryness toobtain Compound 68-1. ¹H NMR (400 MHz, CDCl₃) δ ppm 9.01 (s, 1H), 7.60(dd, J=7.84, 2.07 Hz, 1H), 5.87 (s, 1H), 4.04 (s, 3H).

2) Synthesis of Compound 68-2

In a microwave tube, Compound 68-1 (600 mg), Compound 1-4 (340 mg), DMF(12 mL), water (2.4 mL), potassium carbonate (607 mg), and2-acetylcyclohexanone (31 mg) were added. Under nitrogen purge, cuprouschloride (22 mg) was added, and the resulting mixture was kept at 110°C. for microwave reaction for 3 h. The reaction mixture was directlyconcentrated, and the residue obtained from the concentration waspurified by column chromatography to obtain Compound 68-2. ¹H NMR (400MHz, CD₃OD) δ ppm 7.98 (br s, 1H), 7.40-7.49 (m, 1H), 5.74 (s, 1H), 3.98(s, 3H), 1.60 (s, 6H), 1.58-1.62 (m, 1H).

3) Synthesis of Compound 68-3

In a dry single-necked flask, Compound 68-2 (530 mg), dichloromethane(10 mL), and methanol (1.7 mL) were added. Under nitrogen protection, asolution of trimethylsilyldiazomethane in n-hexane (2M, 3.59 mL) wasadded, and the resulting mixture reacted at 15° C. for 16 h. Thereaction mixture was concentrated, and the residue obtained from theconcentration was purified by column chromatography to obtain Compound68-3. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.16 (d, J=1.38 Hz, 1H), 7.14 (dd,J=10.16, 2.51 Hz, 1H), 5.80 (s, 1H), 4.32 (br s, 1H), 3.99 (s, 3H), 3.80(s, 3H), 1.63 (s, 6H).

4) Synthesis of Compound 68

In a dry reaction flask, Compound 68-3 (120 mg), methylbenzene (2.5 mL),and DMF (0.5 mL) were added. Under nitrogen protection, Compound 1-7(177 mg) was added, and the resulting mixture reacted at 90° C. for 16h. The reaction mixture was purified by preparative HPLC to obtainCompound 68. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.89 (s, 1H), 8.02 (d, J=8.38Hz, 1H), 7.95 (s, 1H), 7.83 (d, J=7.72 Hz, 1H), 7.48 (br d, J=8.16 Hz,1H), 5.92 (s, 1H), 4.08 (s, 3H), 1.69 (s, 6H). LCMS (ESI) m/z: 506(M+1).

Example 68 Synthesis of Compound 69

1) Synthesis of Compound 69-2

In a dry single-necked flask, Compound 34-1 (3.00 g) and polyphosphoricacid (20 mL) were added, and then Compound 69-1 (4.59 g, 31.41 mmol) wasadded. Under nitrogen protection, the resulting mixture was heated to110° C. and stirred for 16 h. 200 mL of water was added to the reactionmixture, and then 200 mL of ethyl acetate was added. The resultingmixture was filtered to remove insolubles. The filtrate was left tostand still for stratification. The organic phase was collected, driedover anhydrous sodium sulfate, and filtered. The filtrate wasconcentrated to dryness under reduced pressure to remove the solvent.The resulting crude product was purified by a chromatographic column toobtain Compound 69-2. ¹H NMR (400 MHz, CDCl₃) δ ppm 9.01 (t, J=1.6 Hz,1H), 7.57 (dd, J=2.0, 8.0 Hz, 1H), 6.74 (s, 1H), 4.53 (s, 2H), 3.56-3.53(m, 3H)_(o) LCMS (ESI) m/z: 287 (M+1).

2) Synthesis of Compound 69-3

In a dry single-necked flask, Compound 69-2 (200 mg), 2-aminoisobutyricacid (216 mg), potassium carbonate (193 mg), DMF (4 mL), water (1 mL),and 2-acetylcyclohexanone (19 mg) were added, and then cuprous chloride(14 mg) was added. After nitrogen purge for 5 min, the single-neckedflask was sealed, and then the resulting mixture was microwaved andstirred at 90° C. for 3 h. The reaction mixture was concentrated todryness under reduced pressure to remove the solvent, and the resultingcrude product was purified by a chromatographic column to obtainCompound 69-3. LCMS (ESI) m/z: 310 (M+1).

3) Synthesis of Compound 69-4

In a dry single-necked flask, Compound 69-3 (150 mg), dichloromethane (3mL), and methanol (0.45 mL) were added, and then a solution of TMSCHN₂in n-hexane (2M, 1.94 mL) was added. Under nitrogen protection, theresulting mixture was stirred at 18° C. for 2 h. The reaction mixturewas concentrated to dryness under reduced pressure to remove thesolvent, and the resulting crude product was purified by achromatographic column to obtain Compound 69-4. LCMS (ESI) m/z: 324(M+1).

4) Synthesis of Compound 69

In a dry single-necked flask, Compound 69-4 (130 mg), DMF (0.2 mL), andmethylbenzene (1.5 mL) were added, and then Compound 1-7 (276 mg) wasadded. Under nitrogen protection, the resulting mixture was heated to90° C., and stirred for 16 h. The reaction mixture was concentrated todryness under reduced pressure. The resulting crude product was purifiedby preparative HPLC to obtain Compound 69. ¹H NMR (400 MHz, CDCl₃) δ ppm8.87 (s, 1H), 8.04 (d, J=8.3 Hz, 1H), 7.97 (s, 1H), 7.85 (dd, J=1.9, 8.3Hz, 1H), 7.45 (dd, J=2.2, 8.7 Hz, 1H), 6.81 (s, 1H), 4.58 (s, 2H), 3.57(s, 3H), 1.72 (s, 6H). LCMS (ESI) m/z: 520 (M+1).

Example 69 Synthesis of Compound 70

1) Synthesis of Compound 70-1

1,1′-Carbonyldiimidazole (1.04 g) was added to a solution of Compound10-3 (1.00 g) in tetrahydrofuran (10 mL). The resulting mixture wasstirred at 70° C. for 16 h. The reaction mixture was filtered, and thefilter cake was dried under reduced pressure to obtain Compound 70-1. ¹HNMR (400 MHz, DMSO-d6) δ ppm 11.59 (br s, 2H), 7.91 (dd, J=2.0, 10.0 Hz,1H), 7.80 (s, 1H).

2) Synthesis of Compound 70-2

N,N-diisopropylethylamine (7.18 g) was added dropwise to a solution ofCompound 70-1 (9.60 g) in phosphorus oxychloride (50 mL). The resultingmixture was stirred at 110° C. for 2 h. The reaction mixture wasconcentrated under reduced pressure, diluted with heated dichloromethane(200 mL), and then slowly poured into ice water (150 mL). After liquidseparation, the aqueous layer was extracted with dichloromethane (100mL×2), and the organic phases were combined, successively washed with asaturated aqueous solution of sodium bicarbonate (200 mL) and saturatedbrine (200 mL), dried over anhydrous sodium sulfate, filtered, andconcentrated. The residue obtained from the concentration was purifiedby a silica gel column to obtain Compound 70-2. ¹H NMR (400 MHz, CDCl₃)δ ppm 8.17 (t, J=1.6 Hz, 1H), 7.76 (dd, J=1.9, 8.7 Hz, 1H); LCMS (ESI)m/z: 297 (M+1).

3) Synthesis of Compound 70-3

An aqueous solution of sodium hydroxide (1M, 40 mL) was added to asolution of Compound 70-2 (4.00 g) in tetrahydrofuran (50 mL), and theresulting mixture was further stirred at 10° C. for 3 h. The reactionmixture was poured into an aqueous solution of hydrochloric acid (1N)(pH about 7), and extracted with ethyl acetate (100 mL×3). The organicphase was washed with saturated brine (150 mL), dried over anhydroussodium sulfate, filtered, and concentrated to obtain Compound 70-3. LCMS(ESI) m/z: 279 (M+1).

4) Synthesis of Compound 70-4

In a microwave tube, sodium ethoxide (660 mg) was added to a mixedsolution of Compound 70-3 (900 mg) and ethanol (12 mL). The resultingmixture was kept at 110° C. for microwave reaction for 1 h. The reactionmixture was concentrated under reduced pressure. The residue obtainedfrom the concentration was dissolved in water (30 mL), and extractedwith ethyl acetate (30 mL×3). Then, the aqueous phase was extracted withdichloromethane/methanol (v/v=10/1, 30 mL×3). The organic phases werecombined, dried over anhydrous sodium sulfate, filtered, andconcentrated to obtain Compound 70-4. ¹H NMR (400 MHz, DMSO-d6) δ ppm7.84 (s, 1H), 7.69 (dd, J=2.0, 10.3 Hz, 1H), 4.35 (q, J=7.0 Hz, 2H),1.30 (t, J=7.0 Hz, 3H).

5) Synthesis of Compound 70-5

N,N-diisopropylethylamine (742 mg) was added dropwise to a solution ofCompound 70-4 (1.10 g) in phosphorus oxychloride (8 mL), and theresulting mixture was stirred at 110° C. for 3 h. The reaction mixturewas concentrated under reduced pressure. The residue obtained from theconcentration was diluted with dichloromethane (150 mL), and poured intoice water. After liquid separation, the organic phase was successivelywashed with a saturated aqueous solution of sodium bicarbonate (150 mL)and saturated brine (150 mL), dried over anhydrous sodium sulfate, andfiltered. The filtrate was concentrated to obtain Compound 70-5. LCMS(ESI) m/z: 307 (M+3).

6) Synthesis of Compound 70-6

Sodium hydride (190 mg, 60% purity) was added to a solution of Compound70-5 (1.20 g) and ethanediol (360 mg) in tetrahydrofuran (20 mL), andthe resulting mixture was stirred at 10° C. for 24 h. The reactionmixture was poured into a saturated aqueous solution of ammoniumchloride (50 mL), and extracted with ethyl acetate (50 mL×3). Theorganic phase was washed with saturated brine (50 mL), dried overanhydrous sodium sulfate, and filtered. The filtrate was concentrated toobtain Compound 70-6. LCMS (ESI) m/z: 333 (M+3). 7) Synthesis ofCompound 70-7

Triethylamine (1.19 g) and 4-dimethylaminopyridine (48 mg) were added toa mixed solution of Compound 70-6 (1.30 g), di-tert-butyl dicarbonate(1.03 g), and dichloromethane (20 mL), and the resulting mixture wasstirred at 15° C. for 1 h. The reaction mixture was concentrated underreduced pressure. The residue obtained from the concentration waspurified by a silica gel column to obtain Compound 70-7. ¹H NMR (400MHz, CDCl₃) δ ppm 7.96-7.92 (m, 1H), 7.49 (dd, J=2.1, 9.7 Hz, 1H),4.73-4.69 (m, 2H), 4.52-4.44 (m, 4H), 1.44 (s, 9H), 1.40 (t, J=7.0 Hz,3H).

8) Synthesis of Compound 70-8

Compound 70-7 (600 mg), Compound 1-4 (215 mg), potassium carbonate (480mg), cuprous chloride (28 mg), 2-acetylcyclohexanone (39 mg),N,N-dimethylformamide (6 mL), and water (0.3 mL) were added to amicrowave tube. The microwave tube was sealed, and the resulting mixturewas kept at 120° C. for microwave reaction for 1 h. The reaction mixturewas filtered, and washed with ethyl acetate (10 mL). The filtrate wasconcentrated under reduced pressure. TN hydrochloric acid was added tothe residue obtained from the concentration (pH=6-7), and the resultingmixture was extracted with tetrahydrofuran/ethyl acetate (1/3, 20 mL×3)for liquid separation. The organic phase was washed with saturated brine(30 mL), dried over anhydrous sodium sulfate, and filtered. The filtratewas concentrated under reduced pressure to obtain Compound 70-8. LCMS(ESI) m/z: 454 (M+1).

9) Synthesis of Compound 70-9

A solution of trimethylsilyldiazomethane in n-hexane (2M, 1.1 mL) wasadded to a solution of Compound 70-8 (650 mg), dichloromethane (10 mL),and methanol (1 mL), and the resulting mixture was stirred at 10° C. for2 h. The reaction mixture was concentrated under reduced pressure. Theresidue obtained from the concentration was purified by a silica gelcolumn to obtain Compound 70-9. LCMS (ESI) m/z: 468 (M+3).

10) Synthesis of Compound 70-10

A mixed solution of Compound 70-9 (100 mg), Compound 1-7 (196 mg),N,N-dimethylformamide (0.5 mL), and methylbenzene (2 mL) was heated to120° C., and stirred for 16 h. Methanol (2 mL) was added to the reactionmixture, which was stirred for 30 min, and then concentrated underreduced pressure. The residue obtained from the concentration waspurified by a preparative chromatoplate to obtain Compound 70-10. LCMS(ESI) m/z: 664 (M+1).

11) Synthesis of Compound 70

Trifluoroacetic acid (1 mL) was added to a solution of Compound 70-10(180 mg) in dichloromethane (4 mL), and the resulting mixture wasstirred at 10° C. for 2 h. A saturated aqueous solution of sodiumbicarbonate was added to the reaction mixture (pH about 8), which wasextracted with dichloromethane (10 mL×3). The organic phase was washedwith saturated brine (15 mL), dried over anhydrous sodium sulfate, andconcentrated under reduced pressure. The residue obtained from theconcentration was separated and purified successively by a preparativechromatoplate and preparative HPLC to obtain Compound 70. ¹H NMR (400MHz, CDCl₃) δ ppm 7.93 (d, J=8.3 Hz, 1H), 7.90 (d, J=1.5 Hz, 1H),7.81-7.74 (m, 2H), 7.33 (dd, J=2.0, 10.0 Hz, 1H), 4.73-4.65 (m, 2H),4.54 (q, J=7.0 Hz, 2H), 4.01 (br d, J=3.3 Hz, 2H), 2.17 (br s, 1H), 1.58(s, 6H), 1.43 (t, J=7.2 Hz, 3H); LCMS (ESI) m/z: 564 (M+1).

Example 70 Synthesis of Compound 71

1) Synthesis of Compound 71-1

In a microwave tube, sodium methoxide (520 mg) was added to a solutionof Compound 70-3 (900 mg) in methanol (10 mL). The resulting mixture waskept at 100° C. for microwave reaction for 1.5 h. The reaction mixturewas concentrated under reduced pressure. Tetrahydrofuran (100 mL) wasadded to the residue obtained from the concentration. The resultingmixture was stirred for 20 min, and then filtered. The filtrate wasconcentrated under reduced pressure to obtain Compound 71-1. ¹H NMR (400MHz, DMSO-d6) δ ppm 7.78-7.73 (m, 1H), 7.42 (dd, J=2.3, 10.3 Hz, 1H),3.72 (s, 3H).

2) Synthesis of Compound 71-2

N,N-diisopropylethylamine (618 mg) was added dropwise to a solution ofCompound 71-1 (870 mg) in phosphorus oxychloride (6 mL), and theresulting mixture was stirred at 110° C. for 4 h. The reaction mixturewas concentrated under reduced pressure. The residue obtained from theconcentration was diluted with dichloromethane (20 mL), and poured intoice water. After liquid separation, the organic phase was successivelywashed with a saturated aqueous solution of sodium bicarbonate (15 mL)and saturated brine (15 mL), dried over anhydrous sodium sulfate, andfiltered. The filtrate was concentrated under reduced pressure to obtainCompound 71-2. LCMS (ESI) m/z: 293 (M+3).

3) Synthesis of Compound 71-3

Sodium hydride (165 mg, 60% purity) was added to a solution of Compound71-2 (1.00 g) and ethanediol (320 mg) in tetrahydrofuran (20 mL), andthe resulting mixture was stirred at 10° C. for 4 h. The reactionmixture was poured into a saturated aqueous solution of ammoniumchloride (40 mL), and extracted with ethyl acetate (50 mL×3). Theorganic phase was washed with saturated brine (50 mL), dried overanhydrous sodium sulfate, and filtered. The filtrate was concentratedunder reduced pressure to obtain Compound 71-3. LCMS (ESI) m/z: 319(M+3).

4) Synthesis of Compound 71-4

Triethylamine (1.05 g) and 4-dimethylaminopyridine (43 mg) were added toa mixed solution of Compound 71-3 (1.10 g), di-tert-butyl dicarbonate(908 mg), and dichloromethane (20 mL), and the resulting mixture wasstirred at 15° C. for 1 h. The reaction mixture was concentrated underreduced pressure. The residue obtained from the concentration waspurified by a silica gel column to obtain Compound 71-4. ¹H NMR (400MHz, CDCl₃) δ ppm 7.98-7.93 (m, 1H), 7.51 (dd, J=2.0, 9.5 Hz, 1H),4.75-4.67 (m, 2H), 4.49-4.43 (m, 2H), 4.05 (s, 3H), 1.44 (s, 9H).

5) Synthesis of Compound 71-5

Compound 71-4 (500 mg), Compound 1-4 (185 mg), potassium carbonate (414mg), cuprous chloride (24 mg), 2-acetylcyclohexanone (34 mg),N,N-dimethylformamide (4 mL), and water (0.2 mL) were added to amicrowave tube. The microwave tube was sealed, and the resulting mixturewas kept at 120° C. for microwave reaction for 1 h. The reaction mixturewas filtered, and washed with ethyl acetate (10 mL). The filtrate wasconcentrated under reduced pressure. TN hydrochloric acid was added tothe residue obtained from the concentration (pH 6-7), and the resultingmixture was extracted with tetrahydrofuran/ethyl acetate (1/3, 20 mL×3)for liquid separation. The organic phase was washed with saturated brine(30 mL), dried over anhydrous sodium sulfate, and filtered. The filtratewas concentrated under reduced pressure to obtain Compound 71-5. LCMS(ESI) m/z: 440 (M+1).

6) Synthesis of Compound 71-6

A solution of trimethylsilyldiazomethane in n-hexane (2M, 1.1 mL) wasadded to a solution of Compound 71-5 (470 mg) in dichloromethane (5 mL)and methanol (1 mL), and the resulting mixture was stirred at 10° C. for4 h. The reaction mixture was concentrated under reduced pressure. Theresidue obtained from the concentration was purified by a silica gelcolumn to obtain Compound 71-6. LCMS (ESI) m/z: 454 (M+1).

7) Synthesis of Compound 71-7

A mixed solution of Compound 71-6 (100 mg), Compound 1-7 (202 mg),N,N-dimethylformamide (0.5 mL), and methylbenzene (2 mL) was heated to120° C., and stirred for 16 h. Methanol (2 mL) was added to the reactionmixture, which was stirred for 30 min, and then concentrated underreduced pressure. The residue obtained from the concentration waspurified by a preparative chromatoplate to obtain Compound 71-7. LCMS(ESI) m/z: 650 (M+1).

8) Synthesis of Compound 71

Trifluoroacetic acid (0.5 mL) was added to a solution of Compound 71-7(100 mg) in dichloromethane (2 mL), and the resulting mixture wasstirred at 10° C. for 2 h. A saturated aqueous solution of sodiumbicarbonate was added to the reaction mixture (pH about 8), and theresulting mixture was extracted with dichloromethane (10 mL×3). Theorganic phase was washed with saturated brine (15 mL), dried overanhydrous sodium sulfate, and concentrated under reduced pressure. Theresidue obtained from the concentration was purified successively by apreparative chromatoplate and preparative HPLC to obtain Compound 71. ¹HNMR (400 MHz, CDCl₃) δ ppm 7.97-7.87 (m, 2H), 7.83-7.73 (m, 2H), 7.35(dd, J=2.3, 10.0 Hz, 1H), 4.73-4.65 (m, 2H), 4.09 (s, 3H), 4.02 (br d,J=3.5 Hz, 2H), 2.21 (br t, J=5.4 Hz, 1H), 1.59 (s, 6H); LCMS (ESI) m/z:550 (M+1).

Example 71 Synthesis of Compound 72

1) Synthesis of Compound 72-1

A mixed solution of Compound 70-9 (60 mg), Compound 23-7 (118 mg),N,N-dimethylformamide (0.5 mL), and methylbenzene (2 mL) was heated to120° C., and stirred for 16 h. Methanol (2 mL) was added to the reactionmixture, which was stirred for 30 min, and then concentrated underreduced pressure. The residue obtained from the concentration waspurified by a preparative chromatoplate to obtain Compound 72-1. LCMS(ESI) m/z: 665 (M+1).

2) Synthesis of Compound 72

Trifluoroacetic acid (0.2 mL) was added to a solution of Compound 72-1(45 mg) in dichloromethane (1 mL). The resulting reaction mixture wasstirred at 10° C. for 2 h. A saturated aqueous solution of sodiumbicarbonate was added to the reaction mixture (pH about 8), and theresulting mixture was extracted with dichloromethane (10 mL×3). Theorganic phase was washed with saturated brine (15 mL), dried overanhydrous sodium sulfate, and concentrated under reduced pressure. Theresidue obtained from the concentration was separated and purified bypreparative HPLC to obtain Compound 72. ¹H NMR (400 MHz, CDCl₃) δ ppm9.03 (d, J=2.3 Hz, 1H), 8.29 (d, J=2.3 Hz, 1H), 7.77 (d, J=1.5 Hz, 1H),7.32 (dd, J=2.3, 10.0 Hz, 1H), 4.70 (dd, J=3.8, 5.3 Hz, 2H), 4.54 (q,J=7.2 Hz, 2H), 4.01 (br s, 2H), 2.15 (br s, 1H), 1.61 (s, 6H), 1.43 (t,J=7.2 Hz, 3H); LCMS (ESI) m/z: 565 (M+1).

Example 72 Synthesis of Compound 73

1) Synthesis of Compound 73-1

A mixed solution of Compound 71-6 (55 mg), Compound 23-7 (112 mg),N,N-dimethylformamide (0.5 mL), and methylbenzene (2 mL) was heated to120° C., and stirred for 16 h. Methanol (2 mL) was added to the reactionmixture, which was stirred for 30 min, and then concentrated underreduced pressure. The residue obtained from the concentration waspurified by a preparative chromatoplate to obtain Compound 73-1. LCMS(ESI) m/z: 651 (M+1).

2) Synthesis of Compound 73

Trifluoroacetic acid (0.2 mL) was added to a solution of Compound 73-1(50 mg) in dichloromethane (1 mL). The resulting reaction mixture wasstirred at 10° C. for 2 h. A saturated aqueous solution of sodiumbicarbonate was added to the reaction mixture (pH about 8), and theresulting mixture was extracted with dichloromethane (10 mL×3). Theorganic phase was washed with saturated brine (15 mL), dried overanhydrous sodium sulfate, and concentrated under reduced pressure. Theresidue obtained from the concentration was separated and purified bypreparative HPLC to obtain Compound 73. ¹H NMR (400 MHz, CDCl₃) δ ppm9.02 (d, J=2.0 Hz, 1H), 8.29 (d, J=2.0 Hz, 1H), 7.78 (s, 1H), 7.33 (dd,J=2.3, 10.0 Hz, 1H), 4.73-4.65 (m, 2H), 4.10 (s, 3H), 4.02 (br s, 2H),2.21 (br s, 1H), 1.61 (s, 6H); LCMS (ESI) m/z: 551 (M+1).

Example 73 Synthesis of Compound 74

1) Synthesis of Compound 74

In a dry reaction flask, Compound 62-5 (100 mg), Compound 23-7 (309 mg),DMF (0.25 mL), and methylbenzene (1 mL) were added. Under nitrogenprotection, sodium hydride (20 mg, 60% purity) was added, and theresulting mixture reacted at 25° C. for 0.5 h. The reaction mixture wasconcentrated. The residue obtained from the concentration was purifiedby acidic preparative HPLC method. Then, the product was left to standstill in a separation eluent (water (0.05% HCl)-acetonitrile), thenadjusted to pH=8 with a saturated aqueous solution of sodiumbicarbonate, and extracted with dichloromethane (10 mL×3). The combinedorganic phase was dried over anhydrous sodium sulfate, filtered, andconcentrated. The resulting concentrate was dissolved in water (20 mL)and acetonitrile (8 mL), and then freeze-dried to obtain Compound 74. ¹HNMR (400 MHz, CDCl₃) δ ppm 9.09 (d, J=2.13 Hz, 1H), 8.89 (s, 1H), 8.35(d, J=2.01 Hz, 1H), 7.54 (dd, J=8.34, 2.07 Hz, 1H), 6.91 (s, 1H),6.42-6.75 (m, 1H), 1.74 (s, 6H). LCMS (ESI) m/z: 527 (M+1).

Example 74 Synthesis of Compound 75

1) Synthesis of Compound 75-2

Tris(dibenzylideneacetone)dipalladium (421 mg) and4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (532 mg) were added to amixed solution of Compound 75-1 (2.00 g), tert-butyl carbamate (1.08 g),sodium tert-butoxide (2.21 g), and methylbenzene (40 mL). Under nitrogenprotection, the resulting mixture was stirred at 100° C. for 3 h. Thereaction mixture was filtered through Celite, and the filtrate wasconcentrated under reduced pressure. The residue obtained from theconcentration was purified by a silica gel column to obtain Compound75-2. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.40 (s, 1H), 8.33 (d, J=2.3 Hz,1H), 6.98 (br s, 1H), 1.55 (s, 9H).

2) Synthesis of Compound 75-3

Trifluoroacetic acid (8 mL) was added to a mixed solution of Compound75-2 (1.70 g) and dichloromethane (20 mL). The resulting reactionmixture was stirred at 10° C. for 3 h. The reaction mixture wasconcentrated under reduced pressure. The residue obtained from theconcentration was diluted with ethyl acetate (60 mL), and washed with asaturated sodium bicarbonate solution (50 mL×3). The resulting organicphase was washed with saturated brine (50 mL), dried over anhydroussodium sulfate, and filtered. The filtrate was concentrated underreduced pressure. The residue obtained from the concentration waspurified by a silica gel column to obtain Compound 75-3. LCMS (ESI) m/z:154 (M+1).

3) Synthesis of Compound 75-4

At 10° C., thiophosgene (900 mg) was added dropwise to water (20 mL),and then Compound 75-3 (920 mg) was added in batches. The resultingmixture was stirred at 10° C. for 1 h. The reaction mixture wasextracted with dichloromethane (30 mL×2). The organic phases werecombined, dried over anhydrous sodium sulfate, and filtered. Thefiltrate was concentrated to dryness under reduced pressure to obtainCompound 75-4.

4) Synthesis of Compound 75

A mixed solution of Compound 35-5 (300 mg) and Compound 75-4 (764 mg) inN,N-dimethylformamide (1.5 mL) and methylbenzene (6 mL) was heated to120° C., and stirred for 16 h. Methanol (5 mL) was added to the reactionmixture, which was stirred for 30 min, and then concentrated underreduced pressure. The residue obtained from the concentration waspurified successively by a silica gel column and preparative HPLC toobtain Compound 75. ¹H NMR (400 MHz, CDCl₃) δ ppm 8.82 (s, 1H), 8.78 (d,J=2.0 Hz, 1H), 8.10 (d, J=2.0 Hz, 1H), 7.39 (dd, J=2.1, 8.7 Hz, 1H),6.49 (s, 1H), 2.82 (q, J=7.5 Hz, 2H), 1.69 (s, 6H), 1.36 (t, J=7.5 Hz,3H); LCMS (ESI) m/z: 471 (M+1).

Example 75 Test of Antagonism of Compounds on Nuclear Translocation ofAndrogen Receptor (AR)

1. PathHunter NHR cell lines were recovered and cultured foramplification.

2. The cells were inoculated onto a 384-well plate prior to testing, andincubated at 37° C. The serum for culture was filtered withcharcoal-dextran to reduce the hormone level therein.

3. In the detection of the antagonistic function, a compound was addedto the cells and incubated for 60 min. The working concentration of thetest compound was diluted from 10 μM at a 3-fold concentration gradient,respectively including: 10000, 3333.3, 1111.1, 370.4, 123.5, 41.2, 13.7,and 4.67 nM. Then, an agonist 6a-Fluorotestosterone 0.06 μM(concentration: EC80, i.e., 80% agonistic compound concentration) wasadded, and the mixture was incubated at 37° C. or at room temperaturefor 3-16 h.

4. Signal detection: 12.5 μL or 15 μL (50%, v/v) PathHunter detectionmixed solution (kit: DiscoverX product catalog number: 93-0001 series)was added, and incubated at room temperature for 1 h. Thechemiluminescent signal was read with a PerkinElmer Envision™instrument.

5. Data analysis: The compound activity was analyzed with CBIS dataanalysis software (ChemInnovation, CA). The calculation formula of theinhibition percent of the antagonist is as follows: IC50 inhibitionratio (%)=1000%×(1−(average RLU value of the test compound−average RLUvalue of the blank control group)/(average RLU value of EC80 controlgroup−average RLU value of the blank control group)).

Test results of the antagonism of the compounds on nuclear translocationof the androgen receptor (AR) are as shown in Table 1 below.

TABLE 1 Test Results of Antagonism of Compounds on Nuclear Translocationof Androgen Receptor Compound No. IC50 1  >10 μM 2  >10 μM 3 1.40 μM 42.19 μM 5 3.65 μM 6 3.07 μM 7 4.26 μM 8 4.27 μM 9 5.35 μM 10 1.71 μM 111.14 μM 12 3.26 μM 13 6.02 μM 14 4.90 μM 15 1.12 μM 16 3.91 μM 17 0.65μM 18 2.84 μM 19 1.86 μM 20 1.56 μM 21 1.89 μM 22 2.36 μM 23 1.15 μM 243.10 μM 25 1.22 μM 26 1.71 μM 27 2.21 μM 28 8.88 μM 29 0.83 μM 30 2.54μM 31 3.80 μM 32 6.76 μM 33 9.58 μM 34 3.23 μM 35 2.31 μM 36 5.65 μM 374.47 μM 38 3.58 μM 39 5.95 μM 40 2.15 μM 41 2.75 μM 42 2.20 μM 43 3.50μM 44 3.76 μM 45 2.64 μM 46 3.08 μM 47 2.57 μM 48 3.67 μM 49 1.43 μM 503.45 μM 51 0.64 μM 52 1.23 μM 53 2.11 μM 54 2.50 μM 55 1.40 μM 56 2.86μM 57 5.47 μM 58 0.95 μM 59 8.92 μM 60 1.83 μM 61 1.45 μM 62 1.69 μM 631.34 μM 64 2.81 μM 65 2.09 μM 66 7.12 μM 67 2.30 μM 68 1.91 μM 69 4.00μM 70 4.27 μM 71 2.76 μM 72 2.41 μM 73 2.13 μM 74 2.96 μM 75 0.92 μM

Example 76 Pharmacokinetic Test of Compound 10

1. Abstract

Taking male CD-1 mice as test animals, drug concentrations in plasma atdifferent moments after intravenous and intragastric administration ofCompound 10 to the mice were determined by the LC/MS/MS method. Thepharmacokinetic behavior of Compound 10 in mice was investigated and itspharmacokinetic profile was evaluated.

2. Experimental Protocol

2.1 Test Drug: Compound 10

2.2 Test Animals: Four healthy adult male CD-1 mice were divided into 2groups, with 2 mice in each group, according to the principle of similarbody weight. The animals were purchased from Shanghai Super-BKLaboratory Animal Co., Ltd., with Animal Production License No.: SCXK(Shanghai) 2013-0016.

2.3 Drug Preparation An appropriate amount of sample was weighed, and anappropriate amount of DMSO, PEG400 and water were added successively ata volume ratio of 10:40:50. After stirring and ultrasonic processing,the resulting mixture reached a clear solution state of 0.4 mg/mL forintravenous administration.

An appropriate amount of sample was weighed, and dissolved in a solutionof 0.5% CMC+0.2% Tween 80. After stirring and ultrasonic processing, theresulting mixture reached a uniform suspension state of 0.4 mg/mL forintragastric administration.

2.4 Administration

Four male CD-1 mice were divided into 2 groups, and fasted overnight.The first group was intravenously administered at an administrationvolume of 2.5 mL/kg in a dose of 1 mg/kg; and the second group wasintragastrically administered at an administration volume of 5 mL/kg ina dose of 2 mg/kg.

3. Operations

After Compound 10 was intravenously administered to the male CD-1 mice,30 μL of blood was collected at 0.0833, 0.25, 0.5, 1, 2, 4, 8, and 24 hrespectively, and placed in test tubes containing 2 μL of EDTA-K2. AfterCompound 10 was administered to the intragastric administration group,30 μL of blood was collected at 0.25, 0.5, 1, 2, 4, 8, and 24 hrespectively, and placed in test tubes containing 2 μL of EDTA-K₂. Thetest tubes were centrifuged at 3000 g for 15 min to separate the plasma,which was stored at −60° C. The animals were allowed to eat 2 hoursafter administration.

After intravenous and intragastric administration to the mice, thecontent of the test compound in plasma was determined by the LC/MS/MSmethod. The linear range of the method was 2.00-6000 nmol/L; and theplasma samples were analyzed after the treatment with acetonitrileprecipitated protein. Pharmacokinetic test results of Compound 10 areshown in Table 2 below.

TABLE 2 Pharmacokinetic Test Results of Compound 10 Time ApparentClearance Curve Curve Bio- to Half Volume of Rate Area Area availabilityPlasma Peak Life Distribution CI (0-t) (0-inf) Bio- Mode ofAdministration Concentration T_(max) T1/2 V_(dss) (mL/min/ AUC_(0-last)AUC_(0-inf) availability Administration Dose C_(max) (nM) (h) (h) (L/kg)kg) (nM · h) (nM · h) (%) Intravenous 1 mg/kg — — 4.88 0.384 0.912 3231633486 — Administration Intragastric 2 mg/kg 2765 4.00 5.50 — — 2626127935 41.7 Administration Note: “—” means that the item does not need tobe tested.

Example 77 Pharmacokinetic Test of Compound 35 and Compound 58

1. Abstract

With reference to Example 76, the pharmacokinetic behaviors of Compound35 and Compound 58 in mice were investigated and their pharmacokineticprofiles were evaluated.

2. Experimental Protocol Refers to Example 76.

3. Operations

After Compound 35 and Compound 58 were intravenously administered to themale CD-1 mice, 30 μL of blood was cross-collected at 0.0833, 0.25, 0.5,1, 2, 4, 8, 24, and 48 h respectively, and placed in test tubescontaining 2 μL of EDTA-K2. After Compound 35 and Compound 58 wereadministered to the intragastric administration group, 30 μL of bloodwas cross-collected at 0.25, 0.5, 1, 2, 4, 8, 24, and 48 h respectively,and placed in test tubes containing 2 μL of EDTA-K2. The test tubes wascentrifuged at 3000 g for 15 min to separate the plasma, which wasstored at −60° C. The animals were allowed to eat 4 hours afteradministration.

After intravenous and intragastric administration to the mice, thecontent of the test compound in plasma was determined by the LC/MS/MSmethod. The linear range of the method was 2.00-6000 nmol/L; and theplasma samples were analyzed after the treatment with acetonitrileprecipitated protein.

Pharmacokinetic test results of Compound 35 and Compound 58 are shown inTable 3 below.

TABLE 3 Pharmacokinetic Test Results of Compound 35 and Compound 58 TimeApparent Clearance Curve Curve Bioavail- to Half Volume of Rate AreaArea ability Plasma Peak Life Distribution CI (0-t) (0-inf) Bioavail-Test Mode of Administration Concentration T_(max) T1/2 V_(dss) (mL/min/AUC_(0-last) AUC_(0-inf) ability Compound Administration Dose C_(max)(nM) (h) (h) (L/kg) kg) (nM · h) (nM · h) (%) Compound Intravenous 1mg/kg — — 45.1 0.667 0.189 58694 194448 — 35 Administration Intragastric2 mg/kg 5775 6.00 ND — — 110377 ND 94 Administration CompoundIntravenous 1 mg/kg — — 36.6 0.248 0.0794 271453 447238 — 58Administration Intragastric 2 mg/kg 12850 8.00 ND — — 369659 ND 68.1Administration Note: “—” means that the item does not need to be tested;and “ND” means that the data are not detected.

Example 78 Tissue Distribution Test of Compound 27 and Compound 10

1. Abstract

Taking male CD-1 mice as test animals, drug concentrations in plasma andbrain after intragastric administration of Compound 27 and Compound 10to the mice were determined by the LC/MS/MS method, respectively.

2. Experimental Protocol

2.1 Test Drug: Compound 27 and Compound 10

2.2 Test Animals: Six healthy adult male CD-1 mice were divided into 2groups, with 3 mice in each group, according to the principle of similarbody weight. The animals were purchased from Shanghai Super-BKLaboratory Animal Co., Ltd., with Animal Production License No.: SCXK(Shanghai) 2013-0016.

2.3 Drug Preparation

An appropriate amount of sample was weighed, and an appropriate amountof DMSO, PEG400 and water were added successively at a volume ratio of10:40:50. After stirring and ultrasonic processing, the resultingmixture reached a clear solution state of 0.4 mg/mL.

2.4 Administration

Six male CD-1 mice were divided into 2 groups, fasted overnight, andintragastrically administered at an administration volume of 5 mL/kg ina dose of 2 mg/kg.

3. Operations

After Compound 27 and Compound 10 were intragastrically administered tothe male CD-1 mice, 100 μL of blood was collected by cardiac puncture at2 h, placed in a test tube containing 2 μl of EDTA-K₂, and centrifugedat 3000 g for 15 min to separate 50 μL of plasma, which was stored at−60° C. Meanwhile, brain tissues were collected, washed, thenhomogenized with 5-fold 15 mM PBS/MeOH (v:v, 2:1), and stored at −60° C.The animals were allowed to eat 2 hours after administration.

After intragastric administration to the mice, the content of the testcompound in plasma and brain was determined by the LC/MS/MS method. Thelinear range of the method was 2.00-6000 nmol/L; and the plasma sampleswere analyzed after the treatment with acetonitrile precipitatedprotein.

The results of tissue distribution parameters are shown in Table 4.

TABLE 4 Results of Tissue Distribution Parameters Plasma ConcentrationConcentration in Brain Compound (nM) (nmol/kg) Brain to Blood RatioCompound 27 9250 ± 2112 85.2 ± 21.9 0.00917 ± 0.0004 compound 10 5000 ±3156 67.38 ± 44.5   0.0133 ± 0.0006

Example 79 Tissue Distribution Test of Compound 35 and Compound 58

1. Abstract

Taking male CD-1 mice as test animals, drug concentrations in plasma andbrain after intragastric administration of Compound 35 and Compound 58to the mice were determined by the LC/MS/MS method, respectively.

2. Experimental Protocol

2.1 Test Drug: Compound 35 and Compound 58

2.2 Test Animals: Two healthy adult male CD-1 mice. The animals werepurchased from Shanghai Sippr-BK Laboratory Animal Co., Ltd.

2.3 Drug Preparation

An appropriate amount of sample was weighed, and added in a solution of0.5% CMC+0.2% Tween in water. After stirring and ultrasonic processing,the resulting mixture reached a suspension state of 0.4 mg/mL.

2.4 Drug administration

Two male CD-1 mice were fasted overnight, and intragastricallyadministered at an administration volume of 5 mL/kg in a dose of 2mg/kg.

3. Operations

After Compound 35 and Compound 58 were intragastrically administered tothe male CD-1 mice, 100 μL of blood was collected by cardiac puncture at4 h, placed in a test tube containing 2 μl of EDTA-K₂, and centrifugedat 3000 g for 15 min to separate 30 μL of plasma, which was stored at−60° C. Meanwhile, brain tissues were collected, washed, thenhomogenized with 9-fold 15 mM PBS/MeOH (v:v, 2:1), and stored at −60° C.The animals were allowed to eat 4 hours after administration.

After intragastric administration to the mice, the content of the testcompound in plasma and brain was determined by the LC/MS/MS method. Thelinear range of the method was 2.00-6000 nmol/L; and the plasma sampleswere analyzed after the treatment with acetonitrile precipitatedprotein.

The tissue distribution test results are shown in Table 5.

TABLE 5 Tissue Distribution Test Results Plasma ConcentrationConcentration in Brain Compound (nM) (mnol/kg) Brain to Blood RatioCompound 35 4125 281 0.0742 Compound 58 8260 265 0.0322

Example 80 In Vivo Pharmacodynamic Study of Compound 27 and Compound 10on Subcutaneous Xenograft Tumor Model of Human Prostate Cancer LNCaP-FGCCells

1. Experimental Design

TABLE 6 Preparation Method of Test Compound Concentration StorageCompound Preparation Method (mg/mL) Condition Vehicle 5% DMSO + 40%PEG400 + 10% Solutol + 45% H₂O — 4° C. Compound 27 9.15 mg of Compound27 was weighed, and added to a brown 5 4° C. 50 mg/kg bottle. 90 μL ofDMSO was added, and fully vortex-mixed. Then, 0.72 mL of PEG400 and 180μL of Solutol were added, and fully vortex-mixed. Finally, 0.81 mL ofH₂O was added, and fully vortex-mixed to obtain Compound 27 at 5 mg/mL.Compound 10 9.05 mg of Compound 10 was weighed, and added to a brown 54° C. 50 mg/kg bottle. 90 μL of DMSO was added, and fully vortex-mixed.Then, 0.72 mL of PEG400 and 180 μL of Solutol were added, and fullyvortex-mixed. Finally, 0.81 mL of H₂O was added, and fully vortex-mixedto obtain Compound 10 at 5 mg/mL. Compound 35 12.64 mg of Compound 35was weighed, 0.63 mL of DMSO was 1 4° C. 10 mg/kg added, and vortexeduntil dissolution. 5.04 mL of PEG400, 1.26 mL of Solutol, and 5.67 mL ofH₂O were added, and fully vortexed to obtain a homogeneous solution.Compound 35 25.27 mg of Compound 35 was weighed, 0.63 mL, of DMSO was 24° C. 20 mg/kg added, and vortexed until dissolution. 5.04 mL of PEG400,1.26 mL of Solutol, and 5.67 mL of H₂O were added, and fully vortexed toobtain a homogeneous solution. Compound 58 12.6 mg of Compound 58 wasweighed, 0.63 mL of DMSO was 1 4° C. 10 mg/kg added, and vortexed untildissolution. 5.04 mL of PEG400, 1.26 mL of Solutol, and 5.67 mL of H₂Owere added, and fully vortexed to obtain a homogeneous solution.Compound 58 25.2 mg of Compound 58 was weighed, 0.63 mL of DMSO was 2 4°C. 20 mg/kg added, and vortexed until dissolution. 5.04 mL of PEG400,1.26 mL of Solutol, and 5.67 mL of H₂O were added, and fully vortexed toobtain a homogeneous solution. Note: The drug needs to be thoroughlymixed gently right before administration to the animals.

TABLE 7 Animal Grouping and Administration Regimen of in vivoPharmacodynamic Experiment Administration Route Number Dose Volume ofAdmini- of Compound (mg/ Parameters Admini- stration Group AnimalsTherapy kg) (μL/g) stration Frequency 1 6 Vehicle — 10 PO QD × 21 days 26 Compound 50 10 PO QD × 21 27 days 3 6 Compound 50 10 PO QD × 21 10days 4 6 Compound 10 10 PO QD × 21 35 days 5 6 Compound 20 10 PO QD × 2135 days 6 6 Compound 10 10 PO QD × 21 58 days 7 6 Compound 20 10 PO QD ×21 58 days2. Experimental Materials

2.1 Experimental Animals

-   -   Species: Mice    -   Strain: CB-17 SCID mice    -   Week age and body weight: 6-8 weeks old, 18-22 g body weight    -   Gender: male    -   Supplier: Beijing Vital River Laboratory Animal Technology Co.,        Ltd    -   Animal Certificate No.: 11400700184227        3. Experimental Method and Steps        3.1 Cell Culture

Human prostate cancer LNCaP-FGC cells (ATCC, Manassas, Virginia) werecultured in vitro monolayers under the culture conditions of RPM11640medium supplemented with 1000 fetal bovine serum at 37° C. with 5% CO₂.Routine digestion treatment with trypsin-EDTA was performed twice a weekfor passage. When the cell saturation was 80%-90%, the cells werecollected, counted, and inoculated.

3.2 Tumor Cell Inoculation

0.2 mL (10×10⁶) of LNCaP-FGC cells (10×10⁶+Matrigel, 1:1) was inoculatedsubcutaneously to the right back of each CB-17 SCID mouse. When theaverage tumor volume reached 100-150 mm³, administration in groups wasstarted.

3.3 Tumor Measurement

The tumor diameters were measured with a vernier caliper twice a week.The calculation formula of the tumor volume is: V=0.5a×b², wherein a andb represent the long diameter and the short diameter of the tumor,respectively. The antitumor efficacy of the compounds were evaluated byTGI (%) or a relative tumor proliferation rate T/C (%).TGI(%)=[(1−(average tumor volume of a treatment group at the end of drugadministration−average tumor volume of the treatment group at thebeginning of drug administration))/(average tumor volume of the vehiclecontrol group at the end of treatment−average tumor volume of thevehicle control group at the beginning of treatment)]×100%. Thecalculation formula of the relative tumor proliferation rate T/C (%) isas follows: T/C %=T_(RTV)/C_(RTV)×100% (T_(RTV): RTV of a treatmentgroup; C_(RTV): RTV of a negative control group). The relative tumorvolume (RTV) is calculated based on the tumor measurement results, andthe calculation formula is RTV=V_(t)/V₀, wherein V₀ is the average tumorvolume measured at the time of administration in groups (i.e., do),V_(t) is the average tumor volume at one measurement, and T_(RTV) andC_(RTV) are the data obtained on the same day.

3.4 Statistical Analysis

The statistical analysis includes mean and standard error of mean (SEM)of the tumor volume at each time point for each group. The treatmentgroup showed the best therapeutic effect on the 21st day afteradministration at the end of the test, and therefore statisticalanalysis was performed to evaluate the differences between the groupsbased on the data. The comparison between two groups was analyzed byT-test, and the comparison between three or more groups was analyzed byone-way ANOVA. If there was a significant difference in the F value, theGames-Howell method was used for testing. If there was no significantdifference in the F value, the Dunnet (2-sided) method was used foranalysis. All data analysis was performed by using SPSS 17.0. “p<0.05”was considered a significant difference.

4. Experimental Results

After 21 days of administration, the test Compound 10 had a significantantitumor effect in the 50 mg/kg group compared with the solvent controlgroup (T/C=23.8%, TGI=83.0%, p≤0.001); and the test Compound 27 had asignificant antitumor effect in the 50 mg/kg group compared with thesolvent control group (T/C=53.1%, TGI=51.0%, p=0.002). At the same time,the animals had good tolerances to the above test compounds.

After 21 days of administration, the test Compound 35 had significantantitumor effects in the 10 mg/kg group and the 20 mg/kg group comparedwith the solvent control group (T/C=47.39% and 32.47%, respectively;TGI=59.36% and 76.00%, respectively; p=0.006 and p<0.001, respectively);and Compound 58 had significant antitumor effects in the 10 mg/kg groupand the 20 mg/kg group compared with the solvent control group(T/C=43.93% and 32.37%, respectively; TGI=62.75% and 76.16%,respectively; p=0.003 and p<0.001, respectively). At the same time, theanimals had good tolerances to the above test compounds.

What is claimed is:
 1. A compound of Formula (I) or a pharmaceuticallyacceptable salt thereof,

wherein, T is selected from the group consisting of CH and N; R¹ isselected from the group consisting of hydrogen, halogen, C₁₋₁₂ alkyl,and halogen-substituted C₁₋₁₂ alkyl; the ring A is selected from thegroup consisting of

R² and R³ are each independently selected from C₁₋₁₂ alkyl, or R² and R³are connected to each other to form a 3- to 6-membered cycloalkyltogether; X¹, X², X³, and X⁴ are each independently selected from thegroup consisting of CH and N, and at least one of them is N; n is 0, 1,2, or 3; each R⁴ is independently selected from C₁₋₁₂ alkyl; the ring Bis

R⁵ is selected from the group consisting of hydrogen, C₁₋₁₂ alkyl, C₁₋₁₂alkoxy, and halogen; R⁶ is selected from C₁₋₁₂ alkylaminocarbonyl; oneof X⁵, X⁶, and X⁷ is N(—R^(a)), and the others are CH or N; R^(a) isselected from 5-membered heterocycloalkyl, wherein the heterocycloalkylis optionally substituted by halogen, C₁₋₄ alkyl, C₂₋₄ alkenyl, C₂₋₄alkynyl, 3- to 6-membered cycloalkyl, 3- to 6-membered heterocycloalkyl,C₁₋₄ alkoxy, hydroxyl, or amino; X⁸, X⁹, X¹⁰, and X¹¹ are eachindependently selected from the group consisting of CH, C(═O), N, andNH, and three of X⁸, X⁹, X¹⁰, and X¹¹ are C(═O), N, and NH,respectively; R^(b) is selected from C₁₋₁₂ alkyl, wherein the C₁₋₁₂alkyl is optionally substituted by halogen; Y⁸, Y⁹, Y¹⁰, and Y¹¹ areeach independently selected from the group consisting of CH and N, andat least two of Y⁸, Y⁹, Y¹⁰, and Y¹¹ are N; m is 0, 1, or 2; each R⁷ isindependently selected from the group consisting of halogen, C₁₋₁₂alkyl, hydroxyl, C₁₋₁₂ alkoxy, amino, 3- to 10-membered cycloalkyl, 3-to 10-membered heterocycloalkyl, 5- to 10-membered heteroaryl, and C₁₋₁₂alkylamino, wherein the C₁₋₁₂ alkyl, 3- to 10-membered cycloalkyl, 3- to10-membered heterocycloalkyl, 5- to 10-membered heteroaryl, or C₁₋₁₂alkylamino is optionally substituted by halogen, and wherein thehydroxyl is substituted by: —C₁₋₁₂ alkyl-OH, —C₁₋₁₂ alkyl-(3- to10-membered heterocycloalkyl), —C₁₋₁₂ alkyl-S(═O)₂R^(c), —C₁₋₁₂alkyl-NR^(d)R^(e), —C₁₋₁₂ alkyl-C(═O)NR^(f)R^(g), —C₁₋₁₂ alkyl-(3- to10-membered cycloalkyl) optionally substituted by halogen or hydroxyl,or 3- to 10-membered heterocycloalkyl optionally substituted by halogenor hydroxyl; Z⁸, Z⁹, Z¹⁰, and Z¹¹ are each independently selected fromthe group consisting of CH, C(═O), and N; j is 0, 1, or 2; each R⁹ isindependently selected from the group consisting of halogen, C₁₋₁₂alkyl, C₁₋₁₂ alkoxy, and hydroxyl, wherein the C₁₋₁₂ alkyl is optionallysubstituted by halogen or C₁₋₁₂ alkoxy, and wherein the hydroxyl isoptionally substituted by: —C₁₋₁₂ alkyl-O—C₁₋₁₂ alkyl, —C₁₋₁₂ alkyl-OH,or —C₁₋₁₂ alkyl-C(═O)NR^(f)R^(g); R^(c), R^(d), R^(e), R^(f), and R^(g)are each independently selected from the group consisting of hydrogen,C₁₋₁₂ alkyl, 3- to 10-membered cycloalkyl, 3- to 10-memberedheterocycloalkyl, C₁₋₁₂ alkoxy, hydroxyl, and amino; two of X¹², X¹³,X¹⁴, X¹⁵, and X¹⁶ are NH and C(═O), respectively, and the others areCH₂, O, or S; q is 0, 1, 2, 3, or 4; and each R⁸ is independentlyselected from the group consisting of halogen, C₁₋₁₂ alkyl, hydroxyl,amino, 3- to 10-membered cycloalkyl, C₁₋₁₂ alkoxy, 3- to 10-memberedheterocycloalkyl, and C₁₋₁₂ alkylamino; provided that: when the ring Ais selected from

the ring B is not

and when R⁷ is selected from C₁₋₁₂ alkoxy, R⁷ substitutes the hydrogenon Y⁹, Y¹⁰, or Y¹¹.
 2. The compound of Formula (I) or a pharmaceuticallyacceptable salt thereof according to claim 1, wherein R² and R³ are eachindependently selected from C₁₋₆ alkyl, or R² and R³ are connected toeach other to form a 3- to 6-membered cycloalkyl together.
 3. Thecompound of Formula (I) or a pharmaceutically acceptable salt thereofaccording to claim 1, wherein R¹ is selected from the group consistingof hydrogen, halogen, C₁₋₆ alkyl, and halogen-substituted C₁₋₆ alkyl. 4.The compound of Formula (I) or a pharmaceutically acceptable saltthereof according to claim 1, wherein R⁵ is selected from the groupconsisting of hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, and halogen.
 5. Thecompound of Formula (I) or a pharmaceutically acceptable salt thereofaccording to claim 1, wherein Y⁸, Y⁹, Y¹⁰, and Y¹¹ are eachindependently selected from the group consisting of CH and N, and two ofY⁸, Y⁹, Y¹⁰, and Y¹¹ are N, and the others are CH.
 6. The compound ofFormula (I) or a pharmaceutically acceptable salt thereof according toclaim 1, wherein R^(c), R^(d), R^(e), R^(f), and R^(g) are eachindependently selected from the group consisting of hydrogen, C₁₋₆alkyl, 3- to 6-membered cycloalkyl, 3- to 6-membered heterocycloalkyl,C₁₋₆ alkoxy, hydroxyl, and amino.
 7. The compound of Formula (I) or apharmaceutically acceptable salt thereof according to claim 1, whereinZ⁸, Z⁹, Z¹⁰, and Z¹¹ are each independently selected from the groupconsisting of CH, C(═O), and N, and wherein at least one of them isselected from N.
 8. The compound of Formula (I) or a pharmaceuticallyacceptable salt thereof according to claim 1, wherein the structuralunit


9. The compound of Formula (I) or a pharmaceutically acceptable saltthereof according to claim 1, wherein each R⁹ is independently selectedfrom the group consisting of halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, andhydroxyl, wherein the C₁₋₆ alkyl is optionally substituted by halogen orC₁₋₆ alkoxy, and wherein the hydroxyl is optionally substituted by:—C₁₋₆ alkyl-O—C₁₋₆ alkyl, —C₁₋₆ alkyl-OH, or —C₁₋₆alkyl-C(═O)NR^(f)R^(g).
 10. The compound of Formula (I) or apharmaceutically acceptable salt thereof according to claim 9, whereineach R⁹ is independently selected from the group consisting of halogen,methyl, ethyl, methoxy, ethoxy, and hydroxyl, wherein the methyl orethyl is optionally substituted by halogen or methoxy, and wherein thehydroxyl is optionally substituted by: -ethyl-O-methyl, -ethyl-OH, or-methyl-C(═O)NR^(f)R^(g).
 11. The compound of Formula (I) or apharmaceutically acceptable salt thereof according to claim 1, whereinthe structural unit

is selected from the group consisting of

wherein each R⁹¹ is independently selected from the group consisting ofC₁₋₁₂ alkyl, C₁₋₁₂ alkoxy, and hydroxyl, wherein the C₁₋₁₂ alkyl isoptionally substituted by C₁₋₁₂ alkoxy or halogen, and wherein thehydroxyl is optionally substituted by —C₁₋₁₂ alkyl-OH, or —C₁₋₁₂alkyl-O—C₁₋₁₂ alkyl; wherein each R⁹² is independently selected from thegroup consisting of hydroxyl, —C₁₋₁₂ alkoxy, and halogen, wherein thehydroxyl is optionally substituted by —C₁₋₁₂ alkyl-OH, —C₁₋₁₂alkyl-O—C₁₋₁₂ alkyl, or —C₁₋₁₂ alkyl-C(═O)NR^(f)R^(g).
 12. The compoundof Formula (I) or a pharmaceutically acceptable salt thereof accordingto claim 1, wherein the structural unit

is selected from the group consisting of


13. The compound of Formula (I) or a pharmaceutically acceptable saltthereof according to claim 1, wherein the compound of Formula (I) is acompound of Formula (VI):

wherein R² and R³ are selected from methyl, or R² and R³ are connectedto each other to form cyclobutyl together.
 14. The compound of Formula(I) or a pharmaceutically acceptable salt thereof according to claim 13,wherein R¹ is selected from the group consisting of fluoro, chloro, andtrifluoromethyl.
 15. The compound of Formula (I) or a pharmaceuticallyacceptable salt thereof according to claim 1, wherein the compound ofFormula (I) is a compound of Formula (VI-1):

wherein R² and R³ are selected from methyl, or R² and R³ are connectedto each other to form cyclobutyl together.
 16. The compound of Formula(I) or a pharmaceutically acceptable salt thereof according to claim 15,wherein R¹ is selected from the group consisting of fluoro, chloro, andtrifluoromethyl.
 17. The compound of Formula (I) or a pharmaceuticallyacceptable salt thereof according to claim 1, wherein the compound ofFormula (I) is a compound of Formula (VII)

wherein the ring B is selected from the group consisting of


18. The compound of Formula (I) or a pharmaceutically acceptable saltthereof according to claim 1, selected from the group consisting of thefollowing compounds:

or a pharmaceutically acceptable salt thereof.
 19. A pharmaceuticalcomposition, comprising the compound of Formula (I) or apharmaceutically acceptable salt thereof according to claim
 1. 20. Amethod for treating an androgen-mediated disease in a mammal, comprisingadministering to a mammal in need of the treatment a therapeuticallyeffective amount of the compound of Formula (I) or a pharmaceuticallyacceptable salt thereof according to claim 1.